

**Jacques P. Brown MD, FRCP(C)**  
CURRICULUM VITAE

Coordinates: Centre de recherche du CHU de Québec-Université Laval  
2705, Laurier boulevard, Room TR-83  
Québec, Province of Quebec, Canada, G1V 4G2

Marital Status: Married

Languages: French/English

Telephone: 418-650-2661  
Fax: 418-650-6574  
E-mail: [jacques.brown@crchudequebec.ulaval.ca](mailto:jacques.brown@crchudequebec.ulaval.ca)  
Assistant: Julie Parrot [julie.parrot@grmo.ca](mailto:julie.parrot@grmo.ca)

## **EDUCATION**

1982 - 1984 Postdoctoral Training in Metabolic Bone Disease, Laënnec University, Lyon, France

1980 - 1982 Residency in Rheumatology, University of Sherbrooke, Sherbrooke, P.Q.

1978 - 1980 Residency in Internal Medicine, Laval University, Quebec, P.Q., Canada

1977 - 1978 Multidisciplinary Internship, Laval University, Quebec, P.Q., Canada

1973 - 1977 Doctorate of Medicine, Laval University, Quebec, P.Q., Canada

## **PROFESSIONAL CERTIFICATIONS**

1982 CSPQ Specialist Certificate of the Province of Quebec - Rheumatology

1982 FRCP(c) Certificate of the Royal College of Physicians - Rheumatology

1977 LMCC License of the Medical Council of Canada

1977 MD Doctorate in medicine, Laval University, Quebec, P.Q., Canada

## **APPOINTMENTS**

### **Université Laval**

2011 - 2015 Head, Division of Rheumatology, Department of Medicine

Since 2006 Clinical Professor, Department of Medicine

1993 - 2005 Program Director – Adult Rheumatology

**CHU de Québec-Université Laval (prior to September 2012, known as Centre hospitalier universitaire de Québec)**

- 1996-2013 Head, Division of Rheumatology
- 1989-2016 Rheumatologist, Division of Rheumatology, Centre hospitalier de l'Université Laval
- 1984 - 1989 Rheumatologist, Department of Physiatry and Rheumatology, L'Hôtel-Dieu de Québec

**Centre de recherche du CHU de Québec-Université Laval  
Centre hospitalier de l'Université Laval**

- Since 1994 Clinical Researcher, Infectiology and Immunology
- 1996-2014 Arthritis Centre Director (Arthritis Society of Canada)

**Groupe de recherche en maladies osseuses Inc.**

- 1994-2020 Founder member and principal investigator of multiple clinical trials in various conditions: post-menopausal osteoporosis, glucocorticoid-induced osteoporosis, male osteoporosis, Paget's disease of bone, rheumatoid arthritis, osteoarthritis, and fibromyalgia)

**Centre de l'ostéoporose et de rhumatologie de Québec**

- 1995-2020 Founder member and Medical Director

**Complexe hospitalier de la Sagamie**

- 1993- 2000 Roving consultant in rheumatology, 10 days per year
- 1984 - 1993 Roving consultant in rheumatology, 2 days per month

**TEACHING**

**Laval University**

- 2005-2010 Annual lecture on the genetics of Paget's disease of bone (1 hour), "Génomique humaine" course, Master's students in science at the Faculty of Medicine.
- 2004-2016 Annual lecture on the metabolic bone diseases (2 hours), "Physiopathologie générale et implications cliniques" course, BA students in physiotherapy, Faculty of Medicine.
- 2000-2018 Annual lecture on metabolic bone diseases (3 hours), "Pharmacologie et Toxicologie III" course, BA students in pharmacy, Faculty of Medicine.
- 1995-2005 Annual lecture on osteoporosis, "L'appareil locomoteur" course, BA students in medicine, Faculty of Medicine.

1989 - 1995 Annual lecture on metabolic bone diseases (6 hours), "Locomoteur médical" course, BA students in medicine, Faculty of Medicine.

### **CHU de Québec-Université Laval -Centre hospitalier de l'Université Laval**

2005 - 2016 Clinical case discussion, two to four times per year

2005 - 2016 Rheumatology seminar, once or twice per year

1999 - 2016 Lecture to residents, two to three times per year

1989 - 1999 Rheumatology Seminars, once every eight weeks

1989 - 1999 Clinical Case discussion, eight to ten times per year

1989 - 1999 Daily hospital rounds of the rheumatology unit, 3 months per year

### **Teaching/Supervision of residents or students**

Since 2014 Supervision of Claudia Beaudoin, PhD candidate in epidemiology, Laval University. Project: Prediction of risk of osteoporotic fractures in Quebec population aged 50 and over, insured by the RAMQ.

Since 2013 Supervision of Nicolas Murray, resident in radiology, Laval University. Project: The radiological diagnosis of vertebral osteoporotic fractures in tomodensitometry: contribution of systematic sagittal reconstructions to improving the quality of the medical act.

2012-2013 Supervision of Andréanne Samson, resident in Internal Medicine, Laval University. Project: Expression of Paget's Disease in patients with the mutation SQSTM1/P392L.

2011 Supervision of Marilou Caron-Cantin, student in biology, Laval University. Project: Impact of DISH on BMD assessment in the CaMOS population.

2007-2011 Supervision of Sonia Jean, PhD, Laval University. Project: Develop and validate an identification algorithm of fracture events from the RAMQ acts file.

2005-2006 Supervision of Sai Yan Yuen, resident in Internal Medicine. Project: Radiographic prevalence of Degenerative Spinal Changes, Scheuermann's Disease, Calcifications and DISH in an Elderly Random Population and Their Effects on Osteoporosis Diagnosis.

2005-2012 Annual Presentation on the genetics of Paget's Disease, course "Human Genomics", Faculty of Medicine, Laval University.

Since 2004 Annual Presentation on Bone Metabolism, course "General Pathophysiology and Clinical Implications", Physiotherapy Program, Faculty of Medicine, Laval University.

2004 - 2008 Supervision of medical student during a rheumatology internship, Canadian Rheumatology Association (21 hours per week for two months per year – June to August).

- 1999-2003 Main Supervisor, Nancy Laurin, PhD, Laval University. Project: Paget's Disease of Bone.
- 1993 - 1999 Supervision of a senior resident in adult rheumatology at the outpatient clinic (four hours per week, six months per year).
- 1993- 1999 Supervision and evaluation of senior residents in adult rheumatology, as the Program Director - Adult rheumatology (4 hours per week, 48 weeks per year).
- Since 1989 Supervision and evaluation of senior residents in internal medicine and junior residents in internal medicine, orthopaedics, pysiastry, and family medicine (20 hours per week, 10 weeks per year at the outpatient clinic).

## **DISTINCTIONS AND AWARDS**

- 2017 Le Diamant *Hommage Héritage*, Conseil des médecins, dentistes et pharmaciens, CHU de Québec-Université Laval
- 2017 Canadian Rheumatology Association Distinguished Investigator Award
- 2012 Queen Elizabeth II Diamond Jubilee Award, to honour significant contributions and achievements by Canadians
- 2009 *Knight of the Ordre national du Québec*, the highest distinction awarded by the government of Quebec (June 17, 2009).
- 2005 John G. Haddad Jr. Research Award, The Paget Foundation (US) (co-recipient with Dr. David Roodman, Pittsburg, USA) for a research project entitled "Measles Virus Nucleocapsid Gene Expression and Abnormal Osteoclast Activity in Patients with a Genetic Predisposition for Paget's Disease of Bone (mutation of the sequestosome 1)."
- 2004 Lindy-Fraser Memorial Award, Osteoporosis Canada (co-recipient with Dr. Robert G. Josse, Toronto, Canada) for his leadership in the writing and publication in the Canadian Medical Association Journal (peer review) of the first evidence-based guidelines on osteoporosis: *2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada*.
- 2003 John G. Haddad Jr. Research Award, The Paget Foundation (US), for his research that resulted in 2002 the identification of the link between Paget's disease of bone (classical form) and the recurrent mutation (P392L) of the gene sequestosome 1. To this day, it remains the only gene linked to this disease.
- 1984 - 1986 Assistantship Award, The Arthritis Society of Canada, to assure his integration as a clinical researcher in metabolic bone diseases.
- 1982 - 1984 Research Fellowship Award, The Arthritis Society of Canada, to undertake post-doctorate training in metabolic bone diseases with Professor Pierre J. Meunier, Rheumatologist, Laboratoire de recherche sur l'histodynamique osseuse, Unité INSERM 234, Université Laënnec, Lyon, France.

1981 - 1982 Clinical Fellowship Award, The Arthritis Society of Canada, to assure his initiation into clinical research with Professor André Lussier, Rheumatologist, Centre hospitalier universitaire de Sherbrooke, Quebec, Canada.

## **OTHER PROFESSIONAL CONTRIBUTIONS**

### **Laval University**

2013 - 2015 Member, Comité sur les tâches académiques, Department of Medicine

2003 - 2004 Continued medical education program on rheumatic diseases: *Académie de rhumatologie*

2001-2003 Workshop: *L'ostéoporose de la prévention au traitement... Osez agir!*

1998-2000 Interactive workshop: *L'ostéoporose au bureau.*

### **Centre hospitalier universitaire de Québec**

1990 - 1993 Chair, Institutional Review Board (Clinical Research), Centre hospitalier de l'Université Laval

1988 - 1989 Secretary, Conseil des médecins, dentistes et pharmaciens, L'Hôtel-Dieu de Québec

1987 - 1988 Chair, Institutional Review Board (Clinical Research), L'Hôtel-Dieu de Québec

1984 - 1987 Member, Institutional Review Board, L'Hôtel-Dieu de Québec

### **Professional Societies**

Since 2020 Fellow of the American Society for Bone and Mineral Research

Since 2018 Ambassador, American Society for Bone and Mineral Research

Since 2016 Member, Editorial Board, Osteoporosis International.

2013-2015 Member, Osteonecrosis of the Jaw American Society for Bone and Mineral Research Task Force

2013-2014 Chair, SAC Nominating Committee, Osteoporosis Canada

2012-2013 Chair, SAC Development Committee, Osteoporosis Canada

2011-2018 Member, Canadian Bone Strength Working Group

2010 Chair, Catalyst Grant: Bone Health Committee, Institute of Musculoskeletal Health and Arthritis, Canadian Institutes of Health Research (CIHR)

2007-2022 Member, Réseau de recherche en santé buccodentaire et osseuse

Since 2007 Member, Canadian Chronic Disease Surveillance System, Public Health Agency of Canada

2005-2011	Member, Scientific Advisory Board, The Arthritis Society of Canada
2004-2006	Chair, Board, Canadian Multicentre Osteoporosis Study (CaMOS)
2004-2012	Medical consultant, Quebec City Chapter, Osteoporosis Canada (previously The Osteoporosis Society of Canada)
2002	External reviewer, “B” Committee in clinical research, Canadian Institutes of Health Research
2001-2006	Vice-chair, Canadian Panel, International Society of Clinical Densitometry
2000 - 2004	Chair, Scientific Advisory Council, The Osteoporosis Society of Canada
Since 2000	External Reviewer, Osteoporosis International (scientific journal)
Since 1999	External Reviewer, Canadian Medical Association Journal
Since 1999	Member, Advisory Medical Panel, The Paget Foundation (US)
1999 - 2006	Member, Board, Section de l’Est du Québec, The Arthritis Society of Canada
1999	Certification course for physicians, International Society of Clinical Densitometry
Since 1998	Member, Canadian Panel, International Society of Clinical Densitometry
1998 - 2000	Vice-chair, Scientific Advisory Council, The Osteoporosis Society of Canada
1997 - 2000	Editor, <i>Osteoporosis Update</i> The Osteoporosis Society of Canada
1995 - 1997	Member, Board of Directors, The Osteoporosis Society of Canada
1993 - 1997	Editor, <i>Bulletin for Physicians</i> , The Osteoporosis Society of Canada
1993 - 1994	Vice-chair, Board of examiners in Rheumatology, Corporation professionnelle des médecins du Québec
1993 - 1994	Secretary, Association des internistes, Rhumatologues et Gériatres du Québec
1992 - 1993	Director, Association des Internistes, Rhumatologues et Gériatres du Québec
1989 -1993	Member, Editorial Committee, <i>Bulletin for Physicians</i> , The Osteoporosis Society of Canada
Since 1984	Member, Scientific Advisory Council, Osteoporosis Canada
1984-2010	Patron of the Association des arthritiques du Saguenay-Lac-St-Jean since its founding

## **INVITED LECTURES AND PRESENTATIONS**

1. **Brown JP**, Raymond V, Morissette J (1999). *Genetic epidemiology of Paget's disease of bone in eastern Québec*. Proceedings of the National Association for the relief of Paget's disease International Symposium, Oxford, UK, July 15-17, 1998. *Bone*; 24 (5) Suppl.
2. *Risedronate in postmenopausal osteoporosis*. Osteoporosis in Canada: Symposium on Diagnosis and Management. Osteoporosis Society of Canada, Niagara Falls, Ontario, Canada. May 11-13, 2001. Scientific Program: 42-46.
3. *The role of SERMs in the long-term management of postmenopausal women*. 57<sup>th</sup> Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada, St. John's, Newfoundland, Canada, June 14-19, 2001.
4. *Genetics of Paget's disease*. 23<sup>rd</sup> European Workshop for Rheumatology Research, Marseille, France, February 28, 2003.
5. *BMD: Is that all there is to osteoporosis?* Osteoporosis: New paradigm in determining fracture risk. Basic science symposium during the 59<sup>th</sup> Annual Meeting of the Canadian rheumatology association. Lake Louise, Alberta, Canada, February 26, 2004.
6. *Current approaches to the diagnosis and management of osteoporosis*. Annual District 1 meeting of the American College of Obstetricians and Gynecologists. Québec, Quebec, Canada, September 16, 2005.
7. *New insights on interpretation of BMD tests*. 61<sup>st</sup> Annual Meeting of the Canadian rheumatology association. First Mexican-Canadian Congress of rheumatology. Acapulco, Mexico, February 18-22, 2006.
8. *L'étude CaMos*. Annual Scientific Meeting of the Network for Oral and Bone Health Research [Réseau de santé buccodentaire et osseuse du Fonds de recherche en santé du Québec (FRSQ)]. Auberge Godefroy, Mauricie, Québec, Canada, May 18, 2007.
9. *La médecine : un art et une science*. Guest Speaker of the Annual Scientific Meeting of the Department of medicine, University of Sherbrooke, Quebec, Canada, November 16, 2007.
10. *WHI lessons learned. No bones about it. Osteoporosis*. J. Kenneth Milne International Symposium: Making Sense of Information and Applying It to Practice: WHI Experience. 64<sup>th</sup> Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada, Calgary, Alberta, Canada, June 27, 2008.
11. *Bazedoxifene and bone*. Symposium 'Hormones and Bone'. 13<sup>th</sup> International Congress on Hormonal Steroids and Hormones & Cancer. Québec, Quebec, Canada, September 29, 2008.
12. *Assessing Vitamin D Nutritional Status: Use of Specific Bone Biomarkers*. American Association of Clinical Chemistry Annual Meeting. Chicago, Illinois, U.S.A., July 19-23, 2009.
13. *Les marqueurs biochimiques du remodelage osseux dans la prise en charge de l'ostéoporose - Consensus Canadien* Congrès annuel de la Société québécoise de biologie clinique SQBC, Shawinigan, Quebec, Canada. October 16, 2009.
14. *Osteoporosis*. Annual Meeting of the Canadian Rheumatology Association. Quebec, Quebec, Canada. February 4-6, 2010.
15. *L'identification des personnes à risque et leur prise en charge*. 13<sup>e</sup> journées annuelles de santé publique – Santé osseuse. Pour vieillir sans fracture. Montréal, Québec, Canada, March 11, 2010.

16. *Nouveautés en ostéoporose*. Pre-symposium to the 41<sup>st</sup> Laurentian Conference of Rheumatology. Mont Tremblant, Quebec, Canada. April 29, 2010.
17. *Nouveautés en ostéoporose*. Familiprix Seminar. La Malbaie, Quebec, Canada. April 30, 2010.
18. *Rôle des marqueurs de remodelage*. Gynaecological Perinatalty Annual Meeting (Congrès annuel de gynécologie périnatalité). Montebello, Quebec, Canada. May 28, 2010.
19. *Améliorer le statut en vitamine D dans la prise en charge de l'ostéoporose (AVANCE) Programme visant à améliorer la pratique clinique*. Symposium : Sujets d'actualité en santé de la femme. Québec, Quebec, Canada. November 20, 2010.
20. *Fracture ostéoporotique : Au-delà de la chirurgie*. Activités académiques du département de médecine du CHUS et de l'Université de Sherbrooke. Sherbrooke, Québec. Canada. February 16, 2011.
21. *La maladie de Paget : physiopathologie et données récentes*. 1<sup>re</sup> rencontre Québéco-Marseillaise en rhumatologie. Rapprochement scientifique France / Canada. Québec, Québec, Canada. February 26, 2011.
22. *Bone Bio Markers: To use or not to use?* 7<sup>th</sup> St. Michael's Hospital Osteoporosis & Metabolic Bone Disease Symposium. Toronto, Ontario, Canada. March 11, 2011.
23. *Addressing key clinical questions in PMO: Fracture risk, bone biology, remodeling and treatment*. Satellite Symposium – 2011 Sun Peaks Medicine Conference. Sun Peaks, BC, Canada. March 20, 2011.
24. *Programme ROCQ : écart thérapeutique, conséquences et solutions*. 4<sup>e</sup> Symposium québécois sur les maladies osseuses. Montreal, Quebec, Canada. April 8, 2011.
25. *Osteoporosis*. 32<sup>nd</sup> Annual Scientific Meeting of the Canadian Geriatrics Society. Quebec, Quebec, Canada. April 20, 2012.
26. *Ostéoporose et maladies osseuses : bar ouvert*. Update in Rheumatology: 9th Edition. Association des médecins rhumatologues du Québec. Montreal, Québec, Canada. December 1, 2012.
27. *Challenges and Strategies in Managing Osteoporosis*. 2013 CRA Annual Scientific Meeting. Ottawa, Ontario, Canada. February 14, 2013.
28. *Bone Density or Bone Turnover Markers for Monitoring Osteoporosis: Point / Counterpoint Discussion*. ProHealth Clinic. Vancouver, British Columbia, Canada. April 10, 2013.
29. *New molecules for the treatment of osteoporosis*. MUHC Bone Rounds. Royal Victoria Hospital. Montreal, Quebec, Canada. May 27, 2013.
30. *Ostéoporose cortisonée - de la procréation à la maturité*. Congrès annuel 2013 de l'AMQR. Château Vaudreuil. Vaudreuil-Dorion, Quebec, Canada. September 27, 2013.
31. *Denosumab Significantly Increases Bone Mineral Density Compared With Ibandronate and Risedronate in Postmenopausal Women Previously Treated With an Oral Bisphosphonate Who Are at Higher Risk for Fracture*. ASBMR Annual Meeting. Baltimore Convention Center. Baltimore, Maryland, USA. October 5, 2013.



32. *Ostéoporose – Les indications de traitement chez la femme ménopausée.* Symposium francophone de médecine – Une réalisation de Médecins francophones du Canada. Palais des congrès de Montréal. Montreal, Quebec, Canada. October 23, 2013.
33. *L'ostéoporose chez la personne vieillissante : mieux comprendre pour mieux agir.* Conférence grand public. Montmatre Canadien. Quebec, Quebec, Canada, October 29, 2013
34. *Os cortical.* Hôpital Notre-Dame. Montréal, Canada. September 05, 2014.
35. *Mise à jour: nouvelles perspectives thérapeutiques pour le traitement et la gestion de l'ostéoporose.* Hôpital Sacré-Coeur. Montréal, Canada. November 06, 2014
36. *Mise à jour en ostéoporose.* Hôpital Granby. Granby, Canada. November 27, 2014.
37. *Os cortical.* Hôpital Maisonneuve Rosemont. Montréal, Canada. December 04, 2014.
38. *Update on Paget's Disease.* University of Toronto. Mount Sinai Hospital. Toronto, Canada. December 05, 2014.
39. *Bone Turnover Markers for Use in Management of Osteoporosis: is it time?* University of Toronto. Toronto General Hospital. Toronto, Canada. December 05, 2014.
40. *Le point sur les fractures.* Une journée sur la santé familiale pour les omnipraticiens. Québec, Canada. September 25 2015.
41. *L'ostéoporose.* Congrès sur l'endocrinologie. Montreal. Canada. December 04, 2015.
42. *10 choses que devrez SAVOIR sur l'ostéoporose.* Hôpital Sacré-Cœur, Montréal, Canada. February 11, 2016.
43. *10 choses que devrez SAVOIR sur l'ostéoporose.* Hôpital Le Gardeur, Terrebonne, Canada. May 11, 2016.
44. *10 choses que devrez SAVOIR sur l'ostéoporose.* Hôpital Maisonneuve-Rosemont, Montréal, Canada. May 12, 2016.
45. *Minéralisation osseuse et traitements de l'ostéoporose.* Faculté de médecine Laennec, Lyon, France. May 26, 2016.
46. *OP: A chronic disease requiring ongoing management.* Western Centre for Health Research and Education. Melbourne, Australia. August 16, 2016.
47. *OP: A chronic disease requiring ongoing management.* Annual Meetings of the Endocrine Society of Australia and Society of Reproductive Biology and Australia and New Zealand Bone and Mineral Society. Gold Coast, Queensland, Australia. August 22, 2016.
48. *Current Evidence re: Osteoporosis Drug Therapies and Drug Holidays.* Canadian Musculoskeletal Conference. Toronto, Canada. October 14, 2016.
49. *The Odyssey of Fracture Prevention.* 2017 Canadian Rheumatology Association Annual Scientific Meeting. Ottawa, Canada. February 10, 2017.

50. *Démystifier l'ostéoporose, le qui, le comment et le pourquoi?* Hôpital de Victoriaville. Victoriaville, Canada. April 19, 2017.
51. *Osteoporosis therapies: a long-term journey.* Meet the Expert. Montreal Jewish Hospital. Montreal, Canada. April 20, 2017.
52. *Démystifier l'ostéoporose, le qui, le comment et le pourquoi?* Vendredi de la Montérégie de l'Association des médecins omnipraticiens du Richelieu-Saint-Laurent. Longueuil, Canada. April 21, 2017.
53. *Long term management on Post-menopausal Osteoporosis.* Advances in Medicine 2017. Department of Medicine & Therapeutics, Chinese University of Hong Kong. Hong Kong, China. May 28, 2017.
54. *Long-term management of osteoporosis – Where do we go from here?* Hong Kong Geriatric Society. Hong Kong, China. May 29, 2017.
55. *Antiresorptives Safety Concerns — Clinical Perspective,* Society of Toxicology Pathology 36<sup>th</sup> Annual Symposium Musculoskeletal System. Montreal, Canada. June 26, 2017.
56. *Chronic kidney disease–metabolic bone disease (CKD-MBD): differentiate and manage accordingly.* Asia Pacific Academy Bone 2017: tackling the crisis in osteoporosis patient care. Incheon, South Korea. December 9, 2017.
57. *Fracture risk assessment and vertebral fractures: could it be simple?* Asia Pacific Academy Bone 2017: tackling the crisis in osteoporosis patient care. Incheon, South Korea. December 10, 2017.
58. *Vertebral Fracture Assessment.* 2<sup>nd</sup> Canadian Musculoskeletal Conference. Toronto, Canada. May 5, 2018.
59. *Goal directed therapy in osteoporosis management.* 6<sup>th</sup> Seoul Symposium on Bone Health & 30<sup>th</sup> Spring Scientific Congress of the Korean Society for Bone and Mineral Research. Seoul, Korea. May 11, 2018.
60. Updated on anti-resorptive therapy for the long-term OP management. 6<sup>th</sup> Seoul Symposium on Bone Health & 30<sup>th</sup> Spring Scientific Congress of the Korean Society for Bone and Mineral Research. Seoul, Korea. May 12, 2018.
61. *L'ostéoporose en 2018.* 40<sup>e</sup> Congrès annuel de gynécologie-périnatalité. Mont Sainte-Anne, Canada. May 18, 2018.
62. *Aspects cliniques des maladies osseuses métaboliques.* Département de rhumatologie, Hôpital Maisonneuve-Rosemont. Montreal, Canada. February 7, 2019.
63. *What's new in a disease of old age?* Rheumatology Department, Jewish General Hospital. Montreal, Canada. February 7, 2019.
64. *10 notions que vous devez savoir sur l'ostéoporose.* Infirmières praticiennes spécialisés. Université Laval, Québec, Canada. February 22, 2019.
65. *When Should we Look for Genetic Bone Diseases? Endocrine rounds.* St. Michael's Hospital. Toronto, Canada. May 15, 2019.
66. *Osteoporosis, a serious chronic disease. Rheumatology rounds.* St. Joe's Hospital. Hamilton, Canada. May 15, 2019.

67. *Osteoporosis therapies: melody or harmony?* Osteoporosis rounds. University Health Networks. Toronto, Canada. May 16, 2019
68. *Long-term treatment of postmenopausal osteoporosis.* Virtual oral presentation at a luncheon symposium on October 30, 2020 during the 17th Asia-Oceania Congress of Endocrinology and the 8th Seoul International Congress of Endocrinology and Metabolism (AOCE-SICEM 2020).
69. *Sclerostin antibody: reaching harmony.* Virtual oral presentation at a luncheon symposium on October 31, 2020 during the 17th Asia-Oceania Congress of Endocrinology and the 8th Seoul International Congress of Endocrinology and Metabolism (AOCE-SICEM 2020)
70. *Defining vertebral fractures and why it matters?* Virtual oral presentation to the Bone Health ECHO Program on November 1, 2022.

## MEMBERSHIPS

American Society for Bone and Mineral Research  
 Association des médecins rhumatologues du Québec  
 Canadian Rheumatology Association  
 European Calcified Tissue Society  
 Fédération des Médecins Spécialistes du Québec  
 International Bone and Mineral Society  
 International Society for Clinical Densitometry  
 Le Collège des médecins du Québec  
 Royal College of Physicians and Surgeons of Canada  
 The Paget Foundation (US)

## PUBLICATIONS

### Book Chapters

1. Roux S, Debiais F, **Brown JP**. *Malignant Bone Diseases (multiple myeloma and metastatic bone disease)* (pp. 728-746). In J.W.J. Bijlsma (Ed.), G. Burmeister, J. Da Silva, K.L. Faarvang, E. Hachulla & X. Mariette (Co-Eds.), EULAR Compendium on Rheumatic Diseases. Affinity Editions, London 2009.
2. Michou L, **Brown JP**. (2016). *Paget's Disease of Bone: Prognosis and Complications*. In *Advances in Pathobiology and Management of Paget's Disease of Bone*. p. 105-118. Elsevier.
3. Michou L, **Brown JP**. (2019). *Paget's disease of Bone*. In Marc Hochberg (Ed) Alan Silman, Ellen Gravallesse, Josef Smolen, Michael Weinblatt, Michael Weisman (Co-Ed.) *Rheumatology, 2-Volume Set, 7<sup>th</sup> Edition*, Elsevier, 8<sup>th</sup> January 2018. eBook ISBN 9780702073069. Hardcover ISBN 9780702068652.
4. Lentle BC, Leslie WD, Hammond I, Ward LM, **Brown JP**, Prior JC, Munk PL, Konji VN, Wong AKO, Goltzman D (2021). *Chapter 1: The Radiology of Osteoporosis*. In Leon V. Berhardt (Ed.) *Advances in Medicine and Biology*. Volume 185. Nova. August 27, 2021. ISBN: 978-1-68507-021-2
5. Michou L, **Brown JP**. (2023). *Paget's disease of Bone*. Section 18, Chapter 205, p. 1803-1810. In Marc C. Hochberg (Ed), Ellen M. Gravallesse, Josef S. Smolen, Désirée van der Heijde, Michael E. Weinblatt, Michael H. Weisman (Co-Ed.) *Rheumatology, 2-Volume Set, 8<sup>th</sup> Edition*, Elsevier, October 11, 2022. eBook ISBN: 978-0-7020-8134-7 Hardcover ISBN 978-0-7020-8133-0

## Published Refereed Papers

1. Ménard HA, De Medicis R, Lussier A, **Brown J** (1981) *Charcot-Leyden crystals in synovial fluid eosinophils*. *Arthritis & Rheumatism*; 24 : 1591.
2. **Brown J**, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ (1984). *Serum bone GLA-protein a specific marker for bone formation in postmenopausal osteoporosis*. *Lancet*; i : 1091-3.
3. Delmas PD, **Brown JP**, Malaval L, Edouard C, Meunier PJ (1984). *Serum bone GLA-protein (BGP) compared to bone histomorphometry in postmenopausal osteoporosis serum BGP can predict histological heterogeneity*. In *Endocrine control of bone and calcium metabolism*. Cohn DV et coll eds., Elsevier Science Publisher BV: 73-7.
4. **Brown JP**, Rola-Pleszczynski M, Ménard HA (1986). *Eosinophilic synovitis clinical observations on a newly recognized subset of patients with dermatographism*. *Arthritis & Rheumatism*; 29(9): 1147-51.
5. **Brown JP**, Delmas PD, Arlot M, Meunier PJ (1987). *Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis*. *J Clin Endocrinol Metab* ; 64(5) : 954-9.
6. **Brown JP**, Kylstra JW, Bekker PJ, Axelrod DW, Siris ES, Altman RD, Singer FR (1994). *Risedronate in Paget's disease : preliminary results of a multicenter study*. *Semin Arthritis Rheum*; 23(4):272.
7. Boulet LP, Giguère MC, Milot J, **Brown J** (1994). *Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism*. *J. Allergy Clin Immunol*; 94(5): 796-803.
8. Adachi JD, Bensen WG, **Brown J**, Hanley D, Hodsman A, Josse R, Kendler D, Olszynski W, Ste-Marie L-G, Tenenhouse A, Chines A (1997). *Intermittent cyclical etidronate therapy in the prevention of corticosteroid-induced osteoporosis*. *N Engl J Med*; 337(6): 382-387.
9. Siris ES, Chines AA, Altman RD, **Brown JP**, Johnston CC Jr., Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ (1998). *Risedronate in the treatment of Paget's disease of bone : an open label, multicenter study*. *J Bone Miner Res*; 13: 1032-1038.
10. Saag KG, Emkey R, Schnitzer TJ, **Brown JP**, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG, Lane N, Correa-Rotter R, Yanover M, Westhovens R, Epstein S, Adachi JD, Poubelle P, Melo-Gomes J, Rodriguez-Portales JA and the Glucocorticoid-induced osteoporosis intervention study group (1998). *Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis*. *N Engl J Med*; 339 (5): 292-299.
11. Boulet LP, Milot J, Gagnon L, Poubelle P, **Brown JP** (1999). *Long-term influence of inhaled corticosteroids on bone metabolism and density are biological markers predictors of bone loss?* *Am J Respir Crit Care Med*; 159(3): 833-844.
12. **Brown JP**, Hosking DJ, Ste-Marie L-G, Johnston CC Jr, Reginster J-Y, Ryan WG, Johnson TD, Bekker PJ (1999). *Risedronate, a highly effective, short-term oral treatment for Paget's disease : a dose response study*. *Calcified Tissue International*; 64: 93-99.
13. **Brown JP**, Raymond V, Morissette J (1999). *Genetic epidemiology of Paget's disease of bone in eastern Québec*. *Proceedings of the National Association for the relief of Paget's disease International Symposium*, Oxford, UK, July 15-17, 1998. *Bone*; 24 (5) Suppl.

14. Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, **Brown JP**, Prior JC, Rittmaster RS (1999). *The Canadian Multicentre Osteoporosis Study (CaMos): Background, rationale, methods*. Canadian Journal on Aging; 18 (3): 376-387.
15. Miller PD, **Brown JP**, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ for the Paget's Risedronate/Etidronate Study (PRES) Group (1999). *A comparative trial of risedronate versus etidronate in the treatment of patients with Paget's disease of bone*. Am J Med; 106: 513-520.
16. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, **Brown JP**, Eriksen EF, Miller PD (1999). *The effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a double-blind, randomized, placebo-controlled trial*. JAMA; 282 (14): 1344-1352.
17. Adachi JD, Olszynski WP, Hanley DA, Hodsmann AB, Kendler DL, Siminoski KG, **Brown J**, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS, Blocka KL, Pollock AP, Sibley J (2000). *Management of corticosteroid-induced osteoporosis*. Semin Arthritis Rheum; 29(4): 228-251.
18. **Brown JP**, Chines AA, Myers WR, Eusebio RA, Ritter-Hrncirik C, Hayes CW (2000). *Improvement of pagetic bone lesions with risedronate treatment: a radiologic study*. Bone; 26(3): 263-267.
19. Crilly RG, Sebaldt RJ, Hodsmann AB, Adachi JD, **Brown JP**, Goldsmith CH, Hanley DA, Olszynski WO, Ste-Marie LG, Stephenson GF (2000). *Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis*. Osteoporos Int. 2000;11(7):607-14.
20. Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C, Joseph L, **Brown JP**, Murray TM, Adachi JD, Hanley DA, Papadimitropoulos E (2000). *Canadian normative data for the SF-36 health survey*. Canadian Multicentre Osteoporosis Study Research Group. CMAJ; 163(3): 265-271.
21. Morissette J, Corn elis F, **Brown J** (2000). * pid miologie g n tique et g n tique mol culaire de la maladie osseuse de Paget*. L'actualit  rhumatologique 2000, Elsevier, Paris. Pages 293-299.
22. Jackson SA, Tenenhouse A, Robertson L and the **CaMos Study Group** (2000) *Vertebral Fracture Definition from Population-Based Data: Preliminary Results from the Canadian Multicenter Osteoporosis Study (CaMos)*. Osteoporos Int 11(8):680-687.
23. Tenenhouse A, Joseph L, Kreiger N, Poliquin S, Murray TM, Blondeau L, Berger C, Hanley DA, Prior JC and the **CaMos Research Group** (2000) *Estimation of the Prevalence of Low Bone Density in Canadian Women and Men Using a Population-Specific DXA Reference Standard: The Canadian Multicentre Osteoporosis Study (CaMos)*. Osteoporos Int 11(10):897-904.
24. Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannadis G, Cawley MID, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, **Brown JP**, Geusens P (2000). *A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid-induced bone loss*. J Rheumatol; 27(10): 2424-2431.
25. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, **Brown J**, Barton I, Chines AA (2000). *Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy*. Calcif Tissue Int; 67(4): 277-285.

26. Ungar WJ, Josse R, Lee S, Ryan N, Adachi R, Hanley D, **Brown J**, Breton MC (2000). *The Canadian SCORE questionnaire: optimizing the use of technology for low bone density assessment. Simple Calculated Osteoporosis Risk Estimate.* J Clin Densitom; 3(3): 269-280.
27. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane, NE, Kaufman J-M, Poubelle PEE, Hawkins F, Corea-Rotter R, Menkes C-J, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, **Brown J**, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MOR, Siminoski KG, Nevitt MC, Sharp JT, Malice M-P, Dumortier T, Czachu M, Carofano W, Daifotis A (2001). *Two-Year Effects of Alendronate on Bone Mineral Density and Vertebral Fracture in Patients Receiving Glucocorticoids : A Randomized, Double-Blind, Placebo-Controlled Extension Trial.* Arthritis & Rheumatism; 44(1): 202-211.
28. Drake WM, Kendler DL, **Brown JP** (2001). *Consensus Statement on the Modern Therapy of Paget's Disease of Bone from a Western Osteoporosis Alliance Symposium.* Clinical Therapeutics; 23 (4): 620-626.
29. **Brown JP**, Fortier M, Khan A, Rowe T (2001). *An evidence-based review of the management of osteoporosis.* J Obstet Gynaecol Can; April Suppl: 1-7.
30. Cadarette SM, Jaglal SB, Murray TM, McIsaac WJ, Joseph L, **Brown JP**, for the Canadian Multicentre Osteoporosis Study (CaMos) (2001). *Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry.* JAMA; 286 (1): 57-63.
31. **Brown JP**, Olszynski WP, Hodsmann A, Bensen WG, Tenenhouse A, Anastassiades TP, Ste-Marie L-G, Kendler DL, Hanley DA, Josse R, Hanly JG, Lentle B, Jovaisas A, Ioannidis G, Stephenson GF, Barton I, Pack S, Chines A, Dias R, Adachi JD (2001). *Positive effect of etidronate therapy is maintained after drug terminated in patients using corticosteroids.* J Clin Densitom; 4(4): 363-71.
32. Laurin N, **Brown JP**, Lemainque A, Duchesne A, Huot D, Lacourcière Y, Drapeau G, Verreault J, Raymond V, Morissette J (2001). *Paget's disease of bone: Mapping of two loci at 5q35-qter and 5q31.* Amer J Human Genetics; 69(3): 528-543.
33. Reid IE, **Brown JP**, Burckhardt P, Zebulun H, Richardson P, Trechsel U, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Meunier P (2002). *Intravenous zoledronic acid in postmenopausal osteoporosis – Dose and dose-interval effects.* New Eng J Med; 346(9):653-661.
34. Hopman W, Berger C, Joseph L, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, **Brown J**, Murray T, Adachi JD, Hanley D, Papadimitropoulos M, CaMos Research Group (2002) *Is There Regional Variation in the SF-36 Scores of Canadian Adults?* Can J Public Health 93(3): 233-237.
35. Drake WD, **Brown JP**, Banville C, Kendler D L (2002). *Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal women.* Osteoporos Int; 13(3):249-256.
36. Khan AA, **Brown J**, Faulkner K, Kendler D, Lentle B, Leslie W, Miller PD, Nicholson L, Olszynski WP, Watts NB; Canadian Panel of International Society for Clinical Densitometry (2002). *Standards and guidelines for performing central dual X-ray densitometry from the Canadian Panel of International Society for Clinical Densitometry.* J Clin Densitom; 5(4): 435-45.
37. Laurin N, **Brown JP**, Morissette J, Raymond V (2002). *Recurrent Mutation of the Gene Encoding sequestosome 1 (SQSTM1/p62) in Paget Disease of Bone.* Am J Hum Genet; 70:1582-1588.

38. **Brown JP**, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R. (2002). *The Efficacy and Tolerability of Risedronate Once-a-Week for the Treatment of Postmenopausal Osteoporosis*. *Calcif Tissue Int*; 71(2):103-111.
39. Adachi JD, Ioannidis G, Olszynski WP, **Brown JP**, Hanley DA, Sebaldt RJ, Petrie A, Tenenhouse A, Stephenson GF, Papaionnou A, Guyatt GH, Goldsmith CH (2002). *The impact of incident vertebral and non-vertebral fractures related quality of life in postmenopausal women*. *BMC Musculoskelet Disord*; 3: 11.
40. Olszynski WP, Ioannidis G, Sebaldt RJ, Hanley DA, Petrie A, **Brown JP**, Josse RG, Murray TM, Goldsmith CH, Stephenson GF, Papaioannou A, Adachi JD; Canadian Database For Osteoporosis and Osteopenia (2002). *The association between iliocostal distance and the number of vertebral and non-vertebral fractures in women and men registered in the Canadian Database For Osteoporosis and Osteopenia (CANDOO)*. *BMC Musculoskelet Disord*; 3: 22.
41. **Brown JP**, Josse RG (2002). *2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada*. *Can Med Assoc J*; 167(10 suppl): S1-S34.
42. Khan AA, **Brown JP**, Kendler DL, Leslie WD, Lentle BC, Lewiecki EM, Miller PD, Nicholson RL, Olszynski WP, Watts NB (2002). *The 2002 Canadian bone densitometry recommendations: take-home messages*. *Can Med Assoc J*; 167(10): 1141-1145.
43. **Brown JP**, Josse RG (2003). *Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'ostéoporose au Canada*. *JAMC* ; 168(6 suppl) : SF1-SF-38.
44. Hanley DA, **Brown JP**, Tenenhouse A, Olszynski WP, Ioannidis G, Berger C, Prior JC, Pickard L, Murray TM, Anastassiades T, Kirkland S, Joyce C, Joseph L, Papaioannou A, Jackson SA, Poliquin S, Adachi JD and the Canadian Multicentre Osteoporosis Study Research Group (2003). *Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study*. *J Bone Miner Res*; 18(4): 784-90.
45. Sawka AM, Adachi JD, Ioannidis G, Olszynski WP, **Brown JP**, Hanley DA, Murray T, Josse R, Sebaldt RJ, Petrie A, Tenenhouse A, Papaioannou A, Goldsmith CH (2003). *What predicts early fracture or bone loss on bisphosphonate therapy?* *J Clin Densitom*; 6(4): 315-322.
46. Watts NB, Lindsay R, Li Z, Kasibhatla C, **Brown J** (2003). *Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate*. *Osteoporos Int*; 14(5): 437-441.
47. Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, **Brown J**, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH. (2003) *Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database*. *Osteoporos Int*; 14(10): 808-13.
48. Adachi JD, Ioannidis G, Pickard L, Berger C, Prior JC, Joseph L, Hanley D, Olszynski WP, Murray TM, Anastassiades T, Hopman W, **Brown JP**, Kirkland S, Joyce C, Papaioannou A, Poliquin S, Tenenhouse A, Papadimitropoulos EA, and the Canadian Multicentre Osteoporosis Study (CaMOS) Research Group (2003). *The Association Between Osteoporotic Fractures and Health Related Quality of Life as Measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMOS)*. *Osteoporos Int*; 14(11):895-904.

49. VanDenKerkhof EG, Hopman WM, Towheed TE, Anastassiades TP, Goldstein DH and the **Canadian Multicentre Osteoporosis Study Research Group** (2003) *The impact of sampling and measurement on the prevalence of self-reported pain in Canada*. Pain Res Manage; 8(3):157-163.
50. Olszynski WP, Davison KS, Adachi JD, **Brown JP**, Cummings SR, Hanley DA, Harris ST, Hodsmann A, Kendler D, McClung M, Miller PD, Yuen CK (2004). *Osteoporosis in Men : Epidemiology, Diagnosis, Prevention and Treatment*. Clinical Therapeutics; 26(1): 15-28.
51. Duran A, Serrano M, Leitges, M, Flores JM, Picard S, **Brown JP**, Moscat J, Idaz-Meco MT (2004). *The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis*. Dev Cell; 6(2): 303-309.
52. Picard D, **Brown JP**, Rosenthal L, Couturier M, Lévesque J, Dumont M, Ste-Marie LG, Tenenhouse A, Dodin S (2004). *Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurement*. J Clin Densitom; 7(1): 111-118.
53. Khan AA, Bachrach L, **Brown JP**, Hanley DA, Josse RG, Kendler DL, Leib ES, Lentle BC, Leslie WD, Lewiecki EM, Miller PD, Nicholson RL, O'Brien C, Olszynski WP, Thériault MY, Watts NB and the Canadian Panel of the International Society of Clinical Densitometry (2004). *Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children*. J Clin Densitom; 7(1): 51-64.
54. Hopman WP, Berger C, Joseph L, Towheed T, vandenKerkhof E, Anastassiades T, Cranney A, Adachi JD, Ioannidis G, Poliquin S, **Brown JP**, Murray TM, Hanley DA, Papadimitropoulos EA, Tenenhouse A and the CaMos Research Group (2004). *Stability of Normative Data for the SF-36: Results of a Three-Year Prospective Study in Middle-Aged Canadians*. Can J Public Health; 95(5): 387-391.
55. Brifka JK, Zacher J, **Brown JP**, Serriolo B, Lee A, Moore A, Gimona A (2004). *Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand*. Clin Exp Rheumatol; 22:589-596.
56. Sawka AM, Adachi JD, Papaioannou A, Thabane L, Ioannidis G, Davison KS, Olszynski WP, **Brown JP**, Hanley, DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH (2004). *Are there differences Between Men and Women Prescribed Bisphosphonate Therapy in Canadian Subspecialty Osteoporosis Practices?* J Rheumatol; 31(10):1993-1995.
57. Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, **Brown JP** (2004). *Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis*. Curr Med Res Opin;20(5):757-64
58. Sawka AM, Ioannidis G, Papaioannou A, Thabane L, Olszynski WP, **Brown JP**, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH, Boulos P, Kouroukis T, Adachi JD (2005). *Are oral bisphosphonates effective in improving lumbar spine density in breast cancer survivors with osteopenia or osteoporosis?* J Obstet Gynaecol Can; 27(8): 759-764.
59. Papaioannou A, Kennedy CC, Ioannidis G, **Brown JP**, Pathak A, Hanley DA, Josse RG, Sebaldt RJ, Olszynski WP, Tenenhouse A, Murray TM, Petrie A, Goldsmith CH, Adachi JD (2005) *Determinants of health-related quality of life in women with vertebral fractures*. Osteoporos Int.;17(3):355-63
60. Sawka AM, Thabane L, Papaioannou A, Gafni A, Ioannidis G, Papadimitropoulos EA, Hopman WM, Cranney A, Hanley DA, Pickard L, Adachi JD, **CaMos Investigators**. *Health-related quality of life measurements*



*in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos)*. Osteoporos Int; 16:1836-40

61. Bensen R, Adachi JD, Papaioannou A, Ioannidis G, Olszynski WP, Sebaldt RJ, Murray TM, Josse RG, **Brown JP**, Hanley DA, Petrie A, Puglia M, Goldsmith CH, Bensen W (2005). *Evaluation of easily measured risk factors in the prediction of osteoporotic fractures*. BMC Musculoskelet Disord 6: 47.
62. Papaioannou A, Joseph L, Ioannidis G, Berger C, Anastassiades T, **Brown JP**, Hanley DA, Hopman W, Josse RG, Kirkland S, Murray TM, Olszynski WP, Picakrd L, Prior JC, Siminoski K, Adachi JD (2005). *Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos)*. Osteoporos Int; 16(5):568-578.
63. Siminoski K, Leslie WD, Frame H, Hodsman A, Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G, **Brown JP** (2005). *Recommendations for bone mineral density reporting in Canada*. Can Assoc Radiol J; 56:178-88.
64. Reid IR, Miller P, Lyles K, Fraser W, **Brown JP**, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005). *Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease*. N Engl J Med; 353(9): 898-908.
65. Berenbaum F, Grifka J, **Brown JP**, Zacher J, Moore A, Krammer G, Dutta D, Sloan VS (2005). *Efficacy of lumiracoxib in osteoarthritis: a review of nine studies*. J Int Med Res; 33(1): 21-41.
66. Olszynski WP, Davison KS, Ioannidis G, **Brown JP**, Hanley DA, Josse RG, Murray TM, Papaioannou A, Sebaldt RJ, Tenenhouse AM, Petrie A, Goldsmith CH, Adachi JD (2005). *Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study*. Osteoporos Int.;17(2):217-24
67. Sawka AM, Papaioannou A, Josse RG, Murray TM, Ioannidis G, Hanley DA, Prior JC, Thabane L, Papadimitropoulos EA, Gafni A, Pickard L, Anastassiades T, Kirkland S, Adachi JD, **The CaMos Research Group**. *What is the number of older Canadians needed to screen by measurement of bone density to detect an undiagnosed case of osteoporosis? a population-based study from CaMos*. J Clin Densitom; 9:413-8
68. Papaioannou A, Kennedy CC, Ioannidis G, **Brown JP**, Pathak A, Hanley DA, Josse RG, Sebaldt RJ, Olszynski WP, Tenenhouse A, Murray TM, Petrie A, Goldsmith CH, Adachi JD (2006). *Determinants of health-related quality of life in women with vertebral fractures*. Osteoporos Int; 17(3): 355-63.
69. Hopman WM, Berger C, Joseph L, Towheed T, VandenKerkhof E, Anastassiades T, Adachi JD, Ioannidis G, **Brown JP**, Hanley DA, Papadimitropoulos EA, CaMos Research Group (2006). *The natural progression of health-related quality of life: results of a five-year prospective study of SF-36 scores in a normative population*. Qual Life Res; 15(3): 527-36.
70. **Brown JP**, Fortier M, Frame H, Lalonde A, Papaioannou A, Senikas V, Yuen CK (2006). *Canadian consensus conference on osteoporosis, 2006 update*. J Obstet Gynaecol Can; 28(2, suppl 1): S95-S112.
71. Khan AA, Hanley DA, Bilezikian JP, Binkley N, **Brown JP**, Hodsman AB, Josse RG, Kendler DL, Lewiecki EM, Miler PD, Olszynski WP, Petak SM, Syed ZA, Theriault D, Watts NB, Canadian Panel of the International Society for Clinical Densitometry (2006). *Standards for performing DXA in individuals with secondary causes of osteoporosis*. J Clin Densitom; 9(1): 47-57.
72. Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman AB, Josse R, Kaiser S, Olszynski WP, Papaioannou A, Ste-Marie LG, Kendler DL, Tenenhouse A, **Brown JP** (2006). *The effects of*

- antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future.* Semin Arthritis Rheum; 36(1): 10-21.
73. Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsmann AB, Josse R, Kaiser S, Olszynski WP, Papaioannou A, Ste-Marie LG, Kendler DL, Tenenhouse A, **Brown JP** (2006). *Bone strength: the whole is greater than the sum of its parts.* Semin Arthritis Rheum; 36(1): 22-31.
  74. Diaz-González F, Alten RHE, Bensen WG, **Brown JP**, Sibley JT, Dougados M, Bombardiere S, Durez P, de Miguel G, Ortiz P, Staab A, Sigmund R, Salin L, Leledy C, Plmar SH (2006). *Clinical Trial of a Leukotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis.* Ann Rheum Dis; 66: 628-632.
  75. Morissette J, Laurin N, **Brown JP** (2006). *Sequestosome 1: Mutation Frequencies, Haplotypes, and Phenotypes in Familial Paget's Disease of Bone.* J Bone Miner Res; 21(Suppl. 2): 38-44.
  76. Hosking D, Lyles K, **Brown JP**, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR. *Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.* J Bone Miner Res.; 22:142-8
  77. Richards JB, Leslie WD, Joseph L, Siminoski K, Hanley DA, Adachi JD, **Brown JP**, Morin S, Papaioannou A, Josse RG, Prior JC, Davison KS, Tenenhouse A, Goltzman D, CaMos Study Group. *Changes to osteoporosis prevalence according to method of risk assessment.* J Bone Miner Res.; 22:228-34
  78. Khan AA, Hodsmann AB, Papaioannou A, Kendler D, **Brown JP**, Olszynski WP (2007). *Management of osteoporosis in men: an update and case example.* CMAJ; 176(3): 345-348.
  79. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, **Brown J**, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Güer C, Goltzman D, Hans D, Krieg M-A, La Croix A, McCloskey E, Mellstrom D, Melton LJ III, Pols H, Reeve J, Sanders K, Schott A-M, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007). *The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.* Osteoporos Int; 18: 1033-1046.
  80. Lentle BC, **Brown JP**, Khan A, Leslie WD, Levesque J, Lyons DJ, Siminoski K, Tarulli G, Josse RG, Hodsmann A (2007). *Recognizing and Reporting Vertebral Fractures: Reducing the Risk of Future Osteoporotic Fractures.* Can Assoc Radiol J; 58(1): 27-36.
  81. Siminoski K, Leslie WD, Frame H, Hodsmann A, Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G, **Brown JP** (2007). *Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment.* J Clin Densitom; 10(2):120-3.
  82. Leslie WD, Siminoski K, **Brown JP** (2007). *Comparative effects of densitometric and absolute fracture risk classification systems on projected intervention rates in postmenopausal women.* J Clin Densitom; 10(2):124-31.
  83. Devogelaer JP, **Brown JP**, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P (2007). *Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.* Osteoporos Int; 18(9): 1211-8.
  84. Hopman WM, Berger C, Joseph L, Barr SI, Gao Y, Prior JC, Poliquin S, Towheed T, Anastassiades T, **CaMos Research Group**. *The association between body mass index and health-related quality of life: data from CaMos, a stratified population study.* Qual Life Res. 16:1595-603.

85. Hopman WM, Leroux C, Berger C, Joseph L, Barr SI, Prior JC, Harrison M, Poliquin S, Towheed T, Anastassiades T, Goltzman D, **CaMos Research Group**. *Changes in body mass index in Canadians over a five-year period: results of a prospective, population-based study*. BMC public health. 7:150.
86. Bessette L, Ste-Marie L-G, Jean S, Davison KS, Beaulieu M, Baranci M., Bessant J, **Brown JP** (2008). *The care gap in diagnosis and treatment of women with a fragility fracture*. Osteoporos Int; 19(1): 79-86
87. Bessette L, Ste-Marie L-G, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, **Brown JP** (2007). *Recognizing Osteoporosis and its Consequences in Quebec (ROCQ): Background, rationale, and methods of an anti-fracture patient health-management programme*. Contemporary Clinical Trials; 29: 194-210.
88. Josse RG, Hanley DA, Kendler D, Ste-Marie L-G, Adachi JD, **Brown J** (2007). *Diagnosis and treatment of Paget's disease of bone*. Clin Invest Med; 30(5): E210-E223.
89. Papaioannou A, Kennedy CC, Ioannidis G, Gao Y, Sawka AM, Goltzman D, Tenenhouse A, Pickard L, Olszynski WP, Davison KS, Kaiser S, Josse RG, Kreiger N, Hanley DA, Prior JC, **Brown JP**, Anastassiades T, Adachi JD, CaMos Research Group (2007). *The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study*. Osteoporosis Int; 19(4):581-7.
90. Adami S, San Martin J, Muñoz-Torres M, Econs M J, Xie L, Dalsky GP, McClung M, Felsenberg D, **Brown JP**, Brandi M L, Sipos A (2008). *Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis*. Osteoporos Int; 19(1):87-94.
91. Schellenberg R, Adachi JDR, Bowie D, **Brown J**, Guenther L, Kader T, Trope GE (2007). *Oral Corticosteroids in asthma: A review of benefits and risks*. Can Respir J; 14 (Suppl C): 1C-7C.
92. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP; Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators (2008) *Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate*. J Clin Endocrinol Metab.; 93(10):3785-93.
93. Langsetmo L, Hanley DA, Kreiger N, Jamal SA, Prior J, Adachi JD, Davison KS, Kovacs C, Anastassiades T, Tenenhouse A, Goltzman D; **CaMos Research Group** (2008) *Geographic variation of bone mineral density and selected risk factors for prediction of incident fracture among Canadians 50 and older*. Bone; 43(4):672-8.
94. Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, Kreiger N, Tenenhouse A, Goltzman D; **Canadian Multicentre Osteoporosis Study Research Group**. (2008) *Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents*. CMAJ. 2008 Jun 17;178(13):1660-8.
95. Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, **Brown J**, Evans AW, Rios L, Compston JE; Canadian Association of Oral and Maxillofacial Surgeons. (2008) *Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw*. J Rheumatol.; 35(7):1391-7. Erratum in: J Rheumatol.; 35(8):1688. J Rheumatol.; 35(10):2084.
96. Picard S, Lapointe NP, **Brown JP**, Guertin PA (2008). *Histomorphometric and densitometric changes in the femora of spinal cord transected mice*. Anat Rec (Hoboken); 291(3):303-7.

97. Saad F, Adachi JD, **Brown JP**, Canning LA, Gelmon KA, Josse RG, Pritchard KI (2008). *Cancer treatment induced bone loss in breast and prostate cancer*. J Clin Oncol; 183(4):597-606.
98. Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L, **Brown JP**, Josse RG, Kaiser S, Anastassiades T, Goltzman D, Papadimitropoulos M, Tenenhouse A, Prior JC, Olszynski WP, Adachi JD, for the CaMos Study Group (2009). *The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study*. Osteoporos Int; 20(5):703-714.
99. **Brown JP**, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009). *Comparison of the Effect of Denosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. ; J Bone Miner Res; 24(1):153-61.
100. Papaioannou A, Kennedy CC, Cranney A, Hawker G, **Brown JP**, Kaiser SM, Leslie WD, O'Brien CJM, Sawka AM, Khan A, Siminoski K, Tarulli G, Webster D, McGowan J, Adachi JD (2009). *Risk Factors for low BMD in healthy men age 50 years or older: a systematic review*. Osteoporos Int; 20(4):507-518.
101. Chen P, Kregge JH, Adachi JD, Prior JC, Tenenhouse A, **Brown JP**, Papadimitropoulos E, Kreiger N, Olszynski WP, Josse RG, Goltzman D; CaMOS Research Group (2009) *Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk*. J Bone Miner Res.;24(3):495-502
102. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; **PEARL Study Investigators** (2010) *Lasofexifene in postmenopausal women with osteoporosis*. N Engl J Med. 362(8):686-96.
103. Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse RG, Prior JC, Kreiger N, Tenenhouse A, Goltzman D; **CaMos Research Group**. (2009) *Association between change in BMD and fragility fracture in women and men*. J Bone Miner Res; 24(2):361-70.
104. Langsetmo LA, Morin S, Richards JB, Davison KS, Olszynski WP, Prior JC, Josse R, Goltzman D; **CaMos Research Group**. (2009) *Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of women*. Osteoporos Int; 20(2):283-90.
105. Guilbert ER, **Brown JP**, Kaunitz AM, Wagner M-S, Bérubé J, Charbonneau L, Francoeur D, Gilbert A, Gilbert F, Roy G, Senikas V, Jacob R, Morin R (2009). *The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health*. Contraception; 79(3):167-77.
106. Hopman WM, Berger C, Joseph L, Towheed T, Prior JC, Anastassiades T, Poliquin S, Zhou W, Adachi JD, Hanley DA, Papadimitropoulos EA, Tenenhouse A, **CaMos Research Group** (2009) *Health-related quality of life in Canadian adolescents and young adults: normative data using the SF-36*. Jcan J Public Health; 100:449-52.
107. Khan A, Sandor G, Dore E, Archie M, Amin F, Peters E, Hanley D, Chaundhry S, Rios L, Lentle B, Dempster D, Glorieux F, Neville A, Talwar R, Paul T, Clokie C, Khosla S, Josse R, Sutherland S, Lam D, Carmichael R, Blanas N, Kendler D, Patek S, Georges L-G, **Brown J**, Evans A, Compston J (2009). *Bisphosphonate-associated Osteonecrosis of the Jaw*. J Rheumatol; 36(3):478-490.

108. Ste-Marie L-G, **Brown JP**, Beary JF, Matzkin E, Lynn M, Darbie LM, Burgio DE, Racewicz AJ (2009) *Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study* Clin Ther; 31(2) 272-85.
109. **Brown JP**, Albert C, Bassam NA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-Wauchope A, Douville P, Hanley DA, Jamal SA, Josse R, Kaiser S, Krahn J, Krause R, Kremer R, Lapage R, Letendre E, Morin S, Ooi, DS, Papaioannou A, Ste-Marie L-G (2009) *Bone turnover markers in the management of postmenopausal osteoporosis*. Clinical Biochemistry; 42 (10-11): 929-942.
110. Fenton TR, Eliasziw M, Lyon AW, Tough SC, **Brown JP**, Hanley DA. (2009) *Low 5-year stability of within-patient ion excretion and urine pH in fasting-morning-urine specimens*. Nutr Res.; 29(5):320-6.
111. Roux S, **Brown JP** (2009) *Osteoclast apoptosis in rheumatic diseases (Osteoporosis, Paget's Disease of Bone, and Rheumatoid Arthritis)*. Current Reviews in Rheumatology; 5:98-110.
112. Leslie WD, O'Donnell S, Jean S, Lagacé C, Walsh P, Bancej C, Morin S, Hanley DA, Papaioannou A; **Osteoporosis Surveillance Expert Working Group** (2009) *Trends in hip fracture rates in Canada*. JAMA.;302(8):883-9
113. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial (2009) *Denosumab for prevention of fractures in postmenopausal women with osteoporosis* N Engl J Med.; 361(8):756-65
114. Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; **HORIZON Pivotal Fracture Trial** (2009) *Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density*. J Clin Endocrinol Metab.; 94(9):3215-25
115. Langsetmo L, Goltzman D, Kovacs CS, Adachi JD, Hanley DA, Kreiger N, Josse R, Papaioannou A, Olszynski WP, Jamal SA; **CaMos Research Group**. (2009) *Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD*. J Bone Miner Res.; 24(9):1515-22.
116. Chamoux E, Couture J, Bisson M, Morissette J, **Brown JP**, Roux S. (2009) *The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts*. Mol Endocrinol.; 23(10):1668-80.
117. Bessette L, Jean S, Davison KS, Roy S, Ste-Marie L-G, **Brown JP**. (2009). *Factors Influencing the Treatment of Osteoporosis Following Fragility Fracture*. Osteoporos Int.; 20(11):1911-9.
118. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, **Brown JP**, Josse RG, Hanley DA, Adachi JD (2009). *Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study*. CMAJ. 2009; 181(5):265-71.
119. Jamal S.A., Swan V.J.D., **Brown J.**, Hanley D.A., Prior J.C., Papaioannou A., Langsetmo L., Josse R.G. for the Canadian Multicentre Osteoporosis Study Research Group (2010) *Kidney Function and Rate of Bone Loss at the Hip and Spine: The Canadian Multicentre Osteoporosis Study*. Am J Kidney Dis. 55(2):291-9.
120. **Brown J** (2009). *Metabolic bone diseases: Treating Paget disease of bone: when matters more than how* Nature Review Rheumatology. 5(12):663-665.

121. Leslie WD, O'Donnell S, Lagacé C, Walsh P, Bancej C, Jean S, Siminoski K, Kaiser S, Kendler DL, Jaglal S; **Osteoporosis Surveillance Expert Working Group** (2009) *Population-based Canadian hip fracture rates with international comparisons*. *Osteoporos Int.* 2010 Aug;21(8):1317-22.
122. Kendler DL, Roux C, Benhamou C-L, **Brown JP**, Lillestol M, Siddhanti S, Man H-S, San Martin J, Bone HG (2010) *Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning from Alendronate Therapy*. *J Bone Miner Res.* 25(1):72-81.
123. Michou L, Chamoux E, Couture J, Morissette J, **Brown JP**, Roux S. (2010) *Gene expression profile in osteoclasts from patients with Paget's disease of bone*. *Bone.* 46(3):598-603
124. Watts NB, Klemens A, Wagner L, **Brown JP** (2010). *Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1 year compared with historical placebo*. *J Clin Densitom.* 13(1):56-62.
125. Langsetmo L, Poliquin S, Hanley DA, Prior JC, Barr S, Anastassiades T, Towheed T, Goltzman D, Kreiger N, CaMOS Research Group (2010) *Dietary patterns in Canadian men and women ages 25 and older: relationships to demographics, body mass index, and bone mineral density*. *BMC Musculoskeletal Disord.*;11:20
126. Fenton T.R., Elizasziw M, Tough S.C., Lyon A.W., **Brown J.P.**, Hanley D.A. (2010) *Low urine pH and acid excretion do not predict bone fractures or the loss of bone mineral density: a prospective cohort study*. *BMC Musculoskeletal Disord.* 11:88.
127. Genant H.K., Engelke K., Hanley D.A., **Brown J. P.**, Omizo M., Bone H. G., Kivitz A. J., Fuerst T., Wang H., Austin M., Libanati C. (2010) *Denosumab Improves Density and Strength Parameters as Measured by QCT of the Radius in Postmenopausal Women With Low Bone Mineral Density*. *Bone.* Jul; 47(1):131-9.
128. Christiansen C, Chesnut CH, Adachi JD, **Brown JP**, Fernandes CE, Kung AWC, Palacios S, Levine AB, Chines AA, Constantine GD (2010) *Safety of Bazedoxifene in a Randomized, Double-blind, Placebo- and Active-Controlled Phase 3 Study of Postmenopausal Women With Osteoporosis*. *BMC Musculoskeletal Disorders.* Jun 22; 11:130.
129. Orwoll E, Miller P.D., Adachi J.D., **Brown J.**, Adler R. A., Kendler D., Bucci-Rechtweg C., Readie A., Mesenbrink P., Weinstein R.S. (2010) *Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study*. *J Bone Miner Res.* 25(10):2239-50.
130. Langsetmo L, Leslie WD, Zhou W, Goltzman D, Kovacs CS, Prior J, Josse R, Olszynski WP, Davison S, Anastassiades T, Towheed T, Hanley DA, Kaiser S, Kreiger N for the **CaMos Research Group** (2010) *Using the same bone density reference database for men and women provides a simpler estimation of fracture risk*. *J Bone Miner Res.* 25(10):2108-14.
131. Zhou W, Langsetmo L, Berger C, Adachi JD, Papaioannou A, Ioannidis G, Webber C, Atkinson SA, Olszynski WP, **Brown JP**, Hanley DA, Josse R, Kreiger N, Prior JC, Kaiser S, Kirkland S, Goltzman D, Davison KS and the CaMos Research Group (2010). *Normative Bone Mineral Density Z-scores for Canadians aged 16-24 years: The Canadian Multicentre Osteoporosis Study*. *J Clin Densitom.* Jul-Sep; 13(3):267-76.
132. Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S, Kreiger N, Tenenhouse A, Davison KS, Josse RG, Prior JC, Hanley DA; **CaMos Research Group**. (2010) *Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis*. *J Bone Miner Res.* 25(9):1948-57.

133. de Villiers T.J., Chines A.A., Palacios S., Lips P., Sawicki A.Z., Levine A.B., Codreanu C., Kelepouris N., **Brown J.P.** (2011) *Safety and Tolerability of Bazedoxifene in Postmenopausal Women With Osteoporosis: Results of a 5-year, Randomized, Placebo-controlled Phase 3 Trial*. *Osteoporos Int.*;22(2):567-576.
134. Reid I., Miller P., **Brown J.P.**, Kendler D., Fahrleitner-Pammer A., Valter I., Maasalu K., Bolognese M., Woodson G., Bone H.G., Ding B., Wagman R.B., Ominsky M.S., San Martin J., Dempster D.W. (2010) *Effects of Denosumab on Bone Histomorphometry: The FREEDOM and STAND Studies*. *J Bone Miner Res.* 25(10):2256-65.
135. Langsetmo L, Hanley DA, Prior JC, Barr SI, Anastassiades T, Towheed T, Goltzman D, Morin S, Poliquin S, Kreiger N and the **CaMOS Research Group** (2011) *Dietary patterns and incident low-trauma fractures in postmenopausal women and men ages 50 and older: a population-based cohort study*. *Am J Clin Nutr.*;93(1):192-199.
136. Papaioannou A, Morin S, Cheung AM, Atkinson S, **Brown JP**, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD; Scientific Advisory Council of Osteoporosis Canada. (2010) *2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary*. *CMAJ* 182(17):1864-73. doi: 10.1503/cmaj.100771.
137. **Brown JP.** (2010) *Administration of annual oral high-dose vitamin D to community-dwelling older women in autumn and winter months increases risk of falls and fractures*. *Evid Based Med.* Dec; 15(6):175-6.
138. Chappell A.S., Desai D., Liu-Seifert H., Zhang S., Skljarevski V., Belenkov Y., **Brown J.P.** (2011) *A Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee*. *Pain Pract.* Jan-Feb; 11:33-41.
139. Fraser L-A, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi JD, Papaioannou A, Josse R, Kovacs CS, Olszynski WP, Towheed T, Hanley DA, Kaiser SM, Prior J, Jamal S, Kreiger N, Brown JP, Johansson H, Oden A, McCloskey E, Kanis JA, Leslie WD, and the **CaMos Research Group** (2010) *Fracture Prediction And Calibration Of A Canadian Frax® Tool: A Population-Based Report From Camos*. *Osteoporos Int.* 22(3):829-37.
140. Fraser L-A, Ioannidis G, Adachi JD, Pickard L, Kaiser SM, Prior J, Brown JP, Hanley DA, Olszynski WP, Anastassiades T, Jamal S, Josse R, Goltzman D, Papaioannou A, and the **CaMOS Research Group**. (2010) *Fragility Fractures and the Osteoporosis Care Gap in Women: the Canadian Multicentre Osteoporosis Study*. *Osteoporos Int.* 22(3):789-96.
141. Greene-Finestone LS, Berger C, De Groh M, Hanley DA, Hidiroglou N, Sarafin K, Poliquin S, Krieger J, Richards JB, Goltzman D, and the **CaMos Research Group** (2010) *25-hydroxyvitamin D in Canadian Adults: biological, environmental and behavioural correlates*. *Osteoporos Int.* 22(5):1389-99.
142. Langsetmo L, Nguyen TV, Nguyen ND, Kovacs CS, Prior JC, Center JR, Morin S, Josse RG, Adachi JD, Hanley DA, Eisman JA; **Canadian Multicentre Osteoporosis Study Research Group** (2011) *Independent external validation of nomograms for predicting risk of low-trauma fracture and hip fracture*. *CMAJ*;183(2):E107-14.
143. Michou L, **Brown JP.** (2011) *Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta*. *Joint Bone Spine.* Joint Bone Spine;78(3):252-8.
144. Jean S, Candas B, Belzile E, Morin S, Bessette L, Dodin S, **Brown JP.** (2011) *Algorithms can be used to identify fragility fracture cases in physician-claims databases*. *Osteoporos Int.*; 23(2):483-501.

145. Kurihara N, Hiruma Y, Yamana K, Michou L, Rousseau C, Morissette J, **Brown JP**, Roodman GD (2011). *Contributions of the Measles Virus Nucleocapsid Gene and the SQSTM1/p62P392L Mutation to Paget's Disease*. Cell Metab. 13(1):5-6.
146. Michou L, **Brown JP**. (2011) *Emerging strategies and therapies for the treatment of Paget's Disease of Bone*. Drug Des Devel Ther.; 5:225-39.
147. Siminoski K, O'Keeffe M, Lévesque J, Hanley D, **Brown JP**. (2011) *CAR Technical Standards for Bone Mineral Densitometry Reporting*. Can Assoc Radiol J.; 62(3):166-175.
148. Reid IR, Lyles K, Su G, **Brown J**, Walsh J, del Pino-Montes J Miller P; Fraser W, Cafoncelli S, Bucci-Rechtweg C, Hosking D. (2011) *A Single Infusion of Zoledronic Acid Produces Sustained Remissions in Paget's Disease - Data to 6.5 Years*. J Bone Miner Res; 26(9):2261-70.
149. **Brown JP**, Adachi JD, Kendler DL, Rigal R, Deutsch G, Lecrlerc J-M (2011) *A community-based clinical trial of Intra-Venous zoledronic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: the IVORY trial*. Contemp Clin Trials.; 32(5):741-6.
150. Kaffashian S, Raina P, Oremus M, Pickard L, Adachi J, Papadimitropoulos E, Papaioannou A; **CaMos Research Group**. (2011) *The burden of osteoporotic fractures beyond acute care: the Canadian Multicentre Osteoporosis Study (CaMos)*. Age Ageing; 40(5):602-7.
151. Leslie WD, Kovacs CS, Olszynski WP, Towheed T, Kaiser SM, Prior JC, Josse RG, Jamal SA, Kreiger N, Goltzman D; **CaMos Research Group** (2011) *Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX®: a population-based report from CAMOS*. J Clin Densitom.; 14(3):286-93.
152. Lentle B, Cheung AM, Hanley DA, Leslie W, Lyons D, Papaioannou A, Atkinson S, **Brown J**, Feldman S, Hodsman A, Jamal AS, Josse R, Kaiser S, Kvern B, Morin S, Siminoski K. (2011) *Osteoporosis Canada 2010 Guidelines for the Assessment of Fracture Risk*. Can Assoc Radiol J. 62(4):243-50.
153. **Brown JP**, Dempster DW, Ding D, Dent R, San Martin J, Grauer A, Wagman RB, Zanchetta J (2011) *Bone Remodeling in Postmenopausal Women who Discontinued Denosumab Treatment: Off-Treatment Biopsy Study*. J Bone Miner Res. 26(11):2737-44.
154. Michou L, Morissette J, Gagnon ER, Marquis A, Dellabadia M, **Brown JP**, Siris ES (2011) *Novel SQSTM1 mutations in patients with Paget's disease of bone in an unrelated multiethnic American population*. Bone; 48:456-60.
155. Langsetmo L, Hitchcock CL, Kingwell EJ, Davison KS, Berger C, Forsmo S, Zhou W, Kreiger N, Prior JC and **The Canadian Multicentre Osteoporosis Study Research Group** (2011) *Physical activity, body mass index and bone mineral density—associations in a prospective population-based cohort of women and men: The Canadian Multicentre Osteoporosis Study (CaMos)*. Bone; 50(1):401-8.
156. Bessette L, Davison KS, Jean S, Roy S, Ste-Marie L-G, **Brown JP** (2011) *The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized-controlled trial*. Osteoporos Int.; 22(12):2963-72.
157. Tarride J-E, Hopkins R, Leslie WD, Morin S, Adachi JD, Papaioannou A, Bessette L, **Brown JP**, Goeree R (2011) *The Burden of Illness of Osteoporosis in Canada*. Osteoporos Int. 23(11):2591-600.



158. McClung MR, Miller PD, **Brown JP**, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough L, Recker RR. (2012) *Efficacy and Safety of a Novel Delayed-release Risedronate 35 mg Once-a-week Tablet*. Osteoporos Int. 23:267–276
159. Watts N, Roux C, Modlin J, **Brown J**, Daniels A, Jackson S, Smith S, Zack D, Zhou L, Grauer A, Ferrari S (2012) *Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?* Osteoporos Int.; 23(1):327-37.
160. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, **Brown JP**, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román JA, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG. (2012) *Five Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension*. JBMR 27(3):694–701.
161. LeMessurier J, O'Donnell S, Walsh P, McRae L, Bancej C for the Osteoporosis Surveillance Expert Working Group (2012) *The development of national indicators for the surveillance of osteoporosis in Canada*. Chronic Diseases and Injuries in Canada; 32(2): 101-107.
162. Tarride J-E, Guo N, Hopkins R, Leslie WD, Morin S, Adachi JD, Papaioannou A, Bessette L, **Brown JP**, Goeree R (2012) *The burden of illness of osteoporosis in Canadian men*. J Bone Miner Res. 27(8):1830-8.
163. Bessette L, Jean S, Lapointe-Garant M-P, Belzile E, Davison KS, Ste-Marie L-G, **Brown JP**. (2012) *Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women*. Osteoporos Int. 23(6):1757-68.
164. Dempster DW, Zhou H, Recker RR, **Brown JP**, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Sudhaker Rao D, Miller PD, Woodson, III GC, Lindsay RL, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA (2012) *Skeletal Histomorphometry in Subjects On Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial*. J Clin Endocrinol Metab. 97(8):2799-808.
165. Michou L, Conceição N, Morissette J, Gagnon E, Miltenberger-Miltenyi G, Siris ES, **Brown JP**, Cancela ML (2012) *Genetic association study of UCMA/GRP and OPTN genes (PDB6 locus) with Paget's disease of bone*. Bone; 51(4):720-8.
166. **Brown JP**, Roux C, Törring O, Ho P-R, Beck Jensen J-E, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) *Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the FREEDOM Trial*. J Bone Miner Res.;28(4):746-52.
167. Jean S, Bessette L, Belzile EL, Davison KS, Candas B, Morin S, Dodin S, **Brown JP** (2013) *Direct medical resources utilization associated with osteoporosis-related non-vertebral fractures in postmenopausal women*. J Bone Miner Res; 28(2):360-71.
168. Teramachi J, Hiruma Y, Ishizuka S, Ishizuka H, **Brown JP**, Michou L, Cao H, Galson DL, Subler MA, Zhou H, Dempster DW, Windle JJ, Roodman GD, Kurihara N. (2013) *Role of ATF7-TAF12 interactions in the VDR hyper-sensitivity of osteoclast precursors in Paget's disease*. J Bone Miner Res. 2013 Jun; 28(6):1489-500.
169. McClung M, Zanchetta JR, Hoiseth A, Kendler DL, Yuen CK, **Brown JP**, Stonkus S, Goemaere S, Recknor C, Woodson GC, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C (2013) *Denosumab Densitometric Changes Assessed by QCT at the Spine and Hip in Postmenopausal Women With Osteoporosis*. J Clin Densitom. Apr-Jun; 16(2):250-6

170. Siminoski K, O'Keeffe M, **Brown JP**, Burrell S, Coupland D, Dumont M, Ganguli SN, Hanley DA, Law-Dillabough A, Lévesque J. (2013) *Canadian association of radiologists technical standards for bone mineral densitometry reporting*. *Can Assoc Radiol J.*; 64(4):281-94.
171. **Brown JP**, Boulay LJ (2013) *Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee*. *Ther Adv Musculoskelet Dis.*; 5(6):291-304
172. Krege JH, Wan X, Lentle BC, Berger C, Langsetmo L, Adachi JD, Prior JC, Tenenhouse A, **Brown JP**, Kreiger N, Olszynski WP, Josse RG, Goltzman D; CaMos Research Group. (2013) *Fracture risk prediction: importance of age, BMD and spine fracture status*. *Bonekey Rep.*; 2:404.
173. Cheung AM, Adachi JD, Hanley DA, Kendler DL, Davison KS, Josse R, **Brown JP**, St. Marie L-G, Kremer R, Erlandson MC, Dian L, Burghardt AJ, Boyd SK (2013) *High-Resolution Peripheral Quantitative Computed Tomography for the Assessment of Bone Strength and Structure: A Review by the Canadian Bone Strength Working Group*. *Curr Osteoporos Rep.* 11:136–146.
174. Jean S, O'Donnell S, Lagacé C, Walsh P, Bancej C, **Brown JP**, Morin S, Papaioannou A, Jaglal SB, Leslie WD (2013) *Trends in hip fracture rates in Canada: an age-period-cohort analysis*. *J Bone Miner Res.* 28(6):1283-9.
175. O'Donnell S and the **Canadian Chronic Disease Surveillance System (CCDSS) Osteoporosis Working Group** (2013) *Use of Administrative Data for National Surveillance of Osteoporosis and Related Fractures in Canada: Results from a Feasibility Study*. *Arch Osteoporos.*;8(1-2):143.
176. Langsetmo L, Kreiger N, Berger C, Hanley DA, Whiting S, Genest J, Hodsman A, Morin S, Kovacs CS, Jamal SA, Prior JC, Lentle B, **Brown JP**, Patel M, Anastasiades T, Towheed T, Goltzman D, and the CaMos Group. *Calcium and Vitamin D Intake and Mortality: Results from the Canadian Multi-centre Osteoporosis Study (CaMos)*. *J Clin Endocrinol Metab.*: 98(7):3010-8.
177. Hamilton CJ, Jamal SA, Beck TJ, Khaled AS, Adachi JD, **Brown JP**, Davison KS; the Canadian Multicentre Osteoporosis Study (CaMos) Research Group. (2013) *Evidence for impaired skeletal load adaptation among Canadian women with type 2 diabetes mellitus: Insight into the BMD and bone fragility paradox*. *Metabolism.* 2013 Oct;62(10):1401-5.
178. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, **Brown JP**, Cohen A, Kim H (2013) *A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy*. *Allergy Asthma Clin Immunol.*: 9(1):30
179. Olszynski WP, **Brown JP**, Adachi JD, Hanley DA, Ioannidis G, Davison KS and the CaMos Research Group (2013) *Multisite Quantitative Ultrasound for the Prediction of Fractures Over Five Years of Follow-up: The Canadian Multicentre Osteoporosis Study*. *J Bone Miner Res.*; 28(9):2027-34.
180. Keaveny TM, McClung MR, Genant H, Zanchetta JR, Kendler d, **Brown JP**, Goemaere s, Recknor C, Brandi ML, Eastell R, Kopperdahl DL, Engelke K, Fuerst T, Radcliffe H, Libanati C (2013) *Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab*. *J Bone Miner Res.*; 29(1):158-65.
181. Beauregard M, Gagnon E, Guay-Bélanger S, Morissette J, **Brown J**, Michou L (2013) *Genetic association study of Dickkopf-1 and Sclerostin genes with Paget's disease of bone*. *Calcif Tissue Int.* 2013 Nov;93(5):405-12.

182. Bone HG, Chapurlat R, Brandi M-L, **Brown JP**, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) *The Effect of 3 or 6 Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension*. *J Clin Endocrinol Metab*; 98(11):4483-92.
183. Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, **Brown JP** (2013) *Denosumab Compared With Risedronate in Postmenopausal Women Suboptimally Adherent to Alendronate Therapy: Efficacy and Safety Results From a Randomized Open-label Study*. *Bone*.; 58:48-54.
184. Siminoski K, O'Keefe M, **Brown JP**, Burrell S, Coupland D, Dumont M, Ganguli SN, Hanley DA, Law-Dillabough A, Lévesque J (2013) *Canadian association of radiologists technical standards for bone mineral densitometry reporting*. *Can Assoc Radiol J*.; 64(4):281-94.
185. McClung MR, Grauer A, Boonen S, Bolognese MA, **Brown JP**, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG (2014) *Romozosumab in Postmenopausal Women With Low Bone Mineral Density*. *N Engl J Med*.; 370(5):412-20.
186. Reid IR, **Brown JP**, Levitt N, Román Ivorra JA, Bachiller-Corral J, Ross IL, Su G, Antunez-Flores O, Aftring RP (2013) *Re-Treatment of Relapsed Paget's Disease of Bone with Zoledronic Acid - Results From An Open-Label Study*. *Bonekey Rep*.; 2:442.
187. Jean S, Candas B, Belzile ÉL, Morin S, Bessette L, **Brown JP**. *Développement de la surveillance de l'ostéoporose au Québec: Utilisation des banques de données médico-administratives*. *Bull Epidémiol Hebd*. 2013; (Hors-série):15-22.
188. **Brown JP**, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J (2014) *Bisphosphonates for treatment of osteoporosis: Expected benefits, potential harms, and drug holidays*. *Can Fam Physician*; 60(4):324-33.
189. Beauregard M, Gagnon E, Guay-Bélanger S, Morissette J, **Brown JP**, Michou L. (2014) *Identification of rare genetic variants in novel loci associated with Paget's disease of bone*. *Hum Genet*.; 133(6):755-68.
190. **Brown JP**, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C. (2014) *Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate*. *Osteoporos Int*.; 25(7):1953-61.
191. Beaudoin C, Bessette L, Jean S, Ste-Marie LG, **Brown JP**. (2014) *The impact of educational interventions on modifiable risk factors for osteoporosis after a fragility fracture*. *Osteoporos Int*.; 25(7):1821-30.
192. Klinck R, Laberge G, Bisson M, McManus S, Michou L, **Brown JP**, Roux S. (2014) *Alternative splicing in osteoclasts and Paget's disease of bone*. *BMC Med Genet*.;15:98.
193. Gajic-Veljanoski O, Tomlinson G, Srighanthan J, Adachi JD, Josse R, **Brown JP**, Cheung AM. (2014) *Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses*. *J Clin Endocrinol Metab*.; 99(9):3070-9.

194. Berger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, Adachi JD, Prior JC, Towheed T, Davison KS, Kaiser SM, **Brown JP**, Goltzman D; the CaMos Research Group. *Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers.* Clin Endocrinol (Oxf).;82(3):359-68.
195. **Brown JP**, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen JE, Bolognese MA, Daizadeh N, Valter I, Zerbini CA, Dempster DW. (2014) *Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension.* J Bone Miner Res; 29(9):2051-6.
196. Poole KE, Treece GM, Gee AH, **Brown JP**, McClung MR, Wang A, Libanati C. (2015) *Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women with Osteoporosis.* J Bone Miner Res.;30(1):46-54.
197. Silverman SL, Siris E, Kendler DL, Belazi D, **Brown JP**, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C. (2014) *Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.* Osteoporos Int.;26(1):361-72.
198. Guay-Bélanger S, Picard S, Gagnon E, Morissette J, Siris ES, Orcel P, **Brown JP**, Michou L. (2014) *Detection of SQSTM1/P392L post-zygotic mutations in Paget's disease of bone.* Hum Genet.;134(1):53-65.
199. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, **Brown JP**, Compston J; International Task Force on Osteonecrosis of the Jaw (2015) *Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.* J Bone Miner Res.;30(1):3-23.
200. Prior JC, Langsetmo L, Lentle BC, Berger C, Goltzman D, Kovacs CS, Kaiser SM, Adachi JD, Papaioannou A, Anastassiades T, Towheed T, Josse RG, **Brown JP**, Leslie WD, Kreiger N; CaMOS Research Group (2015) *Ten-year incident osteoporosis-related fractures in the population-based Canadian Multicentre Osteoporosis Study - comparing site and age-specific risks in women and men.* Bone;71:237-43
201. Palacios S, Agodoa I, Bonnicksen S, Van den Bergh JP, Ferreira I, Ho PR, **Brown JP** (2015) *Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.* J Clin Endocrinol Metab.;100(3):E487-92
202. Iki A, Beaudoin C, **Brown JP**, Bessette L, Fortin PR, Michou L (2015) *Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis.* Joint Bone Spine; 82(5):373-5.
203. Palacios S, Silverman SL, de Villiers TJ, Levine AB, Goemaere S, **Brown JP**, De Cicco Nardone F, Williams R, Hines TL, Mirkin S, Chines AA; Bazedoxifene Study Group. (2015) *A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.* Menopause; 22(8):806-13.
204. Numan MS, **Brown JP**, Michou L. *Impact of air pollutants on oxidative stress in common autophagy-mediated aging diseases.* Int J Environ Res Public Health; 12(2):2289-305.

205. Adachi JD, **Brown JP**, Ioannidis G. *Characterizing the assessment and management of vitamin d levels in patients with osteoporosis in clinical practice: a chart review initiative*. J Osteoporos. 2015 2015:312952.
206. Khan A, Morrison A, Ruggiero S, Tetradis S, Davison KS, Peters E, Compston J; **International ONJ Task Force** (2015) *Response to comments on "diagnosis and management of osteoporosis of the jaw: a systematic review and international consensus"*. J Bone Miner Res. 2015 Jun;30(6):1116-7.
207. Olszynski WP, **Brown JP**, Adachi JD, Hanley DA, Ioannidis G, Davison KS, Camos Research Group. (2014) *Normative data for multisite quantitative ultrasound: the Canadian multicenter osteoporosis study*. J Clin Densitom.; 17(4):534-40.
208. McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, **Brown J**, Chapurlat R, Elders PJ, Fujita Y, Glüer CC, Goltzman D, Iki M, Karlsson M, Kindmark A, Kotowicz M, Kurumatani N, Kwok T, Lamy O, Leung J, Lippuner K, Ljunggren Ö, Lorentzon M, Mellström D, Merlijn T, Oei L, Ohlsson C, Pasco JA, Rivadeneira F, Rosengren B, Sornay-Rendu E, Szulc P, Tamaki J, Kanis JA. *A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX*. J Bone Miner Res.; 31(5):940-8.
209. Olszynski WP, Adachi JD, Hanley DA, Davison KS, **Brown JP** (2015) *Comparison of Speed of Sound Measures Assessed by Multisite Quantitative Ultrasound to Bone Mineral Density Measures Assessed by Dual-Energy X-Ray Absorptiometry in a Large Canadian Cohort: the Canadian Multicentre Osteoporosis Study (CaMos)*. J Clin Densitom. 19(2): 234-41.
210. Poole KE, Treece GM, Gee AH, **Brown JP**, McClung MR, Wang A, Libanati C (2015) *Response to: Comment on: "Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis"*. J Bone Miner Res. 30(10):1939-40.
211. Langsetmo L, Barr SI, Berger C, Kreiger N, Rahme E, Adachi JD, Papaioannou A, Kaiser SM, Prior JC, Hanley DA, Kovacs CS, Josse RG, Goltzman D; **CaMos Research Group** (2015) *Associations of Protein Intake and Protein Source with Bone Mineral Density and Fracture Risk: A Population-Based Cohort Study*. J Nutr Health Aging.; 19(8):861-8.
212. Numan MS, Amiable N, **Brown JP**, Michou L. (2015) *Paget's disease of bone: an osteoimmunological disorder?* Drug Des Devel Ther.; 9:4695-707.
213. Morin SN, Wall M, Belzile EL, Godbout B, Moser TP, Michou L, Ste-Marie LG, de Guise JA, Rahme E, **Brown JP**. (2015) *Assessment of femur geometrical parameters using EOS™ imaging technology in patients with atypical femur fractures; preliminary results*. Bone.; 83:184-189.
214. Mahjoub Z, Jean S, Leclerc JT, **Brown JP**, Boulet D, Pelet S, Grondin C, Dumont J, Belzile ÉL, Michou L (2015) *Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data*. J Bone Miner Res. 31(4): 767-76.
215. Langsetmo L, Barr SI, Dasgupta K, Berger C, Kovacs CS, Josse RG, Adachi JD, Hanley DA, Prior JC, **Brown JP**, Morin SN, Davison KS, Goltzman D, Kreiger N. (2015) *Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism*. Nutr Res.; 36(4):328-36.
216. Lacerte P, Brunet A, Egarnes B, Duchêne B, **Brown JP**, Gosselin J (2016) *Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists*. Arthritis Research & Therapy; 18(1):10.

217. Guay-Bélanger S, Simonyan D, Bureau A, Gagnon E, Albert C, Morissette J, Siris ES, Orcel P, **Brown JP**, Michou L (2016) *Development of a molecular test of Paget's disease of bone*. *Bone*; 84:213-221.
218. Divisato G, Formicola D, Esposito T, Merlotti D, Pazzaglia L, Del Fattore A, Siris E, Orcel P, **Brown JP**, Nuti R, Strazzullo P, Benassi MS, Cancela ML, Michou L, Rendina D, Gennari L, Gianfrancesco F (2016) *ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor*. *The American Journal of Human Genetics* 98, 275–286.
219. Dempster DW, Zhou H, Recker RR, **Brown JP**, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao SD, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Alam J, Ruff VA, Gallagher ER, Taylor KA (2016) *A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women with Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial*. *J Bone Miner Res.* 31(7): 1429-39.
220. Dempster DW, Zhou H, Recker RR, **Brown JP**, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA (2016) *Differential Effects of Teriparatide and Denosumab on Endogenous PTH, Markers of Bone Turnover, and Bone Histomorphometry in Postmenopausal Women with Osteoporosis: Results from the AVA Study*. *The Journal of Clinical Endocrinol. Metab.*; 101(4): 1353-63.
221. Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T, Michou L, **Brown JP**, Windle JJ, Kurihara N, Roodman GD (2016) *Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease*. *J Clin Invest.*; 126(3):1012-22.
222. Eriksen EF, **Brown JP**. (2016) *Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics*. *Bone*; 86:139-42.
223. Mahjoub Z, Jean S, Leclerc JT, **Brown JP**, Boulet D, Pelet S, Grondin C, Dumont J, Belzile EL, Michou L. *Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data*. *J Bone Miner Res.*; 31(4):767-76.
224. **Brown JP** (2016) *Bone turnover markers: Defining a therapeutic target*. *Clinical Biochemistry. Clin Biochem.*; 49(7-8): 527-8.
225. Tarride JE, Burke N, Leslie WD, Morin SN, Adachi JD, Papaioannou A, Bessette L, **Brown JP**, Pericleous L, Muratov S, Hopkins RB. (2016) *Loss of health related quality of life following low-trauma fractures in the elderly*. *BMC Geriatr.*; 16(1):84.
226. Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, **Brown JP** (2016) *Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis*. *Osteoporos Int.*; 27(9):2835-44.
227. Hopkins RB, Burke N, Von Keyserlingk C, Leslie WD, Morin SN, Adachi JD, Papaioannou A, Bessette L, **Brown JP**, Pericleous L, Tarride J. *The current economic burden of illness of osteoporosis in Canada*. *Osteoporos Int.* 27(10):3023-32.
228. Eriksen EF, **Brown JP**. (2016) Response to Letter to the editor by Leder et al. regarding Commentary “Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics”. *Bone*; 89:75-6.
229. Miller PD, Pannacciulli N, **Brown JP**, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) *Denosumab or Zoledronic Acid in*

*Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates*. J Clin Endocrinol Metab.; 101(8): 3163-70.

230. Jamal SA, Swan VJ, **Brown JP**, Hanley DA, Prior JC, Papaioannou A, Langsetmo L, Josse RG; Canadian Multicentre Osteoporosis Study Research Group. (2016) *Retraction Notice to "Kidney Function and Rate of Bone Loss at the Hip and Spine: The Canadian Multicentre Osteoporosis Study" [Am J Kidney Dis. 55(2):291-299]*. Am J Kidney Dis.;68(2):333.
231. Genant HK, Engelke K, Bolognese MA, Mautalen C, **Brown JP**, Recknor C, Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C (2016) *Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass*. J Bone Miner Res.; 32(1):181-187.
232. Handrigan GA, Maltais N, Gagné M, Lamontagne P, Hamel D, Teasdale N, Hue O, Corbeil P, **Brown JP**, Jean S (2016) *Sex-specific association between obesity and self-reported falls and injuries among community-dwelling Canadians aged 65 years and older*. Osteoporos Int.; 28(2):483-494.
233. Brunet A, LeBel M, Egarnes B, Paquet-Bouchard C, Lessard AJ, **Brown JP**, Gosselin J (2016) *NR4A1-dependent Ly6C<sup>low</sup> monocytes contribute to reducing joint inflammation in arthritic mice through Treg cells*. Eur J Immunol.; 46(12):2789-2800.
234. Cheung AM, Frame H, Ho M, Mackinnon ES, **Brown JP** (2016) *Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice*. International Journal of Women's Health.; 8:537-547
235. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, **Brown JP**, Compston J; International Task Force on Osteonecrosis of the Jaw (2017) *Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ*. J Clin Densitom.; 20(1):8-24.
236. Watts NB, **Brown JP**, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, Wagman RB, Wang A, Daizadeh NS, Smith S, Bone HG (2017) *Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension*. J Bone Miner Res.; 32(7):1481-1485.
237. Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, **Brown JP**, Langdahl BL, Yan C, Grauer A, Libanati C. *Greater Gains in Spine and Hip Strength for Romosozumab Compared to Teriparatide in Postmenopausal Women With Low Bone Mass*. J Bone Miner Res. 2017; 32(9):1956-1962.
238. Bone HG, Wagman RB, Brandi ML, **Brown JP**, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannaciuoli N, Dempster DW, Papapoulos S. (2017) *10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension*. Lancet Diabetes Endocrinol.; 5(7):513-523.
239. Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, **Brown JP**, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos

- P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A. (2017) *Romozosumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial*. *Lancet.*; 390(10102):1585-1594.
240. Schneider PS, Wall M, **Brown JP**, Cheung AM, Harvey EJ, Morin SN (2017) *Atypical femur fractures: a survey of current practices in orthopedic surgery*. *Osteoporos Int.*; 28(11):3271-3276.
241. **Brown JP** (2017) *Antiresorptives: Safety Concerns-Clinical Perspective*. *Toxicol Pathol.*; 45(7):859-863
242. Laurier E, Amiable N, Gagnon E, **Brown JP**, Michou L. (2017) *Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with Paget's disease of bone*. *BMC Med Genet.*; 18(1):133.
243. Audet MC, Jean S, Beaudoin C, Guay-Belanger S, Dumont J, **Brown JP**, Michou L. (2017) *Environmental factors associated with familial or non familial forms of Paget's disease of bone*. *Joint Bone Spine*. 84(6):719-723.
244. Gajic-Veljanoski O, Papaioannou A, Kennedy C, Ioannidis G, Berger C, Wong AKO, Rockwood K, Kirkland S, Raina P, Thabane L, Adachi JD; **CaMos Research Group** (2018) *Osteoporotic fractures and obesity affect frailty progression: a longitudinal analysis of the Canadian multicentre osteoporosis study*. *BMC Geriatr.*; 18(1):4.
245. Silva IAL, Conceição N, Gagnon É, Caiado H, **Brown JP**, Gianfrancesco F, Michou L, Cancela ML (2018) *Effect of genetic variants of OPTN in the pathophysiology of Paget's disease of bone*. *Biochim Biophys Acta.*; 1864(1):143-151.
246. LeBel M, Egarnes B, Brunet A, Lacerte P, Paré A, Lacroix S, **Brown JP**, Gosselin J. (2018) *Ly6C<sup>high</sup> monocytes facilitate transport of Murid herpesvirus 68 into inflamed joints of arthritic mice*. *Eur J Immunol.*; 48(2):250-257.
247. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I, Wang AT, **Brown JP**. (2018) *Vertebral Fractures after Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension*. *J Bone Miner Res*. 33(2):190-198.
248. Dempster DW, Zhou H, Recker RR, **Brown JP**, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA. (2018) *Remodeling- and Modeling-Based Bone Formation with Teriparatide versus Denosumab: A Longitudinal Analysis from Baseline to 3 Months in the AVA Study*. *J Bone Miner Res.*; 33(2):298-306.
249. Cummings SR, Ferrari S, **Brown JP**, Wang AT (2018) *Response to Dr. Lamy and Dr. Gonzalez-Rodriguez* *J Bone Miner Res.*; 33(3):548.
250. Lentle BC, Berger C, Probyn L, **Brown JP**, Langsetmo L, Fine B, Lian K, Shergill AK, Trollip J, Jackson S, Leslie WD, Prior JC, Kaiser SM, Hanley DA, Adachi JD, Towheed T, Davison KS, Cheung AM, Goltzman D; **CaMos Research Group**. (2018) *Comparative Analysis of the Radiology of Osteoporotic Vertebral Fractures in Women and Men: Cross-Sectional and Longitudinal Observations from the Canadian Multicentre Osteoporosis Study (CaMos)*. *J Bone Miner Res.*;33(4):569-579.
251. Dempster DW, **Brown JP**, Fahrleitner-Pammer A, Kendler D, Rizzo S, Valter I, Wagman RB, Yin X, Yue SV, Boivin G. (2018) *Effects of Long-term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis*. *J Clin Endocrinol Metab*. 103(7):2498-2509.



252. McClung MR, **Brown JP**, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. (2018) *Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study.* J Bone Miner Res. 33(8):1397-1406.
253. Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie LG, **Brown JP**. (2018) *Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population.* J Bone Miner Res. 33(11):1956-1966.
254. Silva IAL, Conceição N, Gagnon É, **Brown JP**, Cancela ML, Michou L. (2018) *Molecular effect of an OPTN common variant associated to Paget's disease of bone.* PLoS One. 13(5):e0197543.
255. Silverman SL, Siris E, Belazi D, Recknor C, Papaioannou A, **Brown JP**, Gold DT, Lewiecki EM, Quinn G, Balasubramanian A, Yue S, Stolshek B, Kendler DL (2018) *Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.* Arch Osteoporos.; 13(1):85.
256. Lentle B, Koromani F, **Brown JP**, Oei L, Ward L, Goltzman D, Rivadeneira F, Leslie WD, Probyn L, Prior J, Hammond I, Cheung AM, Oei EH; Vertebral Fracture Research Groups of the CaMos, STOPP, and Rotterdam Studies (2019) *The Radiology of Osteoporotic Vertebral Fractures Revisited.*J Bone Miner Res. 2019 Mar;34(3):409-418. doi: 10.1002/jbmr.3669. Epub 2019 Feb 27.PMID: 30645770
257. Beaudoin C, Moore L, Gagné M, Bessette L, Ste-Marie LG, **Brown JP**, Jean S. (2019) *Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression.* Osteoporos Int.; 30(4):721-740.
258. Ferrari S, Libanati C, Lin CJF, **Brown JP**, Cosman F, Czerwiński E, de Gregório LH, Malouf-Sierra J, Reginster JY, Wang A, Wagman RB, Lewiecki EM (2019) *Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.* J Bone Miner Res.; 34(6):1033-1040.
259. Cooke-Hubley S, Gao Z, Mugford G, Kaiser SM, Goltzman D, Leslie WD, Davison KS, **Brown JP**, Probyn L, Lentle B, Prior JC, Kovacs CS (2019) *Parity and lactation are not associated with incident fragility fractures or radiographic vertebral fractures over 16 years of follow-up: Canadian Multicentre Osteoporosis Study (CaMos).* Arch Osteoporos. Apr 29;14(1):49. doi: 10.1007/s11657-019-0601-6. PMID: 31037359
260. Numan MS, Jean S, Dessay M, Gagnon E, Amiable N, **Brown JP**, Michou L (2019) *Gene-environment interactions in Paget's disease of bone.* Joint Bone Spine. 2019 May;86(3):373-380. doi: 10.1016/j.jbspin.2018.12.007. Epub 2018 Dec 27. PMID: 30594595
261. Bilezikian JP, Lin CJF, **Brown JP**, Wang AT, Yin X, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A (2019) *Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.* Osteoporos Int. 2019 Sep;30(9):1855-1864. doi: 10.1007/s00198-019-05020-8. Epub 2019 Jun 14. PMID: 31201481
262. Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, **Brown JP**, Libanati C, Boyce RW, Wang A, Grauer A (2019) *Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.* J Bone Miner Res. 2019 Sep;34(9):1597-1608. doi: 10.1002/jbmr.3735. Epub 2019 Jun 24.PMID: 31233639

263. Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwiński E, Bone HG, Wang C, Huang S, Chines A, Lems W, **Brown JP** (2020) Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. *Osteoporos Int.* 2020 Jan;31(1):181-191. doi: 10.1007/s00198-019-05233-x. Epub 2019 Nov 28. PMID: 31776637
264. Olszynski WP, Davison KS, Adachi JD, **Brown JP**, Hanley DA. (2020) Change in Quantitative Ultrasound-assessed Speed of Sound as a Function of Age in Women and Men and Association With the Use of Antiresorptive Agents: The Canadian Multicentre Osteoporosis Study. *J Clin Densitom.* 2020 Oct-Dec;23(4):549-560. doi: 10.1016/j.jocd.2019.10.001. Epub 2019 Oct 9. PMID: 31735596
265. McClung MR, Bolognese MA, **Brown JP**, Reginster JY, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. *Osteoporos Int.* 2020 Nov;31(11):2231-2241. doi: 10.1007/s00198-020-05502-0. Epub 2020 Jul 4. PMID: 32623487
266. Dessay M, Jobin Gervais F, Simonyan D, Samson A, Gleeton G, Gagnon E, Albert C, **Brown JP**, Michou L (2020) Clinical phenotype of adult offspring carriers of the p.Pro392Leu mutation within the SQSTM1 gene in Paget's disease of bone. *Bone Rep.* 2020 Sep 18;13:100717. doi: 10.1016/j.bonr.2020.100717. eCollection 2020 Dec. PMID: 33015249
267. Kendler DL, Adachi JD, **Brown JP**, Juby AG, Kovacs CS, Duperrouzel C, McTavish RK, Cameron C, Slatkowska L, Burke N (2021) A scorecard for osteoporosis in Canada and seven Canadian provinces. *Osteoporos Int.* 2021 Jan;32(1):123-132. doi: 10.1007/s00198-020-05554-2. Epub 2020 Jul 25. PMID: 32712739
268. **Brown JP**, Adachi JD, Schemitsch E, Tarride JE, Brown V, Bell A, Reiner M, Oliveira T, Motsepe-Ditshego P, Burke N, Slatkowska L (2021) Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario. *BMC Musculoskelet Disord.* 2021 Jan 23;22(1):105. doi: 10.1186/s12891-021-03960-z. PMID: 33485305
269. Tarride JÉ, Adachi JD, **Brown JP**, Schemitsch E, Slatkowska L, Burke N (2021) Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada. *Osteoporos Int.* 2021 Feb 18. doi: 10.1007/s00198-021-05877-8. Online ahead of print. PMID: 33599789
270. Adachi JD, **Brown JP**, Schemitsch E, Tarride JE, Brown V, Bell AD, Reiner M, Packalen M, Motsepe-Ditshego P, Burke N, Slatkowska L (2021) Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. *BMC Musculoskelet Disord.* 2021 Feb 26;22(1):224. doi: 10.1186/s12891-021-04051-9. PMID: 33637078
271. Lentle BC, Berger C, **Brown JP**, Probyn L, Langsetmo L, Hammond I, Hu J, Leslie WD, Prior JC, Hanley DA, Adachi JD, Josse RG, Cheung AM, Kaiser SM, Towheed T, Kovacs CS, Wong AKO, Goltzman D (2021) Vertebral fractures: which radiological criteria are better associated with the clinical course of osteoporosis? *Can Assoc Radiol J.* 2021 Feb;72(1):150-158. doi: 10.1177/0846537120943529. Epub 2020 Aug 5. PMID: 32755312
272. Farlay D, Rizzo S, Ste-Marie LG, Michou L, Morin SN, Qiu S, Chavassieux P, Chapurlat RD, Rao SD, **Brown JP**, Boivin G (2021) Duration-Dependent increase of human bone matrix mineralization in long-term bisphosphonate users with atypical femur fracture. *J Bone Miner Res.* 2021 Jun;36(6):1031-1041. doi: 10.1002/jbmr.4244. Epub 2021 Feb 11. PMID:33434290

273. **Brown JP**. Long-term treatment of postmenopausal osteoporosis. *Endocrinol Metab (Seoul)*. 2021 Jun;36(3):544-552. doi: 10.3803/EnM.2021.301. Epub 2021 Jun 22. PMID: 34154042
274. Billington EO, Leslie WD, **Brown JP**, Prior JC, Morin SN, Kovacs CS, Kaiser SM, Lentle BC, Anastassiades T, Towheed T, Kline GA.(2021) Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study. *Osteoporos Int*. 2021 Jul;32(7):1313-1320. doi: 10.1007/s00198-021-05826-5. Epub 2021 Jan 12. PMID: 33438038
275. McClung MR, Bolognese MA, **Brown JP**, Reginster JY, Langdahl BL, Shi Y, Timoshanko J, Libanati C, Chines A, Oates MK. Skeletal responses to romosozumab after 12 months of denosumab. *JBM Plus*. 2021 Jun 3;5(7):e10512. doi: 10.1002/jbmr.4.10512. eCollection 2021 Jul. PMID: 34258507
276. Lentle B, **Brown JP**, Probyn L, Goltzman D. Vertebral fractures: which radiological criteria are better associated with the clinical course of osteoporosis? *Can Assoc Radiol J*. 2021 Aug;72(3):586. doi: 10.1177/0846537120963692. Epub 2020 Oct 6. PMID: 33023327
277. **Brown JP**, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes J, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini CAF, Wang Z, Oates MK, Recknor C, Libanati C. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the ARCH trial. *J Bone Miner Res*. Nov;36(11):2139-2152. doi: 10.1002/jbmr.4409. Epub 2021 Aug 10. PMID: 34190361
278. Prior JC, Oei EH, **Brown JP**, Oei L, Koromani F, Lentle BC. Where's the break? Critique of radiographic vertebral fracture diagnostic methods. *Osteoporos Int*. 2021 Dec;32(12):2391-2395. doi: 10.1007/s00198-021-06207-8. Epub 2021 Oct 21. PMID: 34674023
279. Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie LG, **Brown JP**. Prediction of osteoporotic fractures in elderly individuals: a derivation and internal validation study using healthcare administrative data. *J Bone Miner Res*. 2021 Dec;36(12): 2329-2342. doi: 10.1002/jbmr.4438. PMID: 34490952.
280. Schemitsch E, Adachi JD, **Brown JP**, Tarride JE, Burke N, Oliveira T, Slatkowska L. Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. *Osteoporos Int*. 2022 Jan;33(1):113-122. doi: 10.1007/s00198-021-06080-5. Epub 2021 Aug 11. PMID: 34379148
281. Eriksen EF, Chapurlat R, Boyce RW, Shi Y, **Brown JP**, Horlait S, Betah D, Libanati C, Chavassieux P. Modeling-based bone formation after 2 months of romosozumab treatment: results from the Frame clinical trial. *J Bone Miner Res*. 2022 Jan;37(1):36-40. doi: 10.1002/jbmr.4457. Epub 2021 Nov 19. PMID: 34633116.
282. Lentle BC, Hammond I, Leslie WD, **Brown JP**, Probyn L, Munk PL, Prior JC, Goltzman D. The diagnosis of osteoporotic vertebral fractures redux. *Clin Radiol*. 2022 Jan;77(1):75-77. doi: 10.1016/j.crad.2021.09.021. Epub 2021 Oct 31. PMID: 34732292
283. Poole KES, Treece GM, Pearson RA, Gee AH, Bolognese MA, **Brown JP**, Goemaere S, Grauer A, Hanley DA, Mautalen C, Recknor C, Yang YC, Rojeski M, Libanati C and Whitmarsh T. Romosozumab enhances vertebral bone structure in women with low bone density. *J Bone Miner Res*. 2022 Feb;37(2):256-264. doi: 10.1002/jbmr.4465. Epub 2021 Dec 16. PMID: 34738660
284. Dessay M, Couture E, Maaroufi H, Fournier F, Gagnon E, Droit A, **Brown JP**, Michou L. Attenuated clinical and osteoclastic phenotypes of Paget's disease of bone linked to the p.Pro392Leu/SQSTM1 mutation by a

- rare variant in the DOCK6 gene. *BMC Med Genomics*. 2022 Mar 3;15(1):41. doi: 10.1186/s12920-022-01198-9. PMID: 35241069
285. Farlay D, Rizzo S, Dempster DW, Huang S, Chines A, **Brown JP**, Boivin G. Bone mineral and organic properties in postmenopausal women treated with denosumab for up to 10 years. *J Bone Miner Res*. 2022 May;37(5):856-864. doi: 10.1002/jbmr.4538. Epub 2022 Mar 24. PMID: 35249242
286. Goeree R, Burke N, Jobin M, **Brown JP**, Lawrence D, Stollenwerk B, Willems D, Johnson B. Cost effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada. *Arch Osteoporos*. 2022 Apr 26;17(1):71. doi: 10.1007/s11657-022-01106-9. PMID: 35471711
287. Oliveira T, Kendler DL, Schneider P, Juby AG, Wani R, Packalen M, Avciil S, Li S, Waters-Banker C, Graves E, McMullen S, **Brown J**. Trends in osteoporotic fractures and related in-hospital complications during the COVID-19 pandemic in Alberta, Canada. *Arch Osteoporos*. 2022 Aug 3;17(1):109. doi: 10.1007/s11657-022-01114-9. PMID: 35920903
288. Oliveira T, **Brown J**, Juby AG, Schneider P, Wani R, Packalen M, Avciil S, Li S, Farris M, Graves E, McMullen S, Kendler DL. Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada. *Arch Osteoporos*. 2022 Aug 3;17(1):110. doi: 10.1007/s11657-022-01132-7. PMID: 35920939
289. **Brown JP**, Don-Wauchope A, Douville P, Albert C, Vasikaran SD. Current use of bone turnover markers in the management of osteoporosis. *Clin Biochem*. 2022 109-110, Nov-Dec:1-10. doi: 10.1016/j.clinbiochem.2022.09.002. Epub 2022 Sep 9. PMID: 36096182 Review.
290. Gendron E, Bouchard F, Singbo N, **Brown JP**, Michou L. Decline in clinical severity of Paget's disease of bone: Comparison between a contemporary cohort and a historical cohort. *Bone*. 2023 May; 170:116721. doi: 10.1016/j.bone.2023.116721. Epub 2023 Feb 27. PMID: 36858336
291. You Y, Simonyan D, Bureau A, Gagnon E, Albert C, Guertin JR, Tarride JE, **Brown JP**, Michou L. Molecular test of Paget's disease of bone in families not linked to SQSTM1 gene mutations. *Bone Rep*. 2023 Feb 28; 18:101670. doi: 10.1016/j.bonr.2023.101670. eCollection 2023 Jun. PMID: 36915391

### Refereed Papers Under Review

1. Michou L, Gamache P, Guertin JR, Tarride JE, **Brown JP**, Jean S. Burden of Paget's Disease of Bone: Temporal Trend Over 20 years in the Province of Quebec, Canada. June 2023.
2. Eriksen EF, Boyce RW, Shi Y, **Brown JP**, Betah D, Libanati C, Oates M, Chapurlat R, Chavassieux P. Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment. June 2023.

## Oral Presentations at Scientific Meetings

1. **Brown JP**, Ménard HA, De Medicis R, Lussier A (1981). *Mise en évidence de cristaux de Charcot-Leyden dans les éosinophiles du liquide synovial*. Journée Scientifique du C.H.U. de Sherbrooke, Sherbrooke, Québec, Canada, 27 May 1981.
2. **Brown JP**, Ménard HA, De Medicis R, Lussier A (1981). *Charcot-Leyden crystals in synovial fluid eosinophils*. Annual Meeting of the Royal College of Physicians and Surgeons of Canada. Toronto, September 15-18, 1981.
3. **Brown JP**, Ménard HA, De Medicis R Lussier A (1981). *Mise en évidence de cristaux de Charcot-Leyden dans les éosinophiles du liquide synovial*. Conférence Laurentienne de rhumatologie, Val David, Québec, Canada, September 25-26, 1981.
4. **Brown JP**, Delmas PD, Malaval L (1983). *L'ostéocalcine ou GLA-protéine osseuse*. Deuxième journée de perfectionnement en pathologie osseuse médicale, Lyon, France, September 23, 1983.
5. **Brown JP**, Delmas PD, Malaval L, Meunier PJ (1984). *Serum bone GLA-protein a specific marker of bone formation in postmenopausal osteoporosis*. Copenhagen International Symposium on Osteoporosis, Copenhagen, Denmark, June 4-8, 1984.
6. **Brown JP**, Delmas PD, Malaval L, Meunier PJ (1984). *Serum bone GLA –protein a specific marker of trabecular and subcortical bone formation in postmenopausal osteoporosis*. Vith Annual Scientific Meeting of the American Society for Bone and Mineral Research, Hartford, Connecticut, USA, June 26-29, 1984.
7. **Brown JP**, Delmas PD, Malaval L, Meunier PJ (1984). *Serum bone GLA-protein a specific marker of trabecular and subcortical bone formation in postmenopausal osteoporosis*. 53rd Annual Meeting of The Royal College of Physicians and Surgeons of Canada, Montréal, Québec, Canada, September 10-13, 1984.
8. **Brown JP** (1985). *L'Ostéoporose*. Réunion annuelle de l'Association québécoise des internistes et rhumatologues. Québec, Québec, Canada, May 19, 1985.
9. **Brown JP** (1986). *Thérapie de l'ostéoporose prévention et traitement*. Journée d'éducation permanente de l'Association des Pharmaciens des Établissements de Santé du Québec, Auberge des Gouverneurs, Ste-Foy, Québec, Canada, November 28, 1986.
10. **Brown JP** (1988). *Rachistime hypercalciurique*. 2e Réunion interhospitalière de rhumatologie. Royal Victoria Hospital, Montréal, March 23, 1988.
11. **Brown JP**, Friede J (1988). *Influence de l'apport alimentaire en calcium sur la masse osseuse des femmes préménopausées*. Colloque ostéodensitométrie et ostéoporose. L'Hôtel-Dieu de Montréal, April 27, 1988.
12. **Brown JP** (1989). *Rhumatisme articulaire aigu en 1989 mythe ou réalité ?* 4e Réunion interhospitalière de rhumatologie. L'Hôtel-Dieu de Québec, Québec, Québec, Canada, April 14, 1989.
13. **Brown JP** (1989). *Les nouveaux marqueurs biochimiques du remodelage osseux*. Club de recherches cliniques du Québec. Ste-Adèle, October 14, 1989.
14. **Brown JP** (1989). *A propos d'un cas de céphalée répondant aux stéroïdes*. 5e Réunion interhospitalière de rhumatologie. Hôpital Sacré-Coeur, Montréal, Québec, Canada, October 20, 1989.

15. **Brown JP**, Kylstra JW, Bekker PJ, Axelrod DW, Siris ES, Altman RD, Singer FR (1992). *Risedronate in Paget's disease : Preliminary results of a multicenter study*. First International Symposium on Paget's disease of Bone, Manchester, U.K., August 26-29, 1992. *Seminars in Arthritis and Rheumatism*; 23(4): 272.
16. **Brown JP**, Poubelle PE, Adachi J, Hawkins F, Goemaere S, Thamsborg G, Delmas P, Menten J, Malice M-P, Czachur M, Daifotis A (1997). *Alendronate increases bone mineral density in patients on glucocorticoid therapy. Results of the multinational study*. Oral presentation made on behalf of Dr Patrice Poubelle who had a last minute contretemps. 61<sup>st</sup> National Scientific Meeting of the American College of Rheumatology, Washington, DC, USA, November 8-12, 1997. *Arthritis and Rheumatism*; 40(9) Suppl: S327. Abstract # 1774.
17. **Brown JP**, Raymond V, Morissette J (1998). *Genetic epidemiology of Paget's disease of bone in eastern Québec*. The National Association for the Relief of Paget's disease International Symposium, Oxford, UK, July 15-17, 1998. *Bone*; 24(5) Suppl: 15S. Abstract # 3.
18. **Brown JP** (2000). *Prevention and treatment of corticosteroid-induced osteoporosis: clinical perspective*. VI Annual Scientific Meeting of the International Society for Clinical Densitometry, Rio de Janeiro, Brazil, May 8-13, 2000. *Scientific Program*: 65.
19. **Brown JP**, Hosking D, Josse R, Johnell O, Leib E, Roux C, Starcke H, Bos K, Horlait S (2000). *Risedronate rapidly and consistently reduces risk of further vertebral fracture in women with multiple prevalent fractures*. 22<sup>nd</sup> Annual Meeting of the American Society of Bone and Mineral Research, Toronto, Ontario, Canada, September 22-26, 2000. *J Bone Miner Res*; 15(Suppl 1): S150. Abstract 1043.
20. **Brown JP** (2001). *The role of SERMs in the long-term management of postmenopausal women*. 57<sup>th</sup> Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada, St. John's, Newfoundland, Canada, June 14-19, 2001.
21. **Brown JP**, Bessette L, Beaulieu M, Baranci M, Jean S, Davison KS, Ste-Marie L-G (2006). *Recognizing Osteoporosis and its Consequences in Québec (ROCQ): The Care Gap Following a Fragility Fracture*. 61<sup>st</sup> Annual Meeting of the Canadian rheumatology association. First Mexican-Canadian Congress of rheumatology. Acapulco, Mexico, February 18-22, 2006.
22. **Brown JP**, Bone H, Recker R, Kiel D, Prince R, Alvaro Gracia JM, Wang H, Austin M, Newmark R, Libanati C, Wagman RB. *Comparison of the effects of denosumab versus alendronate on bone mineral density: Results from a randomized blinded phase 3 trial*. 35<sup>th</sup> European Symposium on Calcified Tissues, Barcelona, Spain, May 28, 2008. *Calc Tissue Int*; 80(suppl. 1): Late breaking abstracts.
23. **Brown JP**, Deal C, de Gregorio LH, Hofbauer LC, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J (2008). *Effect of Denosumab vs Alendronate on Bone Turnover Markers and Bone Mineral Density Changes at 12 Months Based on Baseline Bone Turnover Level*. 30th Annual Meeting of the American Society of Bone and Mineral Research, Montréal, Québec, Canada, September 12-16, 2008. *J Bone Miner Res*; 23:S80. Abstract 1285.
24. **Brown JP**, Dempster DW, Ding B, Dent R, San Martin J, Wagman RB, Zanchetta JR (2010) *Remodeling Status in Postmenopausal Women who Discontinued Denosumab Treatment*. *J Bone Miner Res* 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e439cd5f-ddc8-4ad9-85bc-6bfb3a135203>. Accessed on January 3, 2011.

25. Wagman RB, **Brown JP**, Dempster DW, Ding B, Dent R, San Martin J, Grauer A, Zanchetta JR (2010) *Bone Remodeling in Postmenopausal Women who Discontinued Denosumab Treatment*. 2010 ACR/ARHP Annual Scientific Meeting. Arthritis Rheum 2010.
26. **Brown JP**, Bone HG, Chapurlat R, Franchimont N, Brandi ML, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román JA, Roux C, Daizadeh NS, Geller ML, Smith S, Wagman RB, Cummings SR, Papapoulos S (2011) *Six Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the First Three Years of the FREEDOM Extension*. Annual Scientific Meeting of the American College of Rheumatology. Chicago, Illinois, USA. November 5-9, 2011.
27. **Brown JP**, Wagman R, Dempster DW, Kendler D, Miller P, Bolognese M, Valter I, Beck Jensen J-E, Zerbini C, Zanchetta JR, Daizadeh N, Reid I (2012) *Effects of 5 Years of Denosumab on Bone Histology and Histomorphometry: the FREEDOM Study Extension*. ASBMR Annual Meeting. Minneapolis, Minnesota. October 14, 2012.
28. Roux C, Fahrleitner-Pammer A, Ho PR, Hawkins F, Hofbauer L, Micaelo M, Minisola S, Papaioannou N, Stone M, Zillikens C, Ferreira I, Siddhanti S, Wagman RB, **Brown JP** (2012) Denosumab Compared With Risedronate in Postmenopausal Women Sub-optimally Treated With Alendronate Therapy: Efficacy and Safety Results From a Randomized Open-Label Study. ASBMR Annual Meeting. Minneapolis, Minnesota. October 15, 2012.
29. Roux C, Fahrleitner-Pammer A, Ho PR, Hawkins F, Hofbauer LC, Micaelo M, Minisola S, Papaioannou N, Stone M, Wark J, Zillikens MC, Ferreira I, Siddhanti S, Wagman RB, **Brown JP** (2013) *Denosumab Compared With Risedronate in Postmenopausal Women Suboptimally Adherent With Alendronate Therapy: Efficacy and Safety Results From a Randomized Open-label Study*. 44<sup>th</sup> Laurentian Conference of Rheumatology. May 9-11, 2013.
30. **Brown JP**, Wagman RB, Dempster DW, Kendler D, Miller P, Bolognese M, Valter I, Beck Jensen J-E, Zerbini C, Zanchetta JR, Daizadeh N, Reid I (2013) *Bone Histology and Histomorphometry: Effects of 5 Years of Denosumab in the Freedom Study Extension*. EULAR Annual European Congress of Rheumatology. Madrid, Spain. June 14, 2013.
31. McClung MR, Chines A, **Brown JP**, Diez-Perez A, H Resch, Caminis J, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Rosen O, Bray S, Grauer A (2015) *Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density*. EULAR Annual European Congress of Rheumatology. Ann Rheum Dis 2015;74(Suppl2): 166.
32. Dempster DW, **Brown JP**, Yue S, Farlay D, Rizzo S, Song J, Wang A, Wagman RB, Boivin G (2015) *Effects of Denosumab on Bone Matrix Mineralization: Results From the Phase 3 FREEDOM Trial*. 2015 ASBMR Annual Meeting.
33. Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, **Brown JP**, Langdahl BL, Yan C, Grauer A, Libanati C (2015) *Romosozumab Improves Strength at the Lumbar Spine and Hip in Postmenopausal Women With Low Bone Mass Compared With Teriparatide*. 2015 ASBMR Annual Meeting.
34. **Brown JP**, Bolognese MA, Ho PR, Hall J, Roux C, Bone HG, Bonnick S, van den Bergh J, Ferreira I, Ghelani P, Dakin P, Wagman RB, Recknor C (2015) *Denosumab Significantly Increases Bone Mineral Density Compared With Ibandronate and Risedronate in Postmenopausal Women Previously Treated With an Oral Bisphosphonate Who are at Higher Risk for Fracture*. 2015 ASBMR Annual Meeting.

35. Dempster DW, Zhou H, Recker RR, **Brown JP**, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam JA, Taylor KA, Ruff VA (2016) *Longitudinal Changes in Modeling- and Remodeling-Based Bone Formation with an Anabolic vs. an Antiresorptive Agent in the AVA Osteoporosis Study*. 2016 ASBMR Annual Meeting.
36. Dempster DW, **Brown JP**, Yue S, Rizzo S, Farlay D, Wagman RB, Wang A, Yin X, Boivin G (2016) *Effects of Up to 10 Years of Denosumab Treatment on Bone Matrix Mineralization: Results From the FREEDOM Extension*. 2016 ASBMR Annual Meeting.
37. **Brown JP**, Ferrari S, Gilchrist N, Beck Jensen J-E, Pannacciulli N, Recknor C, Roux C, Törring O, Valter I, Wagman RB, Wang AT, Cummings SR (2016) *Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From FREEDOM and its Extension*. 2016 ASBMR Annual Meeting. Atlanta, GA, USA. September 18, 2016.
38. **Brown JP**, Ferrari S, Gilchrist N, Beck Jensen J-E, Pannacciulli N, Recknor C, Roux C, Smith S, Törring O, Valter I, Wagman RB, Wang AT, Cummings SR (2016) *Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis From a Phase 3 Placebo-controlled Study of Denosumab and its Open-label Extension*. ACR Annual Meeting. Washington, DC. November 13, 2016.
39. Langdahl B, Libanati C, Crittenden DB, Bolognese MA, **Brown JP**, Daizadeh NS, Engelke K, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A (2016) *Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial*. ACR Annual Meeting. Washington, DC. November 13, 2016.
40. Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie LG, **Brown JP** (2017) *History of fractures for prediction of a subsequent fracture in individuals from the general population in Quebec, Canada*. 2017 ASBMR Annual Meeting.
41. Chavassieux P, Chapurlat R, Portero-Muzy N, Roux J-P, Garcia P, **Brown JP**, Horlait S, Libanati C, Boyce R, Wang A, Grauer A (2018) *Effects of romosozumab in postmenopausal women with osteoporosis after 2 and 12 months by micro computed tomography (MicroCT) and histomorphometry on iliac crest bone biopsies*. 2018 ECTS Annual Meeting, Rome.
42. **Brown J**, Dempster DW, Yue S, Rizzo S, Farlay D, Wagman RB, Yin X, Boivin G (2018). *Bone matrix mineralization after denosumab (DMAb) treatment discontinuation*. 2018 ECTS Annual Meeting, Rome.
43. Morin SN, O'Donnell S, Jean S, Jaglal S, Siminoski K, Papaioannou A, **Brown J**, Ix LM, Leslie WD (2018) *Post-Fracture Care gap in Canada from 2000-2001 to 2011-2012: A Nationwide Population-based Analysis*. 2018 ASBMR Annual Meeting.
44. Eriksen EF, Chapurlat R, Boyce R, **Brown JP**, Horlait S, Libanati C, Shi Y, Wagman RB, Chavassieux P (2019). *Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial*. ASBMR 2019 Annual Meeting, Orlando. **Oral presentation 1049**.
45. **Brown JP**, Chines A, Chapurlat R, Foldes J, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbinì C, Yang W, Recknor C, Libanati C (2019). *Romosozumab improves lumbar spine bone mineral density and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial*. ASBMR 2019 Annual Meeting, Orlando. **Oral presentation 1050**.



46. Farlay D, Rizzo S, Ste-Marie LG, Michou L, Morin S, Qiu S, Rao SD, **Brown JP**, Boivin G (2019). Altered Bone Quality in Long-term bisphosphonate Users with Atypical Femur Fracture (AFF). ASBMR 2019 Annual Meeting, Orlando. **Oral presentation 1087.**
47. Eriksen EF, Boyce RW, Shi Y, **Brown JP**, Horlait S, Libanati C, Chapurlat R, Chavassieux P (2020). Kinetic Reconstruction of the Cancellous and Endocortical Remodeling Unit Reveals a Net Positive Bone Balance After 12 Months of Treatment with Romosozumab. ASBMR 2020 Virtual Annual Meeting. **Oral presentation 1041.**
48. Farlay D, Rizzo S, Dempster D, Huang S, Chen L, Chines A, **Brown JP**, Boivin G (2020). Bone Matrix quality in transiliac biopsies from post-menopausal women treated with denosumab for up to 10 years (FREEDOM and FREEDOM Extension Trials). ASBMR 2020 Virtual Annual Meeting. **Oral presentation 1064.**
49. **Brown JP** (2020). Long-term treatment of postmenopausal osteoporosis. Virtual oral presentation at a luncheon symposium on October 30, 2020 during the 17th Asia-Oceania Congress of Endocrinology and the 8th Seoul International Congress of Endocrinology and Metabolism (AOCE-SICEM 2020).
50. **Brown JP** (2020). Sclerostin antibody: reaching harmony. Virtual oral presentation at a luncheon symposium on October 31, 2020 during the 17th Asia-Oceania Congress of Endocrinology and the 8th Seoul International Congress of Endocrinology and Metabolism (AOCE-SICEM 2020).

#### Accepted and Published Abstracts

1. **Brown JP**, Ménard HA, Pleszczynski MR (1982). *Pseudo-allergic monoarthritis*. VIII Pan American Congress of Rheumatology, Washington, DC, USA, June 7-12, 1982. Poster # E068
2. Marceau F, **Brown JP**, St-Pierre S, De Medicis R, Lussier A (1982). *La carboxypeptidase-N (CPN) et les antirhumatismaux d'action lente*. Club de recherches cliniques du Québec. Réunion annuelle, Ste-Adèle, September 24-25, 1982. Oral presentation.
3. Delmas PD, **Brown JP**, Malaval L, Edouard C, Meunier PJ (1983). *Serum bone GLA-protein compared to bone histomorphometry in postmenopausal osteoporosis Serum BGP can predict histological heterogeneity*. VIII International Conference on Calcium Regulating Hormones, Kobe, Japan, October 16-24, 1983. Oral presentation.
4. Malaval L, Delmas PD, Demiaux B, **Brown JP**, Meunier PJ (1984). *Le dosage radioimmunologique de l'ostéocalcine sérique, marqueur spécifique pour l'étude des maladies osseuses*. VI<sup>e</sup> Colloque international de radioimmunologie, Lyon, France, April 12-14, 1984. Oral presentation.
5. Friede J, **Brown JP** (1988). *Validation d'un test d'absorption intestinale du calcium par méthode isotopique simple*. 7<sup>e</sup> réunion annuelle de l'Association québécoise des spécialistes en médecine nucléaire. Estérel, April 22-24, 1988.
6. Lussier A, Madernas P, Laliberté L, **Brown JP**, De Medicis R (1988). *Vertebral hyperostosis induced by vitamin A in the rat*. American College of Rheumatology, Northeast Regional Meeting. Ottawa, Ontario, Canada. September 23-25, 1988. Abstract # B34N.
7. Lussier A, Madernas P, Laliberté L, **Brown JP**, De Medicis R (1988). *Hyperostose vertébrale induite par la vitamine A chez le rat*. Club de recherches cliniques du Québec. Manoir Richelieu, Pointe-au-Pic, Québec, Canada. October 6-8, 1988.

8. Lussier A, Madarnas P, Laliberté L, **Brown JP**, De Medicis R (1989). *Vertebral hyperostosis induced by vitamin A in the rat*. *Arthritis & Rheumatism*; 32 (1 suppl) : R18. Abstract # B34N.
9. De Medicis R, Madarnas P, Guité C, Laliberté L, **Brown JP**, Lussier A (1989). *Maladie hyperostotique induite par la vitamine A chez le rat*. 57e Congrès de l'ACFAS, l'UQAM, Montréal, May 15-19, 1989.
10. Lussier A, Madarnas P, Laliberté L, Guité C, **Brown JP**, De Medicis R (1989). *DISH induced by vitamin A in the rat*. 53rd Annual Meeting of the American College of Rheumatology, Cincinnati, USA, June 12-17, 1989. *Arthritis & Rheumatism*; 32(5 suppl) : S112. Abstract # C125.
11. **Brown JP**, Chevalier M, Friede J, Breton M, Blanchet M-F (1989). *Beneficial effects of a lifelong dietary calcium intake on premenopausal bone mass*. First ICCRH-ASBMR Joint Meeting, Montreal, September 9-14. *J Bone Miner Res*; 4 (Suppl 1) : S229. Abstract # 446.
12. Lussier A, Ménard H, Myhal D, Gagné M, Mathon G, **Brown JP**, Latulippe L, St-Pierre B, Perron JF, De Medicis R (1990). *DISH, diabetes mellitus and retinal metabolism the physiopathologic core*. Xth Pan American Congress of Rheumatology. Guadalajara, Mexico, March 11-16, 1990. *Revista Mexicana de Rheumatologia*; 5 (Suppl.1).
13. Lussier A, Ménard H, Myhal D, St-Pierre B, Perron JD, De Medicis R, Gagné M, Mathon G, **Brown JP**, Latulippe L (1990). *Retinol metabolism, DISH and diabetes mellitus*. American College of Rheumatology Northeast Regional Meeting, New York, USA. May 17-19, 1990.
14. Bekker P, Valentin-Opran A, Kylstra J, **Brown JP**, Siris E, Ste-Marie L, Ryan W, Johnston C, Reginster J, Hosking D, Axelrod D, Singer F (1992). *Risedronate Dose response in Paget's disease*. The XIth International Conference on Calcium Regulating hormones, Florence, Italy, 24-April 29, 1992. *Bone and Mineral*; 17 (Suppl. 1).
15. Bekker P, Valentin-Opran A, Kylstra J, **Brown JP**, Siris E, Ste-Marie L, Ryan W, Johnston C, Reginster J, Hosking D, Axelrod D, Singer F (1992). *Risedronate Dose response in Paget's disease*. Bisphosphonates. From the laboratory to the patient. Satellite Workshop of the XIth ICCRh Conference. Siena, Italy, April 29-30, 1992.
16. Boyle I, **Brown J**, Davies J, Martin TJ, Nicholson G, Siris E, Valentin-Opran A (1992). *Risedronate preliminary results on dose dependency of cumulative doses of a bisphosphonate in Pagetic patients*. 14<sup>th</sup> Annual Meeting of the American Society for Bone and Mineral Research, Minneapolis, Minnesota, USA, 30 september – October 4, 1992. *J Bone Miner Res*; 7(Suppl. 1) : S299. Abstract # 826.
17. Boulet LP, Giguère MC, Milot J, **Brown JP** (1993). *Long-term effects of high-dose inhaled steroids on bone turnover and density*. ALA/ATS International Conference, San Francisco, California, May 16-19, 1993.
18. Bekker P, Kylstra J, Altman R, **Brown J**, Johnston C, Lang R, Mallette L, McClung M, Miller P, Ryan W, Singer F, Siris E, Tucci J, Axelrod D (1994). *A multicenter study of risedronate for Paget's disease*. 16<sup>th</sup> Annual Meeting of the American Society for Bone and Mineral Research, Kansas City, Missouri, USA, September 9-13, 1994. *J Bone Miner Res*; 9(Suppl. 1).
19. Crilly R, Sebaldt R, Adachi JD, **Brown JP**, Hanley DA, Olszynski WP, Petrie A, Ste-Marie L-G, Stephenson GF, Hodsman AH (1997). *Predicting response to intermittent cyclical etidronate in patients with osteoporosis*. Poster session of the 25th European Symposium on Calcified Tissues, Harrogate, U.K., April 25-29, 1997.

20. Potvin F, **Brown JP**, Bouchard L, Rola-Pleszczynski M, Poubelle PE (1997). *Biphasic effects of alendronate on COX-2 and IL-6 in normal human osteoblast-like cells in vitro*. Oral presentation at the Plenary session of the 25th European Symposium on Calcified Tissues, Harrogate, U.K., April 25-29, 1997.
21. **Brown JP**, Adachi JD, Bensen WG, Olszynski WP, Sacco-Gibson NA, Pack S., Chines AA, for the Canadian CIO Research Group (1997). Comparison of bone resorption markers following etidronate therapy in patients on high dose corticosteroids. Poster session of the 25th European Symposium on Calcified Tissues, Harrogate, U.K., April 25-29, 1997.
22. **Brown JP**, Johnston CC, Reginster J-Y, Ryan WG, Ste-Marie L-G, Bekker PJ (1997). Dose response of risedronate for Paget's disease. 79th Annual Meeting of the Endocrine Society, Minneapolis, USA, June 11-14, 1997. Poster # P3-207.
23. Adachi JD, Chines AA, Stephenson GF, Pack S for the Canadian CIO Research Group (1997). Intermittent cyclical therapy with etidronate in the prevention of corticosteroid-induced osteoporosis. XIXth ILAR Congress of Rheumatology, Singapore, June 8-13, 1997. Abstract Book: 88.
24. **Brown JP**, Hanley DA, Ste-Marie L-G, Hodsman AB, Adachi JD, Pack S, Chines AA, Sacco-Gibson NA, for the Canadian CIO Research Group (1997). Comparison of bone resorption markers following etidronate therapy in patients on high dose corticosteroids. XIXth ILAR Congress of Rheumatology, Singapore, June 8-13, 1997. Abstract Book: 89.
25. Bekker PJ, Miller PD, Adachi JD, **Brown JP**, Khairi RA, Lang R, Licata AA, McClung MR, Ryan WR, Singer FR, Siris ES, Tenenhouse A, Wallach S, Axelrod DW (1997). Risedronate treatment improves pain status in patients with Paget's disease of bone. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, USA, September 10-14, 1997. J Bone Miner Res;12 (Suppl. 1) : S270. Abstract # T673.
26. Miller PD, Adachi JD, **Brown JP**, Khairi RA, Lang R, Licata AA, McClung MR, Ryan WR, Singer FR, Siris ES, Tenenhouse A, Wallach S, Bekker PJ, Axelrod DW (1997). Risedronate vs. etidronate Paget's study Durable remission with only two months of 30 mg risedronate. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, USA, September 10-14, 1997. J Bone Miner Res;12(Suppl. 1) : S269. Abstract # T670.
27. Chines A, Bekker P, Ritter-Hmcirik C, **Brown JP**, Hayes C (1997). Improvement of pagetic bone lesions with risedronate treatment a radiographic study. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, USA, September 10-14, 1997. J Bone Miner Res;12(Suppl. 1) : S270. Abstract # T674.
28. Bessette L, **Brown JP**, Migneault N, Tenenhouse A (1997). Predictors of vertebral fractures in the general population aged 50 years and older a Canadian cross-sectional study (CaMos). 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, USA, September 10-14, 1997. J Bone Miner Res;12(Suppl. 1) : S362. Abstract # F546.
29. Bessette L, **Brown JP**, Migneault N, Tenenhouse A (1997). Evaluation of the impact of vertebral fractures on quality of life a cross-sectional survey. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, USA, September 10-14, 1997. J Bone Miner Res;12(Suppl. 1) : S364. Abstract # F552.
30. Tenenhouse A, **Brown J**, Joseph L and the CaMos Research Group (1997). Peak bone mass and prevalence of osteoporosis in a randomly selected Canadian population of women and men. 19th Annual Meeting of

the American Society for Bone and Mineral Research, Cincinnati, Ohio, USA, September 10-14, 1997. *J Bone Miner Res*;12(Suppl. 1) : S246. Abstract # T579.

31. Crilly R, Sebaldt RJ, Adachi JD, **Brown JP**, Hanley DA, Olszynski WP, Petrie A, Ste-Marie L-G, Hodsmann AH (1997). Comparison of BMD measurements at 6 and 12 months in assessing response to etidronate in osteoporosis. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, USA, September 10-14, 1997. *J Bone Miner Res*;12 (Suppl. 1) : S474. Abstract # S486.
32. Hanley D, Sacco-Gibson NA, Adachi JD, Hodsmann AB, **Brown JP**, Pack S, Chines AA for the Canadian CIO Research Group (1997). Etidronate therapy in patients on high dose corticosteroids Differences in bone resorption marker responses. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio, USA, September 10-14, 1997. *J Bone Miner Res*;12 (Suppl. 1): S509. Abstract # S626.
33. Hayes C, Bekker P, Ritter-Hmcirik C, **Brown JP**, Chines A (1997). Improvement of pagetic bone lesions with risedronate treatment. 61st National Scientific Meeting of the American College of Rheumatology, Washington, DC, USA, November 8-12, 1997. *Arthritis and Rheumatism*; 40(9) Suppl: S279. Abstract # 1487. **Oral presentation.**
34. Singer FR, **Brown JP**, Siris ES, Hosking DJ, Miller PD, Bekker PJ, Crusan CE, Axelrod DW (1997). Integrated effectiveness of risedronate in treatment of Paget's disease. 61st National Scientific Meeting of the American College of Rheumatology, Washington, DC, USA, November 8-12, 1997. *Arthritis and Rheumatism*; 40(9) Suppl: S279. Abstract # 1488. **Oral presentation.**
35. Singer FR, **Brown JP**, Siris ES, Hosking DJ, Miller PD, Ethgen D, Axelrod DW (1997). A safety review of the use of risedronate in the treatment of Paget's disease of bone. 61st National Scientific Meeting of the American College of Rheumatology, Washington, DC, USA, November 8-12, 1997. *Arthritis and Rheumatism*; 40(9) Suppl: S279. Abstract # 1489. **Oral presentation.**
36. Bensen WG, Adachi JD, Anastassiades TP, **Brown JP**, Chines AA, Olszynski WP, Hanly JG, for the Canadian CIO Research Group (1997). Intermittent cyclical therapy with etidronate in the prevention of corticosteroid-induced osteoporosis. 61st National Scientific Meeting of the American College of Rheumatology, Washington, DC, USA, November 8-12, 1997. *Arthritis and Rheumatism*; 40(9) Suppl: S327. Abstract # 1773. **Oral presentation.**
37. **Brown JP**, Roux C, Adachi JD, Chines AA, Horlait S, Stephenson GF, Pack S for the Canadian CIOP and European CIBLOS Research Groups (1998). *Prevention of corticosteroid-induced osteoporosis with intermittent cyclical therapy with etidronate*. 4th Workshop on Bisphosphonates-From the Laboratory to the Patient, Davos, Switzerland, March 18-20, 1998. *Bone*; 22(3) Suppl: 55 S. Abstract # B39.
38. Chines A, Bekker P, Ritter-Hrncirik C, **Brown J**, Hayes C (1998). *Improvement of pagetic bone lesions with risedronate treatment a radiographic study*. 4th Workshop on Bisphosphonates-From the Laboratory to the Patient, Davos, Switzerland, March 18-20, 1998. *Bone*; 22(3) Suppl: 56 S. Abstract # B44.
39. Singer FR, **Brown JP**, Siris ES, Hosking DJ, Miller PD, Ethgen D, Axelrod DW (1998). *A safety review of the use of risedronate in the treatment of Paget's disease of bone*. 4th Workshop on Bisphosphonates-From the Laboratory to the Patient, Davos, Switzerland, March 18-20, 1998. *Bone*; 22(3) Suppl: 63 S. Abstract # B72.
40. Singer FR, **Brown JP**, Siris ES, Hosking DJ, Miller PD, Bekker PJ, Crusan CE, Axelrod DW (1998). *Integrated analysis of effectiveness of risedronate for Paget's disease*. 4th Workshop on Bisphosphonates-From the Laboratory to the Patient, Davos, Switzerland, March 18-20, 1998. *Bone*; 22(3) Suppl: 63 S. Abstract # B73.

41. Ste-Marie L-G, Adachi JD, **Brown JP**, Chines AA, Hanley D, Hodsmann AB, Pack S, Sacco-Gibson NA, Stephenson GF for the Canadian CIO Research Group (1998). *The effect of etidronate therapy on markers of bone turnover in patients on high dose corticosteroids*. 4th Workshop on Bisphosphonates-From the Laboratory to the Patient, Davos, Switzerland, March 18-20, 1998. *Bone*; 22(3) Suppl: 63 S. Abstract # B74.
42. Miller PD, **Brown JP**, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ for the Paget's Risedronate/Etidronate Study (PRES) (1998). *A comparative trial of risedronate versus etidronate in the treatment of patients with Paget's disease of bone*. The National Association for the Relief of Paget's disease International Symposium, Oxford, UK, July 15-17, 1998. *Bone*;24(5) Suppl.
43. Singer F, **Brown J**, Siris E, Hosking D, Miller P, Ethgen D, Axelrod D (1998). A safety review of the use of risedronate in the treatment of Paget's disease of bone. European Congress on Osteoporosis, Berlin, Germany, September 11-15, 1998. *Osteoporos Int*; 8(Suppl 3): 111. Abstract # P350.
44. Miller P, Singer F, **Brown J**, Siris E, Hosking D, Chines A, Crusan C, Axelrod D (1998). Integrated analysis of effectiveness of risedronate for Paget's disease of bone. European Congress on Osteoporosis, Berlin, Germany, September 11-15, 1998. *Osteoporos Int*; 8(Suppl 3): 111. Abstract # P351.
45. Morissette J, **Brown JP**, Raymond V (1998). Genetic epidemiology of Paget's disease of bone in eastern Québec. 48th Annual Meeting of the American Society of Human Genetics, Denver, Colorado, USA, October 27-31, 1998. *Am J Hum Gen* ; 63(Suppl): A217. Abstract # 1247.
46. Emkey R, Saag K, **Brown J**, Correa-Rotter R, Malice MP, Carofano W, Daifotis A for the Alendronate Glucocorticoid Study Group (1998). Consistency of effect of alendronate in glucocorticoid-induced and postmenopausal osteoporosis. 62nd National Scientific Meeting of the American College of Rheumatology, San Diego, USA, November 8-14, 1998. *Arthritis & Rheumatism*; 41(9) Suppl: S44. Abstract # 72. **Oral presentation.**
47. Adachi JD, Bensen WG, Anastassiades TP, **Brown JP**, Chines AA, Olszynski WP, Hanly JG, Stephenson GF for the Canadian CIO Research Group (1998). Etidronate in the Prevention of Corticosteroid-Induced Osteoporosis One Year of Follow-up on Calcium only. 62nd National Scientific Meeting of the American College of Rheumatology, San Diego, USA, November 8-14, 1998. *Arthritis & Rheumatism*; 41(9) Suppl: S137. Abstract # 628. **Oral presentation.**
48. Saag K, Emkey R, Cividino A, **Brown J**, Goemaere S, Dumortier T, Daifotis AG, Czachur M for the Alendronate study (1998). Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids. IBMS-ASBMR Joint Meeting, San Francisco, CA, USA, December 1-6, 1998. *Bone*; 23(5) Suppl: S182. Abstract # 1141. **Oral presentation.**
49. Hanley DA, Adachi JD, Anastassiades TP, **Brown JP**, Chines AA, Hodsmann AB, Josse R, Kendler D, Olszynski W, Pack S, Ste-Marie L-G, Stephenson GF, Tenenhouse A, for the Canadian CIO Research Group (1998). Prevention of corticosteroid-induced osteoporosis with etidronate. One year follow-up with calcium only. IBMS-ASBMR Joint Meeting, San Francisco, CA, USA, December 1-6, 1998. *Bone*; 23(5) Suppl: S310. Abstract # T460.
50. Bessette L, **Brown J**, Migneault N, Tenenhouse A (1998). Sensitivity and specificity of SCORE for identification of women with low bone mass density in a French Canadian population. Canadian Multicentre Osteoporosis Study (CAMOS). IBMS-ASBMR Joint Meeting, San Francisco, CA, USA, December 1-6, 1998. *Bone*; 23(5) Suppl: S315. Abstract # T481.

51. Eriksen EF, **Brown JP**, Boling E, Sacco-Gibson N, Sod E, Axelrod DW (1998). Beneficial effects of risedronate in corticosteroid-treated patients Histology and histomorphometry. IBMS-ASBMR Joint Meeting, San Francisco, CA, USA, December 1-6, 1998. Bone; 23(5) Suppl: S403. Abstract # W466.
52. **Brown JP**, Raymond V, Huot D, Lacourcière Y, Drapeau G, Verreault J, Morissette J (1998). Exclusion of genetic linkage between Paget's disease and chromosome 18q in four large French-Canadian pedigrees. IBMS-ASBMR Joint Meeting, San Francisco, CA, USA, December 1-6, 1998. Bone; 23(5) Suppl: S453. Abstract # F177.
53. Wallach S, Siris E, Singer F, Miller P, **Brown J**, Valent D, Chines A, the Risedronate Paget's Disease (1998). Risedronate produces sustained remission in patients with Paget's disease of bone. IBMS-ASBMR Joint Meeting, San Francisco, CA, USA, December 1-6, 1998. Bone; 23(5) Suppl: S454. Abstract # F181.
54. Ungar W, Lee S, Ryan N, Adachi R, Hanley D, Josse R, Breton M-C, **Brown J** (1999). The Canadian SCORE Questionnaire – Optimizing the use of technology for low bone density assessment. 5th Annual Scientific Meeting of the International Society of Clinical Densitometry, New Orleans, Louisiana, USA, January 14-17, 1999. Abstract # P25.
55. Ericksen E, Melsen F, **Brown J**, Sacco-Gibson N, Balena R, Sod E, Axelrod D, Chines A (1999). *Three years of risedronate treatment significantly decreases bone turnover without impairing mineralization.* 21<sup>st</sup> Annual Meeting of the American Society of Bone and Mineral Research, St. Louis, Missouri, USA, September 30th – October 4, 1999. J Bone Miner Res;14(Suppl 1): S404. Abstract SA 378.
56. Burge R, Staveley C, Adachi JD, **Brown J**, Hanley D (1999). *Risedronate minimizes the costs of treating Paget's disease.* 21<sup>st</sup> Annual Meeting of the American Society of Bone and Mineral Research, St. Louis, Missouri, USA, September 30th – October 4, 1999. J Bone Miner Res;14(Suppl 1): S542. Abstract SU 441.
57. Adachi JD, Hanley DA, Ioannidis G, Berger C, Papaioannou A, Pickard L, Papadimitropoulos M, Makrechian N, Murray T, Hopman W, **Brown JP** (1999). *The influence of osteoporotic fractures on health related quality of life (HRQL) in community dwelling men and women across Canada.* 21<sup>st</sup> Annual Meeting of the American Society of Bone and Mineral Research, St. Louis, Missouri, USA, September 30th – October 4, 1999. J Bone Miner Res;14(Suppl 1): S262. Abstract F 264.
58. Raymond V, Laurin NN, Brousseau C, Duchesne A, Huot D, Lacourcière Y, Drapeau G, Verreault J, Morissette J, **Brown JP** (1999). *Further exclusion of genetic linkage between Paget's disease and chromosome 18q in French-Canadian pedigrees.* 21<sup>st</sup> Annual Meeting of the American Society of Bone and Mineral Research, St. Louis, Missouri, USA, September 30th – October 4, 1999. J Bone Miner Res;14(Suppl 1): S541. Abstract SU 439.
59. Vendittoli PA, Major D, Simpson A, Jean S, **Brown JP** (2000). *Descriptive study of osteoporotic fractures and hip fracture risk evaluation of subjects with past minor fractures.* World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18, 2000. Osteoporos Int; 11(suppl 2): S109. Arégé # 197.
60. Lindsay R, Watts N, Roux Ch, **Brown J**, Barton I, Flowers K, Cooper C (2000). Increased risk of new vertebral fracture within 1 year of an incident vertebral fracture. World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18, 2000. Osteoporos Int; 11(suppl 2): S112. Abstract # 209.
61. Sebaldt RJ, Adachi JD, Olszynski W, **Brown J**, Hanley D, Tenenhouse A, Caminis J, Petrie A, Yuen C, Stephenson GF, Goldsmith CH for the Multicentre CANDOO Project (2000). *Patient compliance with bisphosphonate therapy.* World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18, 2000. Osteoporos Int; 11(suppl 2): S200. Abstract # 533.

62. Sebaldt RJ, Adachi JD, Olszynski W, **Brown J**, Hanley D, Tenenhouse A, Caminis J, Petrie A, Yuen C, Ioannidis G, Goldsmith CH for the Multicentre CANDOO Project (2000). *Vertebral fractures and quality of life*. World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18, 2000. *Osteoporos Int*; 11(suppl 2): S200. Abstract # 534.
63. Miller PD, Hosking DH, Singer FR, **Brown J**, Siris ES, Bekker PJ, Crusan CE, Axelrod D (2000). A review of the efficacy of Risedronate in Paget's Disease of Bone. National Osteoporosis Society Conference, Bath, UK, April 9-13, 2000.
64. Cadarette SM, Jaglal SB, Murray TM, McIsaac WJ, Joseph L, **Brown JP** for the CaMos Research Group (2000). *Evaluation of decision rules to refer women for bone densitometry by dual energy x-ray absorptiometry*. 22<sup>nd</sup> Annual Meeting of the American Society of Bone and Mineral Research, Toronto, Ontario, Canada, September 22-26, 2000. *J Bone Miner Res*; 15(Suppl 1): S169. Abstract 1125. **Oral presentation.**
65. Laurin NN, Raymond V, Duchesne A, Brousseau C, Huot D, Lacourcière Y, Drapeau G, Verreault J, **Brown JP**, Morissette J (2000). *Genome-wide scan for Paget's disease of bone in French-Canadian population*. 22<sup>nd</sup> Annual Meeting of the American Society of Bone and Mineral Research, Toronto, Ontario, Canada, September 22-26, 2000. *J Bone Miner Res*; 15(Suppl 1): S443. Abstract SU464.
66. Sebaldt RJ, Adachi JD, Olszynski W, **Brown J**, Hanley D, Tenenhouse A, Caminis J, Petrie A, Papaianou A, Stephenson GF, Goldsmith CH (2000). *Patient adherence to bisphosphonate therapy*. 22<sup>nd</sup> Annual Meeting of the American Society of Bone and Mineral Research, Toronto, Ontario, Canada, September 22-26, 2000. *J Bone Miner Res*; 15(Suppl 1): S433. Abstract SU417.
67. Roux C, Eriksen E, **Brown J**, Barton I, Passeri M, Manhart M, Watts NB, Lindsay R (2000). *One-in-five risk of new vertebral fracture within 1 year of an incident fracture*. 22<sup>nd</sup> Annual Meeting of the American Society of Bone and Mineral Research, Toronto, Ontario, Canada, September 22-26, 2000. *J Bone Miner Res*; 15(Suppl 1): S223. Abstract F320.
68. Sebaldt RJ, Adachi JD, Olszynski W, **Brown J**, Hanley DA, Tenenhouse A, Caminis J, Petrie A, Ioannidis G, Goldsmith CH (2000). *Vertebral fractures and quality of life*. 22<sup>nd</sup> Annual Meeting of the American Society of Bone and Mineral Research, Toronto, Ontario, Canada, September 22-26, 2000. *J Bone Miner Res*; 15(Suppl 1): S562. Abstract M446.
69. Sebaldt RJ, Adachi JD, Olszynski W, **Brown J**, Hanley DA, Tenenhouse A, Caminis J, Petrie A, Ioannidis G, Goldsmith CH (2000). *Non-vertebral fractures and quality of life*. 22<sup>nd</sup> Annual Meeting of the American Society of Bone and Mineral Research, Toronto, Ontario, Canada, September 22-26, 2000. *J Bone Miner Res*; 15(Suppl 1): S562. Abstract M447.
70. Reid IR, **Brown J**, Burckhardt P, Horowitz Z, Richardson PC, Trechsel U, for the Zoledronic Acid Study Group (2001). *A single annual injection of the bisphosphonate, Zoledronic acid, stably reduces bone turnover and increases bone density in postmenopausal osteoporosis*. First Joint Meeting of the IBMS- ECTS, Madrid, Spain, June 5-10, 2001. *Bone*; 28(5) Suppl: S89.
71. Brown D, Picard S, **Brown JP**. *A simple, fast and reproducible fully automated method for structural and dynamic bone histomorphometry*. First Joint Meeting of the IBMS- ECTS, Madrid, Spain, June 5-10, 2001. *Bone*; 28(5) Suppl: S201.
72. Drake WM, **Brown JP**, Banville C, Kendler DL (2001). Can digital BMD and multi-site speed of sound conduction be used to monitor therapy with alendronate in postmenopausal osteoporosis? 23<sup>rd</sup> Annual Meeting

of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S526. Abstract M394.

73. Picard D, Couturier M, Rosenthal L, Lévesque J, Dumont, **Brown J**, Ste-Marie LG, Tenenhouse A, Dodin S, for the Quebec Osteoporosis Study Group (2001). Peripheral bone mass measurement, a helpful tool for the diagnosis of osteoporosis in areas where central DXA is not available. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S340. Abstract SU114.
74. Adachi JD, Ioannidis G, Berger C, Pickard L, Prior J, Hanley DA, Olszynski WP, Murray T, Anastassiades T, **Brown JP**, Kirkland S, Joyce C, Joseph L, Papaioannou A, Poliquin S, Tenenhouse A, and the CaMos Research Group (2001). The impact of comorbid conditions on bone mineral density and vertebral deformities in community dwelling men and women across Canada. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S520. Abstract M366.
75. **Brown JP**, Burckhardt P, Reid IR, Horowitz, Richardson PC, Trechsel U, for the Zoledronic Acid Study Group (2001). Zoledronic acid, at a total annual dose of 4 mg, increases bone density at all sites and stably reduces bone turnover for one year when administered as a single or a 3-monthly intravenous injection in postmenopausal osteoporosis. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S218. Abstract F353.
76. Papadimitropoulos EA, Adachi JD, Ioannidis G, Berger C, Pickard L, Prior J, Hanley DA, Olszynski WP, Murray T, Anastassiades T, **Brown JP**, Kirkland S, Joyce C, Joseph L, Papaioannou A, Poliquin S, Tenenhouse A, and the CaMos Research Group (2001). The impact of osteoporotic fractures on health related quality of life as measured by the health utilities index. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S393. Abstract SU348.
77. **Brown JP**, Banville C, Jean S, Drake WM, Kendler DL (2001). Efficacy, safety and tolerability once weekly (80 vs 160 mg) oral alendronate in postmenopausal osteoporosis. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S528. Abstract M402.
78. Laurin N, **Brown JP**, Lemainque A, Duchesne A, Huot D, Lacourcière Y, Drapeau G, Verreault J, Raymond V and Morissette J (2001). Paget's disease of bone: Mapping of two loci at 5q35-tel and 5q31 and genetic heterogeneity. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S152. Abstract 1065. **Oral presentation.**
79. Hanley DA, Sebaldt RJ, Ioannidis G, Petrie A, Olszynski WP, **Brown JP**, Josse RG, Goldsmith CH, Papaioannou A, Adachi JD (2001). The impact of treatment interventions on health related quality of life (HRQL) in post-menopausal women registered in the Canadian Database of Osteoporosis and Osteopenia (CAN-DOO) Patients. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S541. Abstract M466.
80. Olzynski WP, Polischuk CO, Drinkwater DT, Davison KS, Murray TM, **Brown J**, for the CaMos Research Group (2001). Effect of cigarette smoking and alcohol consumption on bone mineral density in men-Data from the Canadian Multicentre Osteoporosis Study (CaMos). 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S517. Abstract M356.



81. Watts NB, **Brown J**, Hosking D, Adami S, Mulder H, Reginster JY, Kasibhatla C, Chines A (2001). Sustained Fracture Risk Reduction Over 5 Years With Risedronate Therapy. 23rd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. *J Bone Miner Res*; 16(Suppl 1): S217. Abstract F347.
82. Olszynski WP, Ioannidis G, Hanley DA, Sebaldt RJ, Petrie A, **Brown JP**, Josse RG, Goldsmith CH, Stephenson GF, Papaioannou A, Adachi JD (2001). *The impact of thyroid hormone therapy on bone density in patients registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)*. 65<sup>th</sup> National Scientific Meeting of the American College of Rheumatology, San Francisco, California, USA, November 8-14, 1998. *Arthritis & Rheumatism*; 44(9) Suppl.
83. Lindsay R, Kendler D, McClung M, Balske A, Li Z, **Brown J** (2001). *Risedronate 35 mg once a week is as effective as 5 mg daily in postmenopausal women*. 65<sup>th</sup> National Scientific Meeting of the American College of Rheumatology, San Francisco, California, USA, November 8-14, 1998. *Arthritis & Rheumatism*; 44(9) Suppl.
84. Lindsay R, Adachi JD, Emkey RD, Li Z, Balske A, **Brown J** (2002). *Once-A-Week (35 mg) is as Effective as Daily (5 mg)*. World Congress on Osteoporosis, Lisbon, Portugal, May 10-14, 2002. *Osteoporosis Int*; 13(suppl 1): S16. Abstract # P41SA.
85. Picard D, Couturier M, Rosenthal L, **Brown JP**, Lévesque J, Dumont M, Ste-Marie LG, Tenenhouse A, Dodin S (2002). *Peripheral Bone Mass Measurement is a Better Predictor of Central Bone Mass Than Osteoporosis Risk Questionnaires*. World Congress on Osteoporosis, Lisbon, Portugal, May 10-14, 2002. *Osteoporosis Int*; 13(suppl 1): S10. Abstract # O23.
86. Adachi JD, Sebaldt RJ, Olszynski WP, **Brown JP**, Hanley DA, Josse RG, Murray T, Petrie A, Ioannidis G, Goldsmith CH (2002). *CANDOO: A Longitudinal Canadian Multi-Center Tertiary-Care Network For Observational Research in Osteoporosis (OP) and Osteopenia Using Standardized Clinical Practice Data: 11 Years of Follow-Up*. World Congress on Osteoporosis, Lisbon, Portugal, May 10-14, 2002. *Osteoporosis Int*; 13(suppl 1): S28. Abstract # P79MO.
87. Adachi JD, Olszynski WP, Sebaldt RJ, Ioannidis G, Hanley DA, **Brown JP**, Josse RG, Murray T, Petrie A, Goldsmith CH (2002). *Iliacostal Distance (ILCD) is Associated With Prevalent Vertebral (Vert) and Non-Vertebral (NV) Fractures in Patients Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)*. World Congress on Osteoporosis, Lisbon, Portugal, May 10-14, 2002. *Osteoporosis Int*; 13(suppl 1): S79. Abstract # P251MO.
88. **Brown J**, Balske DA, Lindsay R (2002). *Risedronate 35 mg Once-A-Week is as Effective as 5 mg Daily in Osteoporotic Women*. Fifth International Symposium: Clinical Advances in Osteoporosis, Honolulu, Hawaii, USA, March 6-9, 2002. Scientific Program: 26. Poster #98.
89. Papaioannou A, Sebaldt RJ, Olszynski WP, Ioannidis G, Hanley DA, Petrie A, **Brown JP**, Josse RG, Murray T, Goldsmith CH, Adachi JD (2002). *Patient Adherence to Etidronate (ETD), Alendronate (ALD) and Hormone Replacement Therapy (HRT)*. Fifth International Symposium: Clinical Advances in Osteoporosis, Honolulu, Hawaii, USA, March 6-9, 2002. Scientific Program: 1. Poster #2.
90. Drinkwater DT, Polischuk CO, Davison KS, Olszynski WP, Murray TM, **Brown JP** (2002). *Influence of physical Activity on Bone Mineral Density in Men: Data from the Canadian Multi-Centre Osteoporosis (CAMOS)*. Fifth International Symposium: Clinical Advances in Osteoporosis, Honolulu, Hawaii, USA, March 6-9, 2002. Scientific Program: 6. Poster #24.

91. Olszynski WP, Sebaldt RJ, Ioannidis G, Hanley DA, Petrie A, **Brown JP**, Josse RG, Murray T, Goldsmith CH, Papaioannou A, Adachi JD, (2002). *Iliacostal Distance (ILCD) is Associated With Prevalent Vertebral (Vert) and Non-Vertebral (NV) Fractures in Patients Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)*. Fifth International Symposium: Clinical Advances in Osteoporosis, Honolulu, Hawaii, USA, March 6-9, 2002. Scientific Program: 8. Poster #30.
92. Adachi JD, Ioannidis G, Pickard L, Berger C, Prior J, Hanley DA, Olszynski WP, Murray T, Anastassiades T, **Brown JP**, Kirkland S, Joyce C, Joseph L, Papaioannou A, Poliquin S, Tenenhouse A, Papadimitropoulos EA (2002). *Osteoporotic Fractures and Health Related Quality of Life (HRQL) as Measured by the Health Utilities Index (HUI) in the Canadian Multicentre Osteoporosis Study (CaMos)*. Fifth International Symposium: Clinical Advances in Osteoporosis, Honolulu, Hawaii, USA, March 6-9, 2002. Scientific Program: 21. Poster #77.
93. Adachi JD, Sebaldt RJ, Olszynski WP, **Brown JP**, Hanley DA, Josse RG, Murray T, Petrie A, Ioannidis G, Goldsmith CH (2002). *CANDOO: A Longitudinal Canadian Multi-Center Tertiary-Care Network For Observational Research in Osteoporosis (OP) and Osteopenia Using Standardized Clinical Practice Data: 11 Years of Follow-Up*. Fifth International Symposium: Clinical Advances in Osteoporosis, Honolulu, Hawaii, USA, March 6-9, 2002. Scientific Program: 28. Poster #104.
94. **Brown JP**, Ioannidis G, Adachi JD, Petrie A, Ferko N, Boulos P, Stephenson GF (2002). *Secondary Causes of Osteoporosis in Patients Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)* 24th Annual Meeting of the American Society of Bone and Mineral Research, San Antonio, Texas, USA, September 20-24, 2002. J Bone Miner Res; 17(Suppl 1): S261. Abstract SA286.
95. Papaioannou A, Ioannidis G, Sebaldt RJ, Olszynski WP, Hanley DA, Petrie A, **Brown JP**, Josse R, Murray T, Goldsmith CH, Adachi JD (2002) *Adherence Profile of Etidronate (ETD), Alendronate (ALD) and Hormone Replacement Therapy (HRT) in Patients Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)* 24th Annual Meeting of the American Society of Bone and Mineral Research, San Antonio, Texas, USA, September 20-24, 2002. J Bone Miner Res; 17(Suppl 1): S270. Abstract SU340.
96. Sebaldt RJ, Adachi JD, Olszynski W, **Brown JP**, Hanley DA, Josse RG, Murray T, Stephenson, Petrie A, Mark A, Goldsmith CH (2002) *CANDOO: A Longitudinal Canadian Multi-Center Tertiary-Care Network for Observational Research in Osteoporosis and Osteopenia Using Standardized Clinical Practice Data: 11 Years of Follow-up* 24th Annual Meeting of the American Society of Bone and Mineral Research, San Antonio, Texas, USA, September 20-24, 2002. J Bone Miner Res; 17(Suppl 1): S358. Abstract SU296.
97. Adachi JD, Siminoski KG, Cline G, **Brown JP**, Cranney AB, Goltzman, Hanley DA, Hodsman AB, Josse RG, Kendler DL, Ste-Marie L, Olszynski WP, Tenenhouse A, Li Z (2002) *The Impact of Dropouts of the Efficacy of 5 mg Risedronate: An Assessment Based on an Imputation Analysis* 24th Annual Meeting of the American Society of Bone and Mineral Research, San Antonio, Texas, USA, September 20-24, 2002. J Bone Miner Res; 17(Suppl 1): S369. Abstract SU343.
98. Auger S, Laurin N, **Brown JP**, Raymond V, Morissette J (2002) *Genetic Heterogeneity of Paget Disease of Bone in French-Canadian Families* 24th Annual Meeting of the American Society of Bone and Mineral Research, San Antonio, Texas, USA, September 20-24, 2002. J Bone Miner Res; 17(Suppl 1): S380. Abstract SU388.
99. Olszynski W.P., Ioannidis G., Berger C. Papaioannou A., Prior J.C., Joseph L., Hanley D.A., Pickard L., Murray T.M., **Brown J.P.**, Tenenhouse A., Anastassiades T., Hopman W., Kirkland S., Joyce C. Poliquin S., Kreiger N., Adachi J.D. and the CaMos Research Group (2003) *Participant Characteristics that Predict 3-Year Incident Clinically Recognized Vertebral Deformity in Menopausal Women Enrolled in the Canadian*

*Multicentre Osteoporosis Study (CaMoS)* 30<sup>th</sup> European Symposium on Calcified Tissues, Rome, Italy, May 8-12, 2003. *Calcif Tissue Int*; 74: 399. Abstract P-263.

100. Ioannidis G., Papadimitropoulos E.A., Berger C., Papaioannou A., **Brown J.P.**, Joseph L., Hanley D.A., Olszynski W.P., Prior J.C., Pickard L., Murray T.M., Tenenhouse A., Anastassiades T., Hopman W., Kirkland S., Joyce C., Poliquin S., Kreiger N., Adachi J.D., and the CaMos Research Group (2003) *The Relationship Among Osteoporotic Fractures and Health Related Quality of Life (HRQL) as Measured by the Health Utilities Index Mark II and Mark III Systems*. 30<sup>th</sup> European Symposium on Calcified Tissues, Rome, Italy, May 8-12, 2003. *Calcif Tissue Int*; 74: 400. Abstract P-267.
101. Josse R.G., Sawka A.M., Ioannidis G., Murray T.M., Sebaldt R.J., Hanley D.A., **Brown J.P.**, Goldsmith C.H., Papaioannou A., Olszynski W.P., Petrie A., Adachi J.D. (2003) *Predictors of Early Failure of Bisphosphonate Therapy in Patients Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)* 30<sup>th</sup> European Symposium on Calcified Tissues, Rome, Italy, May 8-12, 2003. *Calcif Tissue Int*; 74: 397. Abstract P-256.
102. Papaioannou A., Ioannidis G., Sebaldt R.J., **Brown J.P.**, Goldsmith C.H., Hanley D.A., Olszynski W.P., Petrie A., Josse R.G., Murray T.M., Boulos P., Ferko N., Adachi J.D. (2003) *Adherence to Bisphosphonates and Hormone Replacement Therapy in a Tertiary Care Setting of Patients in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)* 30<sup>th</sup> European Symposium on Calcified Tissues, Rome, Italy, May 8-12, 2003. *Calcif Tissue Int*; 74:397. Abstract # P-258.
103. Olszynski W.P., Ioannidis G., Sebaldt R.J., Hanley D.A., Petrie A., **Brown J.P.**, Josse R.G., Murray T.M., Goldsmith C.H., Papaioannou A., Adachi J.D. (2003) *Effectiveness of Etidronate and Alendronate in the Treatment of Osteoporosis in Men Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)* 30<sup>th</sup> European Symposium on Calcified Tissues, Rome, Italy, May 8-12, 2003. *Calcif Tissue Int*; 74: 398. Abstract # P-262.
104. **Brown JP**, Ioannidis G, Berger C, Hanley DA, Prior JC, Joseph L, Olszynski WP, Papaioannou A, Pickard L, Murray TM, Tenenhouse A, Anastassiades T, Hopman W, Kirkland S, Joyce C, Poliquin S, Kreiger N, Adachi JD and the CaMos Research Group (2003). *Risk Factors that Predict Three Year Incident Non-Vertebral Fragility Fractures in Menopausal Women in the Canadian Multicentre Osteoporosis Study (CAMOS)*. 30<sup>th</sup> European Symposium on Calcified Tissues, Rome, Italy, May 8-12, 2003. *Calcif Tissue Int*; 74: 399. Abstract # P-264.
105. Hanley DA, Ioannidis G, Josse RG, Murray TM, **Brown JP**, Sebaldt RJ, Goldsmith CH, Papaioannou A, Olszynski WP, Petrie A, Adachi JD (2003). *Risk Factors Associated with Health Related Quality of Life (HRQL) in Postmenopausal Women with Vertebral Fractures Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)*. 30<sup>th</sup> European Symposium on Calcified Tissues, Rome, Italy, May 8-12, 2003. *Calcif Tissue Int*; 74:421. Abstract # P-352.
106. **Brown JP**, Bessette L, Beaulieu M, Lafortune L, Jean S, Morescu E, Ste-Marie L-G (2003). *ROCQ: Recognizing Osteoporosis and its Consequences in Quebec (ROCQ), a Patient Health Management Programme*. 30<sup>th</sup> European Symposium on Calcified Tissues, Rome, Italy, May 8-12, 2003. *Calcif Tissue Int*; 74: 398. Abstract # P-261.
107. **Brown JP**, Ioannidis G, Papaioannou A, Tenenhouse A, Prior JC, Joseph L, Hanley DA, Olszynski WP, Adachi JD (2003). *Risk Factors that Predict the Time of First Non-Vertebral Fracture in Postmenopausal Women Recruited from the Canadian Multicentre Osteoporosis Study (CAMOS)*. 1<sup>st</sup> Joint Meeting of the International Bone and Mineral Society and the Japanese Society for Bone and Mineral Research, Osaka, Japan, June 3-7, 2003. *Bone*; 32: S188.

108. Olszynski WP, Ioannidis G, Sebaldt RJ, Hanley DA, Petrie A, **Brown JP**, Josse RG, Murray TM, Goldsmith CH, Adachi JD (2003). *Effectiveness of Etidronate and Alendronate in the Treatment of Osteoporosis in Men Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO)*. 1<sup>st</sup> Joint Meeting of the International Bone and Mineral Society and the Japanese Society for Bone and Mineral Research, Osaka, Japan, June 3-7, 2003. *Bone*; 32: S204.
109. Adachi JD, Ioannidis G, Papaioannou A, Tenenhouse A, Prior JC, Joseph L, Hanley DA, Olszynski WP, **Brown JP**, and the CaMos Research Group (2003). *Patient Characteristics that Predict the Time to First Clinically Recognized Vertebral Deformity in Postmenopausal Women Enrolled in the Canadian Multicentre Osteoporosis Study (CAMOS)*. 1<sup>st</sup> Joint Meeting of the International Bone and Mineral Society and the Japanese Society for Bone and Mineral Research, Osaka, Japan, June 3-7, 2003. *Bone*; 32: S187
110. Grifka J, Zacher J, **Brown JP**, Seriola B, Lee A, Moore A, Gimona A (2003). *Lumiracoxib is Effective and Well Tolerated in Patients with Osteoarthritis of the Hand: Results from a Randomized, Placebo-Controlled Trial*. EULAR Meeting, Lisbon, Portugal, June 18-21, 2003. *Ann Rheum Dis*; 62(Suppl. 1): 263. Abstract FRI02222.
111. Morissette J, Laurin N, Auger S, Raymond V, **Brown JP** (2003). *Genetic Heterogeneity of Paget Disease of Bone in French-Canadian Families*. NARPD Symposium, Oxford, UK, July 17-18, 2003.
112. Laurin N, Morissette J, Raymond V, **Brown JP** (2003). *Large Phenotypic Variability of Paget Disease of Bone Caused by the P392L Sequestosome 1/P62 Mutation*. NARPD Symposium, Oxford, UK, July 17-18, 2003.
113. Papaioannou A, Ioannidis G, **Brown JP**, Berger C, Hanley DA, Prior JC, Joseph L, Olszynski WP, Murray TM, Tenenhouse A, Anastassiades T, Kirkland S, Joyce C, Poliquin S, Kreiger N, Siminoski K, Adachi JD (2003). *Risk Factors that Predict New Non-Vertebral Fracture in Postmenopausal Women: The Canadian Multicentre Osteoporosis Study (CaMos)*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. *J Bone Miner Res*; 18(Suppl 2): S246. Abstract SU276.
114. Olszynski WP, Ioannidis G, Berger C, Papaioannou A, Prior JC, Joseph L, Hanley DA, Murray TM, **Brown JP**, Tenenhouse A, Anastassiades T, Kirkland S, Joyce C, Poliquin S, Kreiger N, Siminoski K, Adachi JD (2003). *Participant Characteristics that Predict New Clinically Recognized Vertebral Fracture in Postmenopausal Women: The Canadian Multicentre Osteoporosis Study (CaMos)*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. *J Bone Miner Res*; 18(Suppl 2): S246. Abstract SU277.
115. Ioannidis G, **Brown JP**, Berger C, Hanley DA, Prior JC, Joseph L, Olszynski WP, Pickard L, Murray TM, Tenenhouse A, Anastassiades T, Hopman W, Kirkland S, Joyce C, Papaioannou A, Cranney A, Johnell O, Papadimitropoulos EA, Adachi JD (2003). *Predicting Previous Fracture with the Health Utility Index (HUI) Mark II and Mark III Systems in Both Women and Men: The Canadian Multicentre Osteoporosis Study (CaMos)*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. *J Bone Miner Res*; 18(Suppl 2): S249. Abstract SU288.
116. Hanley DA, Ioannidis G, Josse RJ, Murray TM, **Brown JP**, Sebaldt RJ, Goldsmith CH, Papaioannou A, Olszynski WP, Petrie A, Davison KS, Adachi JD (2003). *Risk Factors Related with Quality of Life (QOL) in Postmenopausal Women with Prevalent Vertebral Fractures: The Canadian Database of Osteoporosis and Osteopenia (CANDOO)*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. *J Bone Miner Res*; 18(Suppl 2): S247. Abstract SU282.

117. Picard S, Brown D, **Brown JP** (2003). *Development, Optimization and Validation of Automated/Interactive Strut Analysis Software: a New Quality Assessment Approach*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. J Bone Miner Res; 18(Suppl 2): S320. Abstract M102.
118. Picard S, Brown D, Rauch F, Travers R, Glorieux F-H, **Brown JP** (2003). *Micro-Architectural Strut Analysis Study on Paediatric*. Bone 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. J Bone Miner Res; 18(Suppl 2): S183. Abstract SU012.
119. **Brown JP**, Banville C, Jean S, Drake WL, Kendler DL (2003). *Efficacy, Safety and Tolerability of Once Weekly (80mg vs 160mg) Oral Alendronate Over 2 Years in Postmenopausal Osteoporosis*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. J Bone Miner Res; 18(Suppl 2): S375. Abstract M335.
120. **Brown JP**, Bessette L, Beaulieu M, Chin C, Jean S, Ste-Marie L-G (2003). *Recognizing Osteoporosis and its Consequences in Quebec (ROCQ), a Patient Health Management Programme*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. J Bone Miner Res; 18(Suppl 2): S361. Abstract M276.
121. Sawka AM, Papaioannou A, Adachi JD, Ioannidis G, Olszynski W, **Brown JP**, Hanley DA, Murray T, Josse R, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH (2003). *Men Present with a Higher Rate of Prevalent Fractures than Women When Started on Bisphosphonate in Canadian Specialty Osteoporosis Practices*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. J Bone Miner Res; 18(Suppl 2): S364. Abstract M291.
122. Picard D, **Brown JP**, Couturier M, Rosenthal L, Lévesque J, Dumont M, Ste-Marie L-G, Tenenhouse A, Dodin S (2003). *Correcting Phalanx Bone Mass Measurement for Clinical Risk Factors Increases its Validity in the Diagnosis of Osteoporosis*. 25th Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, USA, September 19-23, 2003. J Bone Miner Res; 18(Suppl 2): S203. Abstract SU098.
123. **Brown JP**, Yuen S, Banville C, Picard S, Jean S, Adachi JD, Kendler DL (2004). *Rapid resolution of the reduction of bone turnover markers after discontinuation of risedronate in postmenopausal women with osteoporosis previously treated for 2 years*. 59<sup>th</sup> Annual Meeting of the Canadian rheumatology association. Lake Louise, Alberta, February 26-28, 2004.
124. **Brown JP**, Yuen S, Banville C, Picard S, Jean S, Adachi JD, Kendler DL (2004). *Rapid resolution of the reduction of bone turnover markers after discontinuation of risedronate in postmenopausal women with osteoporosis previously treated for 2 years*. 31<sup>st</sup> European Symposium on Calcified Tissues, Nice, France, June 5-8, 2004. Calcif Tissue Int. Abstract 0373.
125. Sebaldt RJ, Shane LG, Pham B, Cook R, Thabane L, Petrie A, Olszynski WP, Hanley DA, **Brown J**, Adachi J, Murray T, Josse R, Papaioannou A (2004). *Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care*. IOF World Congress on Osteoporosis, Rio, May 14-18, 2004. Abstract P391SA.
126. Miller P, **Brown JP**, Stepan JJ, Schimer RC, Bauss F, Pfister T (2004). *Intermittent intravenous ibandronate injections: Renal safety profile*. IOF World Congress on Osteoporosis, Rio, May 14-18, 2004.

127. Bensen R, Papaioanou A, Adachi JD, Ioannidi G, Olszynski W, Sebaldt R, Murray T, Josse R, **Brown J**, Hanley D, Petrie A, Goldsmith C (2004). *Evaluation of Easily Measured Risk Factors in the Prediction of Osteoporotic Fractures*. 26<sup>th</sup> Annual Meeting of the American Society of Bone and Mineral Research, Seattle, Washington, USA, October 1-5, 2004. J Bone Miner Res; 19(Suppl 1): S90. Abstract F371.
128. Hosking DJ, Miller P, **Brown J**, Fraser W, Lyles K, Reid I, Mesenbrink P (2004). *Zoledronic Acid Produces Greater Clinically Relevant Reductions in Biochemical Markers in Patients with Paget's Disease Versus Risedronate*. 26<sup>th</sup> Annual Meeting of the American Society of Bone and Mineral Research, Seattle, Washington, USA, October 1-5, 2004. J Bone Miner Res; 19(Suppl 1): S101. Abstract F482.
129. Miller P, Magowan S, Barton I, **Brown J**, Siris E (2004). *Risedronate 30mg/day Exhibits Renal & Hepatic Safety Over Wide Range of Serum Steady State Concentrations*. 26<sup>th</sup> Annual Meeting of the American Society of Bone and Mineral Research, Seattle, Washington, USA, October 1-5, 2004. J Bone Miner Res; 19(Suppl 1): S309. Abstract SU438.
130. Sebaldt RJ, Shane LG, Pham BZ, Cook RJ, Thabane L, Petrie A, Olszynski WP, Hanley DA, **Brown J**, Adachi JD, Murray T, Josse R, Papaioannou A (2004). *Impact of Non-Persistence with Daily Bisphosphonates on Long-Term Effectiveness Outcomes in Patients with Osteoporosis*. 26<sup>th</sup> Annual Meeting of the American Society of Bone and Mineral Research, Seattle, Washington, USA, October 1-5, 2004. J Bone Miner Res; 19(Suppl 1): S445. Abstract M423.
131. Bensen R, Adachi JD, Ioannidis G, Papaioannou A, Murray T, Olszynski W, **Brown J**, Josse R, Sebaldt R, Goldsmith C, Hanley D, Petrie A (2004). *The Usefulness of Seven Measureable Risk Factors for Early Recognition of Future Osteoporotic Fracture*. Arthritis and Rheumatism; 50(9 suppl.): S290. Abstract 667.
132. Hosking DJ, Miller P, **Brown J**, Fraser W, Lyles K, Reid I, Mesenbrink P. *Determinants of Response in Patients With Paget's Disease Treated With Zoledronic Acid Versus Risedronate*. Arthritis and Rheumatism; 50(9 suppl.): S670. Abstract 1794.
133. Olszynski WP, Adachi JD, Ioannidis G, Hanley DA, **Brown J P**, Davison KS (2005). *Multisite Ultrasound and Vertebral Deformity : Findings from the Canadian Multicentre Osteoporosis Study (CaMos)*. Bone; 36(Suppl 2): S343. Abstract P462.
134. **Brown JP**, Bessette L, Beaulieu M, Sauriol L, Jean S, Davison KS, Ste-Marie L-G (2005). *Recognizing Osteoporosis and Its Consequences in Québec (ROCQ) : Fragility Fracture Rate Among Women Who Sustained a Fracture*. Bone; 36(Suppl 2): S350. Abstract P475.
135. Reid IR, Lyles KW, Miller PD, **Brown JP**, Fraser WD, Saidi Y, Pak J, Mesenbrink P, Su G, Zelenakas K, Krasnow J, Hosking DJ (2005). *Zoledronic Acid Shows Superior Effect on Paget's Disease Activity that is not Blunted by Previous Treatment Status: A Randomized Controlled Comparison with Risedronate*. Bone; 36(Suppl 2): S452. Abstract P695.
136. Leslie WD, Siminoski K, **Brown J** (2005). *Comparison of Ten-Year Absolute Fracture Risk and WHO Risk Categorization in Menopausal Females*. J Bone Miner Res; 20(Suppl 1): S11. Abstract 1037.
137. Olszynski WP, Ioannidis G, **Brown JP**, Hanley DA, Adachi JD, Davison KS (2005). *Multisite Ultrasound and Vertebral Deformity : Findings from the Canadian Multicentre Osteoporosis Study (CaMOS)*. J Bone Miner Res; 20(Suppl 1) : S121. Abstract SA097.
138. **Brown JP**, Bessette L, Beaulieu M, Baranci M, Jean S, Davison KS, Ste-Marie L-G (2005). *Recognizing Osteoporosis and its Consequences in Quebec (ROCQ): The Care Gap Following a Fragility Fracture*. J Bone Miner Res; 20(Suppl 1): S158. Abstract SA335.

139. Watts NB, Magowan S, **Brown JP**, Miller PD, Barton IP (2005). *Risedronate Demonstrates Efficacy to Reduce Fragility Fractures Independent of Treatment-Related BMD Changes*. J Bone Miner Res; 20(Suppl 1): S169. Abstract SA407.
140. Picard S, **Brown JP**, Frenette J, Jean S, Guertin PA (2005). *Bone Loss in Mice after Spinal Cord Injury; an histomorphometrical, Biomechanical and Densitometrical Study*. J Bone Miner Res; 20(Suppl 1): S176. Abstract SA448.
141. **Brown J**, Ng KW, Toss G, Zhou C, Wong M, Draper MW (2005). *Effects of Raloxifene on Bone Mineral Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women Pre-treated with Raloxifene or Alendronate for One Year*. J Bone Miner Res; 20(Suppl 1): S407. Abstract M397.
142. Yuen SY, Jean S, Gendreau M, Bessette L, **Brown JP** and the CaMos Research Group (2006). *Radio-graphic prevalence of degenerative spinal changes, Scheuermann's disease, calcifications and diffuse idiopathic skeletal hyperostosis in an elderly random population and their effects on osteoporosis diagnosis*. 61<sup>st</sup> Annual Meeting of the Canadian rheumatology association. First Mexican-Canadian Congress of rheumatology. Acapulco, Mexico, February 18-22, 2006.
143. **Brown J**, Emery P, Russell A, Zhou Y, Mokliatchouk O, Li T, Westhovens R, Abud-Mendoza C, Teng J (2006). *In rheumatoid arthritis patients with inadequate responses to methotrexate, abatacept induces sustained improvements in quality of life, sleep quality and fatigue over 3 years*. 61<sup>st</sup> Annual Meeting of the Canadian rheumatology association. First Mexican-Canadian Congress of rheumatology. Acapulco, Mexico, February 18-22, 2006.
144. Sawka AM, Papaioannou A, Josse RG, Murray TM, Thabane L, Hanley DA, Ioannidis G, Olszynski WP, **Brown JP**, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH, Boulos P, Adachi JD (2006). *Low Rates of Vitamin D Supplementation in Canadians with Low Bone Mass or Fractures*. Osteoporos Int; 17(Suppl 2): S105. Abstract P366.
145. Bessette L, **Brown JP**, Beaulieu M, Baranci M, Jean S, Davison KS, Ste-Marie L-G (2006). *Recognizing Osteoporosis and its Consequences in Québec (ROCQ): The Care Gap Following a Fragility Fracture*. Osteoporos Int; 17(Suppl 2): S58. Abstract P214SA.
146. Adami S, Munoz-Torres M, Econs MJ, Sipos A, Xie L, Dalsky GP, McClung M, Felsenberg D, **Brown JP**, Brandi ML, San Martin J (2006). *Effect of Raloxifene after Teriparatide Treatment in Post-Menopausal Women with Osteoporosis*. Osteoporos Int; 17(Suppl 2): S13. Abstract OC22. **Oral presentation.**
147. Richards JB, Leslie WD, Joseph L, Adachi JD, **Brown JP**, Hanley DA, Josse RG, Papaioannou A, Prior JC, Siminoski K, Tenenhouse AT, Galtzman, D (2006). *A Comparison of Fracture Risk Classification Systems and Estimated Rates of Treatable Osteoporosis*. Osteoporos Int; 17(Suppl 2): S24. Abstract P114MO.
148. Papaioannou A, Ioannidis G, Tenenhouse A, Gao Y, Berger C, Prior JC, Josse RG, Hanley DA, **Brown JP**, Olszynski WP, Kaiser SM, Murray TM, Anastassiades T, Kirland S, Joyce C, Poliquin S, Kreiger N, Davison KS, Kennedy CC, Siminoski K, Leslie WD, Cranney A, Goltzman D, Adachi JD (2006). *Fragility Fracture Prevalence in Women and Men According to T-Score Values: The Canadian Multicentre Osteoporosis Study (CAMOS)*. Osteoporos Int; 17(Suppl 2): S27. Abstract P124SA.
149. Ste-Marie L-G, **Brown JP**, Beary JF, Darbie L, Burgio DE, Racewicz A (2006). *Once-a-Month 150 mg Oral Risedronate is as Effective as Oral Daily 5 mg Risedronate in Postmenopausal Osteoporosis: Phase II Study Results*. Osteoporos Int; 17(Suppl 2): S86. Abstract P311SU.

150. Devogelaer JP, Burckhardt P, Meunier P, Kaufman JM, Lippuner K, Body JJ, Samsioe G, Felsenberg D, **Brown J**, Garnero P, Sanna L, Ortmann CE, Krasnow J, Eriksen EF, Fashola T, Trechsel U (2006). *Zoledronic Acid Safety and Efficacy Over 5 Years in Postmenopausal Osteoporosis*. *Osteoporos Int*; 17(Suppl 2): S89. Abstract P318MO.
151. Ioannidis G, Papaionnou A, Tenenhouse A, Gao Y, Berger C, Prior JC, Kaiser SM, Hanley DA, Brown JP, Olszynski WP, Josse RG, Murray TM Anastassiades T (2006). *The Bisphosphonate Treatment Care Gap in Community Dwelling Men Who Have Incident Fragility Fractures: The Canadian Multicentre Osteoporosis Study (CAMOS)*. *Osteoporos Int*; 17(Suppl 2): S102. Abstract P357MO.
152. Sawka AM, Papaioannou A, Josse RG, Murray TM, Thabane L, Hanley DA, Ioannidis G, Olszynski WP, **Brown JP**, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH, Boulos P, Adachi JD (2006). *Low Rates of Vitamin D Supplementation in Canadians With Low Bone Mass or Fractures*. *Osteoporos Int*; 17(Suppl 2): S105. Abstract P366MO.
153. Ioannidis G, Papaioannou A, Tenenhouse A, Gao Y, Berger C, Prior JC, Kaiser SM, Hanley DA, Josse RG, **Brown JP**, Olszynski WP, Murray TM, Anastassiades T (2006). *Bisphosphonate and the Therapeutic Care Gap in Women Who Have Fragility Fractures: The Canadian Multicentre Osteoporosis Study (CAMOS)*. *Osteoporos Int*; 17(Suppl 2): S117. Abstract P400SA.
154. Papaioannou A, Ioannidis G, Tenenhouse A, Gao Y, Berger C, Prior JC, Kaiser SM, Hanley DA, **Brown JP**, Olszynski WP, Josse RG, Murray TM, Anastassiades T (2006). *Diagnostic and Therapeutic Care Gap in Both Women and Men Who Have Been Told They Have Osteoporosis: The Canadian Multicentre Osteoporosis Study (CAMOS)*. *Osteoporos Int*; 17(Suppl 2): S120. Abstract P413SU.
155. **Brown J**, Lyles K, Fraser W, Reid I, Hosking D, Devogelaer JP, Moniz C, Hooper M, Saidi Y, Su G, Pak J, Davis J, Fashola T, Krasnow J, Zolenaka K, Miller P (2006). *A Single Dose of Zoledronic Acid 5 mg Achieves More Sustained Biochemical Remission Versus Daily 30 MG Risedronate in Patients with Paget's Disease*. *Osteoporos Int*; 17(Suppl 2): S131. Abstract P450MO.
156. Reid IR, Miller P, **Brown J**, Fraser W, Hosking D, Diaz CM, Stone M, Devegelaer JP, Moiz C, Hooper M, Saidi Y, Su G, Pak J, Davis J, Fashola T, Krasnow, Zelenakas K, Lyles K (2006). *A Single Dose of Zoledronic Acid 5 mg Achieves More Sustained Biochemical Remission Versus Daily 30 mg Risedronate in Patients with Paget's Disease*. *J Bone Miner Res*; 21(Suppl 1): S437. Abstract M426.
157. Bessette L, Beaulieu M, Baranci M, Jean S, Davison KS, **Brown JP**, Ste-Marie L-G (2006). *Comparison of Two Different Recruitment Methods for Women with Fragility Fractures Participating in an Epidemiologic Study*. *J Bone Miner Res*; 21(Suppl 1): S421. Abstract M365.
158. Chamoux E, Couture J, **Brown JP**, Roux S (2006). *Expression and Localisation of P62 (SQSTM1) in Human Osteoclasts*. *J Bone Miner Res*; 21(Suppl 1): S399. Abstract M282.
159. Ste-Marie L, **Brown JP**, Beary JF, Darbie L, Burgio DE, Racwicz A (2006). *Oral Risedronate 150 mg Once Monthly is as Effective as Oral Daily 5mg Risedronate in Postmenopausal Osteoporosis: Phase II Results*. *J Bone Miner Res*; 21(Suppl 1): S111. Abstract F361.
160. Adami S, Spronik J, Hala T, **Brown JP**, Garnero P, Haemmerle S, Ortmann CE, Bouisset F, Trechsel U (2006). *Effect of One Year Treatment with the Cathepsin-K Inhibitor, Balicatib, on Bone Mineral Density (BMD) in Postmenopausal Women with Osteopenia/Osteoporosis*. *J Bone Miner Res*; 21(Suppl 1): S24. Abstract 1085. **Oral presentation.**



161. Bessette L, **Brown JP**, Beaulieu M, Baranci M, Jean S, Davison KS, Ste-Marie L-G (2007). *Recognizing Osteoporosis and its Consequences in Québec (ROCQ): The Care Gap Following a Fragility Fracture*. Bone; 40(suppl 2): S304. Abstract 314Th.
162. Johansson H, McCloskey E, Odén A, Johnell O, De Laet C, **Brown J**, Eisman J, Fujiwara S, Goltzman D, Mellström D, Melton III LJ, Pols H, Reeve J, Silman, Torgerson D, Kanis JA (2007). *Clinical risk factors enhance the performance of BMD in the predictors of fractures*. Calf Tissue Int; 80(suppl. 1): S29. Abstract OC021. **Oral presentation.**
163. Bessette L, **Brown JP**, Beaulieu M, Baranci M, Jean S, Davison KS, Ste-Marie L-G (2007). *Recognizing Osteoporosis and its consequences in Quebec (ROCQ): The care gap following a fragility fracture*. Calf Tissue Int; 80(suppl. 1): S117, Abstract P303-S.
164. Bessette L, **Brown JP**, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Ste-Marie L-G (2007). *Factors Influencing the Diagnosis and the Treatment of Osteoporosis Following a Fragility Fracture*. J Bone Miner Res; 22(Suppl 1): S120. Abstract M364.
165. **Brown JP**, Bessette L, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Ste-Marie L-G (2007). *Validation of a Clinical Definition for Fragility Fracture*. J Bone Miner Res; 22(Suppl 1): S198. Abstract M350.
166. Sarmasik A, Hiruma Y, Okumura S, **Brown JP**, Windle JJ, Roodman GD, Kurihara N, Galson DL (2007). *Measles Virus Nucleoprotein (MVNP) Enhances NFATc1 Activation During Osteoclastogenesis In Paget's Disease*. J Bone Miner Res; 22(Suppl 1): S221. Abstract M479.
167. Chamoux E, Couture JN, Lemenchick BG, **Brown JP**, Roux S (2007). *RANKL Signaling in Human Osteoclasts: Effect of P62 Mutations*. J Bone Miner Res; 22(Suppl 1): S220. Abstract M474.
168. Kurihara N, Hiruma Y, Yamana K, Rousseau C, Morissette J, **Brown JP**, Roodman GD (2007). *Measles Virus Nucleocapsid Gene Expression is Required for Abnormal Osteoclast Activity in Paget's Disease of Bone*. J Bone Miner Res; 22(Suppl 1): S43. Abstract 1152. **Oral presentation.**
169. Hodsmann AB, Bone H, Gallagher C, Kendler D, **Brown JP**, Greenspan S, Barclay CL, Morley P, Anderson R, MacDonald BR (2007). *Ostablolin-C<sup>TM</sup> Increases Lumbar Spine and Hip BMD after 1 Year of Therapy: Results of a Phase II Clinical Trial*. J Bone Miner Res; 22(Suppl 1): S38. Abstract 1130. **Oral presentation.**
170. Papaioannou A, Ioannidis G, Kennedy C, Pickard L, Tenenhouse A, **Brown JP**, Josse R, Sawka AM, Kaiser SM, Anastassiades T, Hopman W, Adachi JD (2007). *A Five Year Longitudinal Study of Health Related Quality of Life in Individuals with and without Incident Fractures: The Canadian Multicentre Osteoporosis Study (CaMOS)*. J Bone Miner Res; 22(Suppl 1): S314. Abstract T333.
171. Davison KS, Adachi JD, Hanley DA, **Brown JP**, Olszynski WP (2007). *Associations Between Bone Mineral Density and Speed of Sound: Canadian Multicentre Osteoporosis Study*. J Bone Miner Res; 22(Suppl 1): S305. Abstract T298.
172. Olszynski WP, **Brown JP**, Adachi JD, Hanley DA, Davison KS (2007). *Canadian Normative Data for Sunlight Omnisense Quantitative Ultrasound: Canadian Multicentre Osteoporosis Study*. J Bone Miner Res; 22(Suppl 1): S306. Abstract T303.
173. Kaiser SM, Ioannidis G, Lorraine J, Olszynski WP, Prior JC, Hanley DA, **Brown JP**, Papaioannou A, Josse RG, Anastassiades T, Siminoski K, Kirkland S, Joyce C, Goltzman D, Adachi JD (2007). *5 Year Incidence*

*of Fractures in Patients with Severe Osteoporosis: The Canadian Multicentre Osteoporosis Study (CaMOS).* J Bone Miner Res; 22(Suppl 1): S432. Abstract W281.

174. Adachi JD, Chesnut CH, **Brown JP**, Christiansen C, Russo LA, Fernandes CE, Menegoci JC, Kung A, Chines AA, Bessac L (2007). *Safety and Tolerability of Bazedoxifene in Postmenopausal Women with Osteoporosis: Results from a 3-Year, Randomized, Placebo – and Active-Controlled Clinical Trial.* J Bone Miner Res; 22(Suppl 1): S460. Abstract W385.
175. Watts N, **Brown J**, Cline G, Delmas PD (2007). *Two-Consecutive Days-a-Month Risedronate 75 mg (2Cd) Reduces Vertebral Fracture Risk at One Year.* J Bone Miner Res; 22(Suppl 1): S456. Abstract W373.
176. Adachi JD, Chesnut CH, **Brown JP**, Christiansen C, Russo LA, Fernandes CE, Menegoci JC, Kung A, Chines AA, Bessac L (2008). *Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis : Results from a 3-year, randomized, placebo- and active-controlled clinical trial.* Calf Tissue Int; 80(suppl. 1).
177. Fernandes CE, Adachi JD, Chestnut CH, **Brown JP**, Christiansen C, Russo LA, Menegoci JC, Kung A, Chines AA, Bessac L (2008) *Safety and Tolerability of Bazedoxifene in Postmenopausal Women with Osteoporosis: Results from a 3-Year, Randomized, Placebo- and Active-controlled Clinical Trial.* 8<sup>th</sup> European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, April 9-12<sup>th</sup>, Istanbul, Turkey.
178. Bessette L, Davison SK, Ste-Marie L, Jean S, Beaulieu M, Baranci M, **Brown JP** (2008) *Impact of an Educational Intervention on Knowledge about Osteoporosis Following a Fragility Fracture.* J Bone Miner Res; 23:S200. Abstract SA353.
179. Michou L, Morissette J, Marquis A, Brochu ER, **Brown JP**, Siris ES (2008) *Two Novel SQSTM1 Mutations in American Patients with Paget's disease of Bone.* J Bone Miner Res; 23:S294. Abstract SU216.
180. Zhou W, Berger C, Adachi JD, Papaioannou A, Ioannidis G, Webber C, Atkinson S, Olszynski WP, **Brown JP**, Hanley DA, Josse R, Kreiger N, Prior J, Kaiser S, Kirkland S, Goltzman D, Davison KS (2008) *Normative Z-scores from the Canadian Multicentre Osteoporosis Study Youth Cohort.* J Bone Miner Res; 23:S315. Abstract SU292.
181. Bessette L, **Brown JP**, Jean S, Davison SK, Beaulieu M, Baranci M, Ste-Marie L. (2008) *Evaluation of Bone Mineral Density Following an Education Intervention on Osteoporosis Offered to Women after a Fragility Fracture.* J Bone Miner Res; 23:S325. Abstract SU330.
182. Kennedy CC, Papaioannou A, Cranney A, Hawker G, **Brown JP**, Kaiser SM, Leslie WD, O'Brien CJM (2008) *Risk Factors for Low BMD in Healthy Men Age 50 Years or Older: A Systematic Review.* J Bone Miner Res; 23:S328. Abstract SU341.
183. Ioannidis G, Papaioannou A, Akhtar-Danesh N, Hopman WM, Anastassiades T, Prior JC, Pickard L, Davison KS, Kennedy CC, Olszynski WP, Goltzman D, Papadimitropoulos E, **Brown JP**, Thabane L, Gafni A, Josse RG, Hanley DA, Adachi JD (2008). *Fractures of the Spine and Hip Increase the Risk of Death in Canadians.* J Bone Miner Res; 23:S331. Abstract SU351.
184. Watts N, Klemes A, Wagner L, **Brown J** (2008) *Once-A-Month (OAM) Risedronate 150 mg Reduced Vertebral Fracture Risk at One Year in a Historical Control Analysis.* J Bone Miner Res; 23:S344. Abstract SU403.

185. Kendler DL, Benhamou CL, **Brown JP**, Lillestol M, Roux C, Man HS, Siddhanti S, San Martin J, Bone HG (2008) *Effects of Denosumab vs Alendronate on Bone Mineral Density (BMD), Bone Turnover Markers (BTM), and Safety in Women Previously Treated with Alendronate*. J Bone Miner Res; 23:S473. Abstract M395.
186. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Prior JC, Kennedy CC, Pickard L, Davison KS, Anastassiades T, Thabane L, Gafni A, **Brown JP**, Olszynski WP, Hanley DA, Papadimitropoulos E, Josse RG, Goltzman D, Adachi JD and the CaMos Research Group (2008). *Absolute Death Rates by Fracture Type in Canadians*. Arthritis and Rheumatism; 58(9 suppl.): S747. Abstract 1572.
187. Deal C, **Brown JP**, Recker R, Prince R, Kiel DP, Alvaro-Gracia JM, de Gregorio LH, Hadji P, Hofbauer LC, Wang H, Austin M, Newmark R, Libanati C, Wagman RB, San Martin J (2008). *Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass Treated with 6-monthly Denosumab or Weekly Alendronate (Fosamax®)*. Arthritis and Rheumatism; 58(9 suppl.): S940. Abstract 2102. Oral presentation.
188. Kendler DL, Roux C, Benhamou CL, **Brown JP**, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2009) *Effects of Denosumab in Postmenopausal Women Transitioning from Alendronate Therapy in Comparison with Continued Alendronate*. Canadian Rheumatology Association Annual Meeting. February 19-21<sup>st</sup>, Banff, AB, Canada.
189. **Brown JP**, Deal C, Hofbauer LC, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J (2009) *Effects of Denosumab vs. Alendronate on Bone Turnover Markers and Bone Mineral Density Changes at 12 Months Based on Baseline Bone Turnover Level*. Canadian Rheumatology Association Annual Meeting. February 19-21<sup>st</sup>, Banff, AB, Canada.
190. **Brown JP**, Kendler DL, Silverman SL, Christiansen C, Genant HK, Zanchetta JR, Vukicevic S, Walter I, de Villiers TJ, Ciesielksa M, Chines AA (2009) *Efficacy of Bazedoxifene in Reducing the Incident of Non-vertebral Fractures in Postmenopausal Osteoporotic Women at Higher Fracture Risk*. 2009 Annual Meeting of the Canadian Rheumatology Association, February 18-21, Banff, Alberta, Canada.
191. Roux C, **Brown JP**, Kendler DL, Lillestol M, Siddhanti S, Man HS, San Martin S, Bone HG, Benhamou CL (2009) *Assessment of Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women Transitioned from Alendronate to Denosumab*. 9<sup>th</sup> European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Athens, Greece, March 18-21<sup>st</sup>. Abstract number OC22. Oral presentation.
192. Bone H, de Gregorio LH, Kendler DL, Hofbauer LC, Deal C, Brandi ML, Wang H, Man HS, Austin M, Siddhanti S, Wagman RB, Libanati C, San Martin J, **Brown JP** (2009) *Comparison of changes in bone mineral density and bone turnover markers in postmenopausal women treated with Denosumab or Alendronate: Results from 2 randomized phase 3 trials*. EULAR, Copenhagen, Denmark June 10-13<sup>th</sup>. Abstract number OP-0218. Oral presentation.
193. Bone H, de Gregorio LH, Kendler DL, Hofbauer LC, Deal C, Brandi ML, Wang H, Man HS, Austin M, Siddhanti S, Wagman RB, Libanati C, San Martin J, **Brown JP** (2009) *Effects of Denosumab Versus Alendronate on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women: Results from 2 randomized phase 3 trials*. Endocrine Society's 91<sup>st</sup> Annual Meeting, Washington DC, U.S.A., June 10-13<sup>th</sup>. Oral presentation.
194. Bessette L, Jean S, Roy S, Davison KS, Ste-Marie L-G, **Brown J.** (2009) *Accuracy of self-report of DXA results in women with a fragility fracture*. J Bone Miner Res 24 (Suppl 1). Available at

<http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=3d0a2be9-f804-4d7d-8fa6-6afd9b537d9d>. Accessed October 14, 2009.

195. Bessette L, Jean S, Roy S, Davison KS, Ste-Marie L-G, **Brown J**, (2009) *Comparison of clinical risk factors for osteoporosis between subjects who sustained a traumatic or a fragility fracture*. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=fc8da93e-5070-4a31-b65f-92828a78b5f4>. Accessed October 14, 2009.
196. Reid I, Benhamou CL, Bolognese M, **Brown J**, Hoeck HC, Cummings S, Eastell R, Fahrleitner-Pammer A, Gallagher JC, Halse J, Kendler D, Maasalu K, Miller P, Ortolani S, Valter I, Ding B, Wagman R, San Martin J, Dempster D (2009) *Effects of Denosumab on Bone Histology and Histomorphometry: the FREEDOM and STAND Studies*. J Bone Miner Res 24 (Suppl 1) Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=1778e37e-cc4c-482c-a20d-6ae66570d65d>. Accessed October 14, 2009. **Oral presentation**.
197. Watts N, Wagner L, Klemes A, **Brown J**. (2009) *Once-A-Month Risedronate 150 Mg Reduced Fracture Risk At Two Years Vs. Historical Control*. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e4aafcc2-a86c-42fc-af47-b6400cf752e1>. Accessed October 14, 2009.
198. Watts N, Borah B, **Brown J**, Wagner L, Nurre J, Chmielewski P, Recker R. (2009) *Risedronate Bone Turnover, Bone Quality And Historical Control Vertebral And Nonvertebral Fracture Data Support That The 150 Mg Once-A-Month Risedronate Dose Is As Efficacious As The 5 Mg Daily Dose*. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=ef93a3b7-1191-4055-a08a-fe471a355bec>. Accessed October 14, 2009.
199. de Villiers TJ, Kendler D, Chines A, Lips P, Kaufman J-M, Levine AB, Mairon N, Codreanu C, Felsenberg D, Brown J. (2009) *Safety and Tolerability of Bazedoxifene in Postmenopausal Women With Osteoporosis: Results of a 5-year, Randomized, Placebo-controlled Phase 3 Trial* J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=1dae18c8-99a0-4757-957b-689b21823623>. Accessed on October 14, 2009.
200. Ioannidis G, Papaioannou A, Prior JC, Kennedy CC, Pickard L, Davison KS, Anastassiades T, **Brown JP**, Olszynski WP, Hanley DA, Josse RG, Goltzman D, Adachi JD (2009) *The Prevalence of Participants at High Risk for Fracture based on the Recommendation for Bone Mineral Density (BMD) Reporting in Canada*. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=0dfe5994-2588-4b2f-a02a-2a55141bc248>. Accessed October 14, 2009.
201. Jean S, Morin S, Candas B, Belzile E, Bessette L, **Brown J**, Dodin S. (2009) *Validation of Population-based Algorithms for Fracture Identification in Medico-administrative Databases*. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e0b9114a-5ea5-4a01-a16b-2ecb554fddef>. Accessed on October 14, 2009.
202. Kendler D, Roux C, Benhamou CL, **Brown JP**, Lilestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2009) *Denosumab Following Long-Term Alendronate in Postmenopausal Women with Low Bone Mineral Density*. International Symposium on Osteoporosis / National Osteoporosis Foundation Meeting.

203. Kendler D, Gold DT, **Brown JP**, Bessette L, Coon CD, Wang H, Man HS, Siddhanti S, Wagman RB, Macarios D, Bone HG (2009) *BMD Results and Patient Preference and Satisfaction with Mode of Treatment Administration from Two Phase 3 Trials Comparing Denosumab and Alendronate*. Presented at the North American Menopause Society, San Diego, CA USA, September 30<sup>th</sup>-October 4<sup>th</sup>. **Oral presentation.**
204. Bessette L, Jean S, Davison KS, Ste-Marie L-G, **Brown JP**. (2010) *Comparison of Clinical Risk Factors for Osteoporosis Between Subjects who Sustained a Traumatic or a Fragility Fracture*. The Journal of Rheumatology: 1279. Poster 15.
205. Michou L, Glorieux F, **Brown JP** (2010) *Heterozygous Mutation in LRP5 Gene Is Associated with Osteoporosis, Metaphyseal Dysplasia and Maxillary Hypoplasia in Two Sisters*. The Journal of Rheumatology: 1301. Poster 81
206. de Villiers TJ, Kendler DL, Chines AA, Lips P, Kaufman J-M, Levine AB, Malron N, Codreanu C, Felsenberg D, **Brown JP** (2010) *Safety and Tolerability of Bazedoxifene in Postmenopausal Women with Osteoporosis: Results of a 5-year Randomized, Placebo-controlled Phase 3 Trial*. 2<sup>nd</sup> International Bone and Mineral Society (IBMS) Davos Workshops, Davos Switzerland, March 14-19<sup>th</sup>. Poster and **oral presentations.**
207. Zanchetta JR, Høiseth A, Kendler DL, Yuen CK, **Brown JP**, Stonkus S, Goemaere S, Recknor C, Woodson G, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C, McClung M (2010) *Denosumab increased BMD of the lumbar spine, total hip, femoral neck, and trochanter as measured by QCT in postmenopausal women with osteoporosis*. Clinical Osteoporosis 2010: An ISCD-NOF Symposium, San Antonio, Texas, USA. March 10-13<sup>th</sup>. **Oral presentation.**
208. **Brown JP**, Dempster DW, Ding B, Dent R, San Martin J, Wagman RB (2010) *Effects of Denosumab Discontinuation on Bone Histology and Histomorphometry*. IOF World Congress on Osteoporosis-ECCEO, Florence Italy. May 5-8<sup>th</sup>.
209. Adachi JD, **Brown JP** (2010) *Characterization of the Clinical Assessment and Management of Vitamin D Levels in Canadian Osteoporosis Patients through a Chart Review Initiative*. IOF World Congress on Osteoporosis-ECCEO, Florence Italy. May 5-8<sup>th</sup>.
210. De Villiers TJ, Kendler DL, Chines AA, Lips P, Kaufman JM, Levine AB, Mairon N, Codreanu C, Felsenberg D, **Brown JP** (2010) *Safety and Tolerability of Bazedoxifene in Postmenopausal Women With Osteoporosis: Results of a 5-year, Randomized, Placebo-controlled Phase 3 Trial* IOF World Congress on Osteoporosis-ECCEO, Florence Italy. May 5-8<sup>th</sup>.
211. Reid IR, Lyles K, Guoqin S, **Brown J**, Walsh J, del Pino J, Miller P, Fraser W, Gall M, Saidi Y, Bucci-Rechtweg C, Hosking D (2010) *Long-term Efficacy of Zoledronic Acid Compared with Risedronate in Paget's Disease*. 37<sup>th</sup> European Symposium on Calcified Tissues. Glasgow, Scotland. 26-30 June 2010. **Oral presentation.**
212. Papapoulos S, Bone HG, Brandi ML, **Brown JP**, Chapurlat R, Czerwinski E, Daizedah N, Grauer A, Haller C, Krieg M-A, Libanati C, Man Z, Mellström D, Radominski S, Reginster J-Y, Resch H, Román JA, Roux C, Cummings SR (2010) *Four Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results from the First Year Extension of the FREEDOM Trial*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=bf987496-1278-41ba-9bc5-a24df0956414>. Accessed on January 3, 2011.

213. Fraser L-A, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi J, Papaioannou A, Josse R, Kovacs C, Olszynski WP, Hanley D, Kaiser S, Prior J, Jamal S, Kreiger N, **Brown J**, Johansson H, Kanis J, Leslie W. (2010) *Fracture Prediction and Calibration of a Canadian FRAX® Tool: A Population-Based Report From CaMos*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=25ab6108-4c3b-416c-8608-c8dbdc5f8c48>. Accessed on January 3, 2011.
214. Fraser L-A, Ioannidis G, Adachi J, Pickard L, Kaiser S, Prior J, Brown J, Hanley D, Olszynski WP, Anastasiades T, Jamal S, Josse R, Goltzman D, Papaioannou A (2010) *Fragility Fractures and the Osteoporosis Care Gap in Women: the Canadian Multicentre Osteoporosis Study* J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=506e8824-e26e-47b2-a18c-00ef188811ab>. Accessed on January 3, 2011.
215. Le-Genoc AA, Cheung A, Brown J, Jiwa F, Papaioannou A, Morin S (2010) *Involving Patients in the Osteoporosis Care Gap and the Research Agenda: the Canadian Osteoporosis Patient Network*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=acb9d7ed-b362-4895-ae54-e26d026cf22b>. Accessed on January 3, 2011.
216. Keaveny T, McClung M, Genant H, Zanchetta J, Kendler D, **Brown JP**, Goemaere S, Recknor C, Brandi ML, Eastell R, Engelke K, Fuerst T, Radcliffe H, Libanati C (2010) *Denosumab Improves Both Femoral and Vertebral Strength in Women with Osteoporosis: Results From the FREEDOM Trial*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=4f3ef6f9-bc5b-40e7-870a-acdd7fa90ede>. Accessed on January 3, 2011. **Oral presentation.**
217. Adachi JD, **Brown JP** (2010) *Chart Review Initiative to Characterize the Assessment and Management of Vitamin D Levels in Osteoporosis Patients in Clinical Practice*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=b6145512-2e39-40dc-ba38-d904b25a97fb>. Accessed on January 3, 2011.
218. Bessette L, Jean S, Roy S, Davison KS, Ste-Marie L-G, **Brown JP** (2010) *The relationship between body mass index and the risk of peripheral fragility fracture*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=cc1290c3-f940-4030-8292-d56c96246d9d>. Accessed on January 3, 2011.
219. Bessette L, Jean S, Lapointe-Garant M-P, Belzile E, Davison K, Ste-Marie L-G, **Brown JP** (2010) *Direct medical costs attributable to peripheral fractures in post-menopausal women*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=b6c51c71-c87f-4c55-af90-c10899f41f62>. Accessed on January 3, 2011.
220. Bessette L, Jean S, Roy S, Davison KS, Ste-Marie L-G, **Brown JP** (2010) *The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a randomized-controlled trial*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=ebd3ce95-b747-4041-a40a-3461ef4b8eb8>. Accessed on January 3, 2011.

221. Jean S, Belzile E, Bessette L, Davison K, Candas B, Dodin S, Morin S, **Brown JP** (2010) *An epidemiological study of fragility fracture incidence and associated mortality*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=acb9d7ed-b362-4895-ae54-e26d026cf22b>. Accessed on January 3, 2011.
222. Michou L, Gagnon E, Morissette J, Brown J (2010) *Detection of Low Copy Numbers of Mutant SQSTM1 Alleles in DNA from Peripheral Blood Cells in Paget's Disease of Bone*. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=074cfb1d-2e12-46df-a770-8475cc85b38f>. Accessed on January 3, 2011.
223. McClung M, Bolognese M, Miller P, Sarley J, McCullough L, Brown J, Recker R. (2010) BMD Response to a Novel Delayed-release Risedronate 35 mg Once-a-Week Formulation Taken With or Without Breakfast: One Year Results. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=ac64fbee-55dc-4827-8a0c-5dcddc1f5e54>. Accessed on January 3, 2011.
224. Kurihara N, Zhou H, Dempster D, Windle J, Brown J, Roodman GD (2010) Measles Virus Nucleocapsid Gene Expression and the SQSTM1 Mutation Both Contribute to the Increased Osteoclast Activity in Paget's Disease. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=f1eccb59-b94a-4724-a344-aae1ddd38be6>. Accessed on January 3, 2011.
225. Chamoux E, Bisson M, Michou L, Brown J, Roux S. (2010) P62, PKCzeta and NF-kappaB Signaling in Human Osteoclasts: a Link With Paget's Disease of Bone. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=70d9325c-474e-404d-9fa5-dc0b5a86b201>. Accessed on January 3, 2011.
226. Berger C, Langsetmo L, Kreiger N, Greene-Finestone L, Kovacs C, Richards B, Hidiroglou N, Sarafin K, Davison SK, Adachi J, Brown J, Hanley D, Goltzman D. (2010) Temporal Trends and Determinants of Longitudinal Change in 25-Hydroxyvitamin D Levels in a Population-based Study. J Bone Miner Res 25 (Suppl 1). Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=02813797-9be1-4d33-b60c-a5f23d9ff0af>. Accessed on January 3, 2011.
227. Chapurlat R, Papapoulos S, Bone HG, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Grauer A, Haller C, Krieg M-A, Libanati C, Man Z, Mellstrom D, Radominski S, Reginster J-Y, Resch H, Román JA, Cummings SR (2010) *Long-term Denosumab Treatment of Postmenopausal Women With Osteoporosis: Results from the First Year Extension Study of the FREEDOM Trial*. Arthritis Rheum 2010.
228. Bone HG, Papaoulos S, Brandi ML, **Brown JP**, Chapurlat R, Czerwinski E, Daizadeh, Grauer A, Haller C, Krieg M-A, Libanati C, Man Z, Mellström D, Radominski S, Reginster JY, Resch H, Román JA, Roux C, Cummings SR (2010) *FREEDOM Trial First-Year Extension: Results From 4 Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis*. Presented at the IOF Regionals – 1<sup>st</sup> Asia-Pacific Osteoporosis Meeting. Singapore, Japan. 10-13 December 2010.
229. S Papapoulos, R Chapurlat, ML Brandi, JP Brown, E Czerwinski, NS Daizadeh, A Grauer, M-A Krieg, C Libanati, Z Man, D Mellstrom, S Radominski, J-Y Reginster, H Resch, JA Román, C Roux, SR Cummings, HG Bone. (2011) *Five-Year Denosumab Treatment of Postmenopausal Women With Osteoporosis: Results From the First Two Years of the FREEDOM Extension Trial*. Presented at the 11<sup>th</sup> European Congress on

Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Valencia, Spain. 23-26 March 2011.  
**Oral Presentation.**

230. Benhamou C-L, Zanchetta JR, Kaufman J-M, **Brown JP**, Maasalu K, Lakatos P, Badurski JE, Wenderoth D, McClung MR (2011) *A novel delayed-release risedronate 35 mg once-a-week formulation taken with or without breakfast: 2-year BMD data*. Presented at the 11<sup>th</sup> European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Valencia, Spain. 23-26 March 2011.
231. Genant H, Zanchetta J, Kendler D, **Brown JP**, Goemaere S, Recknor C, Brandi ML, Eastell R, Kopperdahl DL, Engelke K, Fuerst T, Radcliffe H, Libanati C, Keaveny T. (2011) *Denosumab Significantly Improves Total, Trabecular, and Cortical Estimated Strength at the Hip and Spine Over the Duration of the FREEDOM Trial*. Presented at the 17th Annual Meeting of the International Society for Clinical Densitometry. Miami, Florida. USA. April 6-9, 2011. **Oral Presentation.**
232. Bone HG, Chapurlat R, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Grauer A, Krieg M-A, Libanati C, Man Z, Mellstrom D, Radominski S, Reginster J-Y, Resch H, Román JA, Roux C, Cummings SR, Papapoulos S. (2011) *Denosumab Treatment for 5 Years of Postmenopausal Women With Osteoporosis: Results from the First Two Years of the FREEDOM Trial Extension*. Presented at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists. San Diego, USA. 13-17 April 2011.
233. Man Z, Papapoulos S, Chapurlat R, Cummings S, Brandi ML, **Brown J**, Czerwiński E, Daizadeh N, Grauer A, Krieg M-A, Mellström D, Radominski S, Reginster J-Y, Resch H, Roman Ivorra JA, Roux C, Libanati C, Bone HG (2011) *5-Year denosumab treatment in postmenopausal women with osteoporosis: First 2 years of the FREEDOM trial extension*. Presented at the 1<sup>st</sup> Symposium of the Asia Pacific League of Associations for Rheumatology. Taipie, Taiwan. 15-17 April 2011. **Oral presentation.**
234. Hamilton C, Beck TJ, Kaled A, Jamal SA, Adachi JD, **Brown JP**, Davison SK, Canadian Multicentre Osteoporosis Study Research Group (2011) *Participation in strenuous sports reduces stance stress at the medial femoral neck in Canadian men and women*. Submitted to the 3<sup>rd</sup> Joint Meeting of the European Symposium on Calcified Tissues & the International Bone and Mineral Society. Athens, Greece. 7-11 May 2011.
235. Olszynski WP, **Brown JP**, Adachi JD, Ioannidis G, Davison KS (2011) *Peripheral quantitative ultrasound for the prediction of fracture over five years: The Canadian Multicentre Osteoporosis Study (CaMOS)*. Presented at the 3<sup>rd</sup> Joint Meeting of the European Symposium on Calcified Tissues & the International Bone and Mineral Society. Athens, Greece. 7-11 May 2011.
236. H Genant, J Zanchetta, D Kendler, **JP Brown**, S Goemaere, C Recknor, ML Brandi, R Eastell, DL Kopperdahl, K Engelke, T Fuerst, H Radcliffe, C Libanati, T Keaveny (2011) *Denosumab Increases Total, Trabecular, and Cortical Estimated Hip and Spine Strength in Postmenopausal Women With Osteoporosis*. Presented at the 3<sup>rd</sup> Joint Meeting of the European Symposium on Calcified Tissues & the International Bone and Mineral Society. Athens, Greece. 7-11 May 2011. **Oral presentation.**
237. Resch H, Papapoulos S, Chapurlat R, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Grauer A, Krieg M-A, Man Z, Mellstrom D, Radominski S, Reginster J-Y, Román JA, Roux C, Cummings SR, Libanati C, Bone HG. (2011) *Denosumab Treatment of Postmenopausal Women With Osteoporosis: Results From the First 2 Years of the FREEDOM Trial Extension*. Maritime Meeting of the Austrian Senology Society. Crete, Grece. 16 May 2011. **Oral presentation.**
238. Papapoulos S, Chapurlat R, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Grauer A, Krieg M-A, Man Z, Mellstrom D, Radominski S, Reginster J-Y, Resch H, Román FA, Roux C, Cummings SR, Libanati



- C, Bone HG (2011) *Five Years of Denosumab Treatment in Women With Postmenopausal Osteoporosis: Preliminary Results From the FREEDOM Extension Study*. 52<sup>nd</sup> Annual Scientific Meeting of the Australian Rheumatology Association. Brisbane, Australia. May 14-17, 2011.
239. Román JA, Man Z, Papapoulos S, Chapurlat R, Cummings SR, Brandi ML, Brown JP, Czerwinski E, Daizadeh NS, Grauer A, Krieg M-A, Mellstrom D, Radominski S, Reginster J-Y, Resch H, Roux C, Libanati C, Bone HG (2011) *Tratamiento con denosumab durante 5 años en mujeres posmenopáusicas con osteoporosis: Resultados de los primeros 2 años de la fase de extensión del estudio FREEDOM*. XXXVII Congreso Nacional de la Sociedad Española de Reumatología. May 2011.
240. R Chapurlat, HG Bone, ML Brandi, **JP Brown**, E Czerwinski, NS Daizadeh, A Grauer, M-A Krieg, C Libanati, Z Man, D Mellstrom, S Radominski, J-Y Reginster, H Resch, JA Román, C Roux, SR Cummings, S Papapoulos. (2011) *Treatment of Postmenopausal Women With Osteoporosis for 5 Years with Denosumab: Two-Year Results From the FREEDOM Trial Extension*. *Ann Rheum Dis* 2011;70(Suppl3):166. **Oral Presentation**
241. Schlesinger N, Alten R, Bardin T, Bloch M, Schumacher HR, **Brown JP**, Gimona A, Shpilsky A, Krammer G, So A. (2011) *Efficacy of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients: Results of the B-relieved II study (response in acute flare and in prevention of episodes of re-flare in gout)*. *Ann Rheum Dis* 2011;70(Suppl3):186.
242. Adachi JD, **Brown JP** (2011) *Chart review initiative to characterize the assessment and management of vitamin D levels in osteoporosis patients in clinical practice*. *Ann Rheum Dis* 2011;70(Suppl3):232.
243. **Brown JP**, Dempster DW, Ding B, Dent R, San Martin J, Grauer A, Wagman RB, Zanchetta JR (2011) *Denosumab discontinuation and bone remodelling in postmenopausal women with osteoporosis*. *Ann Rheum Dis* 2011;70(Suppl3):135.
244. Tarride J-E, Hopkins R, Leslie WD, Morin S, Adachi JD, Papaioannou A, Bessette L, **Brown JP**, Goeree R (2011) *The Burden of Illness of Osteoporosis in Canada*. Presented at the CAPT 2011 Congress.
245. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Daizadeh NS, Grauer A, Krieg M-A, Man Z, Mellstrom D, Radominski R, Reginster J-Y, Resch H, Román JA, Roux C, Cummings SR, Libanati C, Papapoulos S. (2011) *Denosumab Therapy in Postmenopausal Women with Osteoporosis: Results from the First Two Years of the Freedom Trial Extension*. 93<sup>rd</sup> Annual Meeting & Expo. Boston, MA, USA. June 4-7, 2011. **Oral Presentation**.
246. Grauer A, Papapoulos S, Chapurlat R, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Krieg M-A, Libanati C, Man Z, Mellstrom D, Radominski S, Reginster J-Y, Resch H, Román JA, Roux C, Cummings SR, Bone HG (2011) *5 Jahre Therapie mit Denosumab bei postmenopausalen Frauen mit Osteoporose: Erste Ergebnisse aus der Verlängerung der FREEDOM-Studie*. National rheumatology congress (DGRh). September 2, 2011.
247. Bone HG, Chapurlat R, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Grauer A, Krieg M-A, Man Z, Mellstrom D, Radominski S, Reginster J-Y, Resch H, Román JA, Roux C, Thiebaud D, Cummings SR, Libanati C, Papapoulos S. (2011) *Long-Term Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the First 2 Years of the FREEDOM Trial Extension*. 2<sup>nd</sup> Pacific-Asia Osteoporosis and Bone Meeting. IOF Regionals /ANZBMS Annual and Scientific Meeting. Australia. September 4-8, 2011.
248. Palacios S, Silverman S, Levine AB, Kaufman JM, **Brown JP**, Fiorenzo de Cicco Nardone, Chines AA. (2011) *Long-term Efficacy and Safety of Bazedoxifene in Postmenopausal Women With Osteoporosis*:

- Results of a 7-year, Randomized, Placebo-controlled Study.* ASBMR Annual Meeting. San Diego, CA, USA. September 16-20, 2011.
249. Kregg J, Wan X, Lentle B, Berger C, Adachi JD, Prior JC, Tenenhouse A, **Brown JP**, Krieger N, Olszynski WP, Josse RG, Goltzman D and the CaMoS Research Group (2011) *Age, Bone Mineral Density, and Spine Fracture Status for Predicting Fracture Risk.* J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=81afa51a-9b57-4745-9352-a94a9beab97c>. Accessed October 4, 2012. **Oral presentation.**
  250. Dempster D, Zhou Hua, Recker RR, **Brown JP**, Bolognese MA, Recknor CP, Kendler DL, Lewiecki M, Hanley DA, Rao D, Miller PD, Woodson III GC, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA. (2011) *Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: 6-Month Results of a Randomized Clinical Trial.* J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=2a48c364-edbb-4900-ad36-7793e783c17e> Accessed on October 4, 2012.
  251. Berger C, Greene-Finestone L, Langsetmo L, Joseph L, Kreiger N, Richards B, Kovacs CS, Sarafin K, Davison KS, Adachi JD, **Brown JP**, Hanley DA, Goltzman D and the Canadian Multicentre Osteoporosis Study (CaMos) Research Group. (2011) *Temporal Trends in 25-Hydroxyvitamin D levels and parathyroid hormone in a population-based study.* J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=39b61daa-911a-4386-8dae-024d15429dc2>. Accessed on October 4, 2012.
  252. Hamilton CJ, Beck TJ, Khaled A, Jamal SA, Adachi JD, **Brown JP**, Davison KS and the Canadian Multicentre Osteoporosis Study (CaMos) Research Group. (2011) *Heterogeneity in mechanosensitivity among Canadian postmenopausal women with and without fractures.* J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=f39da980-179e-4e50-b34e-15a24f8b86dd>. Accessed on October 4, 2012.
  253. Michou L, Collet C, Morissette J, Audran M, Thomas T, Gagnon E, Launay J-M, Laplanche J-L, Brown JP, Orcel P (2011) *Epidemiogenetic study of French families affected by Paget's disease of bone.* J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e2704e31-719d-4e7e-bd84-68e680aeb096>. Accessed on October 4, 2012.
  254. Morin S, Behloul H, Leslie WD, **Brown JP**, Goltzman D, Pilote L (2011) *Use of oral Bisphosphonates and the Risk of Subtrochanteric and Diaphyseal Fractures in Older Men and Women.* J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=3aa0b07b-845a-45ef-8d8a-a2b9e71f630f>. Accessed on October 4, 2012. **Oral presentation.**
  255. Morin S, Papaioannou A, Belanger A, **Brown JP**, Cheung A, Hanley D, Kendler D, Ngui D (2011) *Variability in Screening Practices for Post-menopausal Osteoporosis by Canadian Family Practice Physicians.* J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6a2cbe3f-1d91-4eb5-a3d2-4f9536b153ba>. Accessed on October 4, 2012.
  256. Kendler D, Adachi JA, **Brown JP**, Julien M, Leclerc J-M Vaillancourt M (2011) *The Intra-Venous zoledronic acid once Yearly (IVORY) observational study: baseline characteristics and one year data.* J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e3f70214-e557-4fdf-83b5-47a496d61e95>. Accessed on October 4, 2012.

257. **Brown JP**, Beck-Jensen JE, Gilchrist N, Recknor C, Roux C, Törring O, Austin M, Wang A, Grauer A, Wagman R (2011) *Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the FREEDOM Trial*. J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=b9792260-ce7e-4525-8e45-7e533db1fecb>. Accessed on October 4, 2012. **Plenary poster.**
258. Bone HG, Chapurlat R, Libanati C, Brandi ML, **Brown JP**, Czerwinski E, Krieg M-A, Man Z, Mellstrom D, Radominski S, Reginster J-Y, Resch H, Román JA, Roux C, Daizadeh NS, Grauer A, Cummings SR, Papapoulos S (2011) *Safety Observations From Denosumab Long-term Extension and Cross-over Studies in Postmenopausal Women With Osteoporosis*. J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e8ef8692-3b9c-4b42-937c-bc5117766877>. Accessed on October 4, 2012. **Oral presentation.**
259. Berger C, Langsetmo L, Hanley DA, Adachi JD, Kovacs CS, **Brown JP**, Josse RG, Goltzman D and the CaMos Research Group. (2011) *Relative Prevalence of Normocalcemic and Hypercalcemic Hyperparathyroidism in a Community-Dwelling Cohort*. J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6f4e2d52-fc9a-44db-a69a-55bda37dfa18>. Accessed on October 4, 2012.
260. Cummings SR, Daizadeh N, Vittinghoff E, Libanati C, **Brown JP**, Roux C, Austin M, Grauer A, Papapoulos S, Bone HG (2011) *Efficacy of Five Years of Denosumab: A Novel ‘Virtual Twins’ Method for Minimizing Bias in Extensions of Trials*. J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=c0a48c4e-80aa-4edb-a63e-b173ab6ed368>. Accessed on October 4, 2012. **Oral presentation.**
261. Jean S, Bessette L, Belzile E, Morin S, Davison KS, Ste-Marie L-G, Candas B, Dodin S, **Brown JP** (2011) *Direct medical resources utilization associated with osteoporosis-related fractures in postmenopausal women*. J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=9287ee65-4358-4273-b2da-7a68548a5747>. Accessed on October 4, 2012. **Oral presentation.**
262. Jean S, O’Donnell S, Lagacé C, Walsh P, Bancej C, Morin S, **Brown JP**, Leslie WD (2011) *Trends in hip fracture rates in Canada: an age-period-cohort analysis*. J Bone Miner Res 26 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6dfa0ef4-21f4-4f27-8898-18f9e8a7e70f>. Accessed on October 4, 2012.
263. Resch H, Papapoulos S, Chapurlat R, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Grauer A, Krieg M-A, Man Z, Mellstrom D, Radominski S, Reginster J-Y, Román JA, Roux C, Cummings SR, Libanati C, Bone HG. (2011) *Denosumab Treatment of Postmenopausal Women with Osteoporosis: Results from the First 2 Years of the FREEDOM Trial Extension*. 28<sup>th</sup> Annual Meeting, of the Austrian Society of Surgical Oncology (ACO-ASSO) &, Annual Meeting of the Austrian Society of Senology. St. Wolfgang, Salzburg. October 5-8, 2011.
264. Guay-Bélanger S, Gagnon E, Morissette J, **Brown JP**, Michou L (2011) *Loss of SQSTM1 copy number in Paget’s disease of bone*. The American Society of Human Genetics Annual Meeting. Montreal, Quebec, Canada. October 11-15, 2011.
265. Beauregard M, Gagnon E, Morissette J, **Brown JP**, Michou L. (2011) *Genetic association of the Dickkopf 1 gene with Paget’s disease of bone*. The American Society of Human Genetics Annual Meeting. Montreal, Quebec, Canada. October 11-15, 2011.

266. Morin S, Papaioannou A, Belanger A, **Brown JP**, Cheung A, Hanley D, Kendler D, Ngui D (2011) *Variability in Screening Practices for Post-menopausal Osteoporosis by Canadian Family Practice Physicians*. CDA/CSEM Professional Conference and Annual Meeting. Toronto, Ontario, Canada. October 26-29, 2011.
267. Román JA, Man Z, Papapoulos S, Chapurlat R, Cummings SR, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Grauer A (2011) *Eficacia y seguridad a largo plazo de denosumab en mujeres posmenopáusicas con osteoporosis: resultados de los 2 primeros años de la fase de extensión del estudio FREEDOM*. XVI Congreso de la Sociedad Española de Investigación Ósea y Metabolismo Mineral, La Coruña, November 2-4, 2011. **Oral presentation**.
268. Tarride J-E, Hopkins R, Leslie WD, Morin S, Adachi R, Papaioannou A, Bessette L, **Brown J**, Goeree R (2011) *The Burden of Illness of Osteoporosis in Canada*. ISPOR 14th Annual European Congress. November 5-8, 2011.
269. **Brown JP**, Bone HG, Chapurlat R, Libanati C, Brandi ML, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román Ivorra JA, Roux C, Daizadeh NS, Grauer A, Cummings SR, Papapoulos S (2011) *Extended Safety Observations From Denosumab Administration in Postmenopausal Women From the FREEDOM and FREEDOM Extension Trials*. *Arthritis Rheum*; 63 Suppl 10:1103.
270. **Brown JP**, So A, Dikranian A, Alten R, Bardin T, Schumacher HR, Gimona A, Krammer G, Karpov A, Schlesinger N (2011) *Long-term efficacy and safety of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients*. *Arthritis Rheum*; 63 Suppl 10:1016.
271. Schlesinger N, **Brown JP**, Bardin T, Kiechle T, Shpilsky A, Alten R, So A (2011) *Comparison of Pain Intensity, Incidence of New Flares, Safety and Tolerability of Canakinumab vs Triamcinolone Acetonide in Gouty Arthritis Patients with Cardiovascular Diseases or with Cardiovascular Risk Factors*. *Arthritis Rheum*; 63 Suppl 10:1028.
272. **Brown JP**, Jensen J-E B, Recknor C, Roux C, Topping O, Austin M, et al; *The Analysis of Denosumab Discontinuation and Associated Fracture Incidence in the FREEDOM Trial*. *Arthritis Rheum*; 63 Suppl 10:1098.
273. Mellstrom D, Papapoulos S, Man Z, Radominski S, Reginster J-Y, Resch H, Román J, Roux C, Cummings S, Bone H, Chapurlat R, Brandi M, **Brown JP**, Czerwinski E, Daizadeh N, Grauer A, Krieg M-A, Libanati C (2011) *Fem Års Behandling Med Denosumab Hos Kvinnor Med Postmenopausal Osteoporos: Resultat Från De Första Två Åren Av Freedom-Studiens Uppföljning*. Medicinska Riksstämman. Stockholm, Sweden. November 30-December 2, 2011. **Oral presentation**.
274. Reginster J-Y, Papapoulos S, Chapurlat R, Brandi ML, **Brown JP**, Czerwinski E, Daizadeh NS, Grauer A, Krieg M-A, Libanati C, Man Z, Mellstrom D, Radominski S, Resch H, Román JA, Roux C, Cummings SR, Bone HG (2011) *5-Year Denosumab Treatment of Postmenopausal Osteoporosis: 2-Year Results From the Freedom Trial Extension*. National congress of the Royal Belgian Society of Physical and Rehabilitation Medicine. Brussels, Belgium. December 2-3, 2011.
275. Schlesinger N, **Brown JP**, Bardin T, Kiechle T, Yadao A, Shpilsky A, Alten R, So A (2011). *Safety and Efficacy of Canakinumab in Gouty Arthritis Patients with Comorbid Cardiovascular Disease or Cardiovascular Disease Risk Factors:  $\beta$ -RELIEVED and  $\beta$ -RELIEVED-II*. American College of Cardiology 61st Annual Scientific Session & Expo. Chicago, Illinois, USA. March 24-27, 2012.

276. Dempster DW, Zhou H, Recker RR, **Brown JP**, Bolognese MA, Recknor CL, Kendler DL, Lewiecki EM, Hanley DA, Sudhaker Rao D, Miller PD, Woodson III, GC, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA (2012) *Skeletal Histomorphometry in Patients On Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: 6-Month Results of a Randomized Clinical Trial*. European Congress on Osteoporosis and Osteoarthritis (ECCEO). Bordeaux, France. March 21-24, 2012.
277. Román JA, **Brown JP**, Bone HG, Chapurlat R, Franchimont N, Brandi ML, Czerwinski E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Roux C, Daizadeh NS, Geller ML, Smith S, Wagman RB, Cummings SR, Papapoulos S (2012) *Seis años de tratamiento continuado con denosumab en mujeres posmenopáusicas con osteoporosis: Resultados de los primeros 3 años de la fase de extensión del estudio FREEDOM*. XXXVIII Congreso Nacional de la Sociedad Española de Reumatología. Zaragoza, Spain. May 15-18, 2012.
278. Mellström D, **Brown J**, Bone H, Chapurlat R, Franchimont N, Brandi M, Czerwiński E, Krieg M-A, Man Z, Radominski S, Resch H, Román J, Roux C, Daizadeh N, Geller M, Smith S, Wagman R, Cummings S, Papapoulos S (2012) *Denosumab Treatment For 6 Years In Postmenopausal Women With Osteoporosis: The First 3 Years Of The Freedom Extension*. 39<sup>th</sup> European Symposium on Calcified Tissues. Stockholm, Sweden. May 19-23, 2012. **Oral presentation**.
279. Olszynski W, **Brown JP**, Adachi J, Hanley DA, Davison KS and Canadian Multicentre Osteoporosis Study (2011) *Five-Year Incident Fracture Risk Assessed By Quantitative Multisite Ultrasound: The Canadian Multicentre Osteoporosis Centre*. 39<sup>th</sup> European Symposium on Calcified Tissues. Stockholm, Sweden. May 19-23, 2012.
280. Hamilton C, Beck TJ, Khaled A, Jamal SA, Adachi JD, **Brown JP**, Davison KS, and the Canadian Multicentre Osteoporosis Study (CaMos) Research Group (2011) *Evidence For Diminished Skeletal Load Response In Women Who Fracture Early Vs. Those Who Fracture Late In Life*. 39<sup>th</sup> European Symposium on Calcified Tissues. Stockholm, Sweden. May 19-23, 2012. **Short oral presentation for New Investigator Seminars**.
281. Papapoulos S, **Brown JP**, Bone HG, Chapurlat R, Franchimont N, Brandi ML, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román Ja, Roux C, Daizadeh NZ, Geller ML, Smith S, Wagman RB, Cummings SR (2011) *6 Years' Denosumab Treatment in Postmenopausal Women With Osteoporosis: First 3 Years of the FREEDOM Extension*. IOF Regionals - 1<sup>st</sup> Latin America Osteoporosis Meeting. Sao Paulo, Brazil. May 24-27, 2012. **Oral Presentation**.
282. Bone HG, Chapurlat R, Libanati C, Brandi ML, **Brown JP**, Czerwinski E, Krieg M.-A, Man Z, Mellström D, Radominski SC, Reginster J.-Y, Resch H, Román Ivorra JA, Roux R, Daizadeh NS, Grauer A, Cummings SR, Papapoulos S (2011) *Observações Sobre Segurança A Partir De Estudos Cruzados E De Extensão De Longo Prazo Do Denosumab Em Mulheres Com Osteoporose Pós-Menopausa*. IOF Regionals - 1<sup>st</sup> Latin America Osteoporosis Meeting. Sao Paulo, Brazil. May 24-27, 2012.
283. Tørring O, **Brown JP**, Beck Jensen J-E, Gilchrist N, Recknor C, Roux C, Austin M, Wang A, Grauer A, Ho P-R, Wagman R (2012) *Denosumab (DMAb) discontinuation and associated fracture incidence: Analysis from the FREEDOM trial*. Ann Rheum Dis 2012;71(Suppl3):65. **Oral presentation**.
284. Chapurlat R, Papapoulos S, **Brown JP**, Franchimont N, Brandi ML, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román JA, Roux C, Daizadeh NS, Geller ML, Smith S, Wagman RB, Cummings SR, Bone HG (2012) *Treatment Of Postmenopausal Women With*

- Osteoporosis For Six Years With Denosumab: Three-Year Results From The Freedom Extension*. Ann Rheum Dis 2012;71(Suppl3):588.
285. Bone HG, **Brown JP**, Chapurlat R, Franchimont N, Brandi ML, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román JA, Roux C, Daizadeh NS, Wang A, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2012) *The Effect of Six Years of Denosumab Treatment on New Vertebral and Nonvertebral Fractures in Postmenopausal Women With Osteoporosis: Results from the FREEDOM Extension Trial*. Endo 2012: The 94th Annual Meeting & Expo. Houston, Texas, USA. June 23-26, 2012. **Oral presentation**.
286. Franchimont N, Bone HG, **Brown JP**, Chapurlat R, Brandi ML, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román JA, Roux C, Daizadeh NS, Geller ML, Smith S, Wagman RB, Cummings SR, Papapoulos S (2012) *Six Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the First Three Years of the FREEDOM Extension*. American Academy of Nurse Practitioners 27<sup>th</sup> National Conference. Orlando, Florida, USA. June 20-24, 2012.
287. Franchimont N, Papapoulos S, **Brown JP**, Chapurlat R, Brandi ML, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román JA, Roux C, Daizadeh NS, Geller ML, Smith S, Wagman RB, Cummings SR, Bone HG (2012) *6 years of treatment with denosumab in postmenopausal women with osteoporosis: Results from the first 3 years of the FREEDOM open-label extension study*. Australia and New Zealand Bone and Mineral Society (ANZBMS) Annual Meeting. Perth, Australia. September 2-5, 2012. **Oral Presentation**.
288. Poole K, Treece G, Gee A, **Brown JP**, McClung MR, Wang A, Libanati C (2012) *Denosumab Administration is Associated With Progressive Improvement in Cortical Mass and Thickness Throughout the Hip*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e3e125b2-d89b-47e7-8416-9a07e55116de>. Accessed on December 12, 2012. **Oral Presentation**.
289. Berger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, Adachi JD, Prior JC, Towheed T, Davison KS, Kaiser SM, **Brown JP**, Goltzman D and the CaMos Research Group (2012) *Predictors of PTH and association of PTH with Skeletal outcomes in a population-based study*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=dadad410-9895-49ad-b8fa-5e199295a7d5>. Accessed on December 12, 2012.
290. Dempster DW, Zhou H, Recker RR, **Brown JP**, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson, III GC, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor K (2012) *Differential Effects of Teriparatide and Zoledronic Acid on the Outer and Inner Surfaces of Cortical Bone in Postmenopausal Women with Osteoporosis: Results from the SHOTZ Trial*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=9f76118c-a41f-4093-8363-49b29146530a>. Accessed on December 12, 2012. **Oral Presentation**.
291. Langsetmo L, Berger C, Kreiger N, Hanley D, **Brown JP**, Adachi JD, Jamal S, Josse R, Prior J, Kovacs C, Davison KS, Goltzman D (2012) *Dietary Patterns in Men and Women Aged 25 Years and Older: Relationship with Body Mass Index, 25-hydroxyvitamin D Levels, Fasting Glucose, and Risk of Diabetes*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=bccba7de-0e46-4927-bb75-e75b50836275>. Accessed on December 12, 2012.

292. McClung MR, Grauer A, Boonen S, **Brown JP**, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG (2012) *Inhibition of Sclerostin With AMG 785 in Postmenopausal Women With Low Bone Mineral Density: Phase 2 Trial Results*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=9fa27a06-d9b5-4429-a95f-517048985173>. Accessed on December 12, 2012. **Oral Presentation.**
293. Leslie W, **Canadian Chronic Disease Surveillance System Osteoporosis Working Group** (2012) *Use of Administrative Data for the Surveillance of Osteoporosis in Canada*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=535decae-d30d-428d-85b2-3bd4c25697b4>. Accessed on December 12, 2012.
294. Morin SN, Berger C, **Brown JP**, Leslie WD, Wall M, Kaiser SM, Prior JC, Josse RG, Hanley DA, Papaioannou A, Adachi JD, Kovacs C, Davison KS, Olszynski W, Towheed T, Goltzman D. (2012) *Clinical characteristics among patients with different femur fracture subtypes*. Available at: <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=f6c131fa-cffc-4abf-b75d-62ac3f9d3039>. J Bone Miner Res 27 (Suppl 1). Accessed on December 12, 2012. **Oral Presentation.**
295. Morin S, Bell A, Ngui D, Josse R, Frame H, **Brown JP**, Cheung AM, Burns B, Papaioannou A (2012) *Has Primary Care Physicians' (PCPs') Understanding and Use of the 2010 Osteoporosis Canada Clinical Practice Guidelines (OC CPG) Increased Since Publication?* Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=006114e1-1e60-42de-8b1a-ca703d1a6eae> at . J Bone Miner Res 27 (Suppl 1). Accessed on December 12, 2012.
296. Cheung AM, Tomlinson G, Tile L, Khan A, Josse R, Bogoch E, McDonald-Blumer H, Ridout R, Cardew S, Kapral M, Davison KS, Bleakney R, Syed K, Chang J, Wong Q, Morin S, **Brown J**, Papaioannou A, Adachi JD (2012) *Hip Structural Analysis of Patients with Atypical Femur Fractures (AFF): Data from the Ontario AFF Cohort*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=54e3a0de-cabf-4f5b-bc15-0d05fb784275>. Accessed on December 12, 2012.
297. Bessette L, Beaudoin C, Jean S, Ste-Marie L-G, **Brown JP** (2012) *The Impact of Educational Interventions for Osteoporosis on Calcium and Vitamin D Supplementations After a Fragility Fracture*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6ee7dcf8-788b-40f9-9e10-a1e1a98757cb>. Accessed on December 12, 2012.
298. Bessette L, Beaudoin C, Jean S, Ste-Marie L-G, **Brown JP** (2012) *The Influence of Educational Interventions on Modifiable Risk Factors for Osteoporosis After a Fragility Fracture*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=edfc1679-662d-47e6-bb42-911ac1512d35>. Accessed on December 12, 2012.
299. Beaudoin C, Jean S, Laurin E, Adachi JD, Barr SI, **Brown JP** (2012) *Evaluating the Effect of Yogurt fortified with calcium, vitamin D and Milk Basic Protein on Bone Remodelling in Early Postmenopausal Women*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=64b2c1cf-20e1-4b8f-a3a3-a12a55a18b0a>. Accessed on December 12, 2012.

300. Beauregard M, Gagnon E, Morissette J, **Brown J**, Michou L (2012) *Identification of Rare Genetic Variants on Ip13 and 8q22 Loci in Paget's Disease of Bone*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=84d9170a-d873-4f6c-abf0-e99e5a6788e3>. Accessed on December 12, 2012.
301. Guay-Bélanger S, Gagnon E, Morissette J, **Brown J**, Michou L (2012) *Study of the Sequestosome 1 Gene Copy Number in Paget's Disease of Bone*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=ce25325b-8264-4f4a-bdf7-3ca9aa82e6e1>. Accessed on December 12, 2012.
302. **Brown JP**, Ste-Marie L-G (2012) *PINP as an Aid for Monitoring Patients Treated with Teriparatide: Canadian Pilot Study*. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=37bac613-9f7e-459c-84c9-dad0e73216b4>. Accessed on December 12, 2012.
303. Prior J, Macdonald H, Zhou W, Berger C, Kovacs C, Hanley D, Anastassiades T, Kaiser S, **CaMOS Research Group** (2012) *Combined Hormonal Oral Contraceptive Use and Bone Mineral Density Change in the Premenopausal Population—10-year data from the Canadian Multicentre Osteoporosis Study*. Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=5bf00647-f096-4169-816f-081e1c49515c>. Accessed on December 12, 2012.
304. Wong AK, Beattie K, Bhargava A, Webber C, Inglis D, Pickard L, Cheung A, Papaioannou A, Adachi J, **CaMos Research Group** (2012) *Comparison of Bone Quality on 1T pMRI, pQCT and hr-pQCT: Precision, Least Significant Change & Cross-Calibration*. Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=f99b1331-a689-4002-95ce-68f458bb5afe>. Accessed on December 12, 2012.
305. Wong AK, Beattie K, Bhargava A, Shaker S, Webber C, Gordon C, Pickard L, Papaioannou A, Adachi J, **CaMos Research Group** (2012) *Inter and Intramuscular Adiposity Explains Only a Proportion of the Association between Muscle Density and Fractures*. Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=2e211d9c-66aa-4e1a-9f06-f778bd667fc4>. Accessed on December 12, 2012.
306. Poole K, Treece G, Gee A1, **Brown JP**, McClung MR, Wang A, Libanati C (2012) *Progressive Improvements in Cortical Mass and Thickness Throughout the Hip Were Observed With Denosumab Treatment in the FREEDOM Trial*. Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e3e125b2-d89b-47e7-8416-9a07e55116de>. Accessed on December 12, 2012. **Oral Presentation.**
307. Bruyere O, Bellamy N, **Brown JP**, Richette P, Punzi L, Chevalier X, Cooper C, Reginster JY (2012) *Clinically meaningful effect of strontium ranelate on knee osteoarthritis symptoms*. Arthritis & Rheumatism 2012; 64(10): S110.
308. Poole K, Treece G, Gee A, **Brown JP**, McClung MR, Wang A, Libanati C (2012) *Progressive Improvements in Cortical Mass and Thickness throughout the Hip Were Observed with Denosumab Treatment in the Freedom Trial*. Arthritis & Rheumatism 2012; 64(10): S358
309. Roux C, **Brown JP**, Beck Jensen, J-E, Gilchrist N, Recknor C, Törring O, Austin M, Wang A, Grauer A, Ho P-R, Wagman R (2012) *Incidence des fractures à l'arrêt du denosumab : analyse de l'essai FREEDOM*. 25e Congrès Français de Rhumatologie. Paris, France. December 9-12, 2012.



310. Ikić A, Beaudoin C, **Brown J**, Bessette L, Grondin C, Chetaille A-L, Adams K, Lang J-Y, Fortin PR, Michou L (2012) *Évaluation du niveau de connaissances des patients sclérodermiques sur les complications de leur maladie*. 25e Congrès Français de Rhumatologie. Paris, France. December 9-12, 2012.
311. Mahjoub Z, Jean S, Leclerc JT, **Brown JP**, Boulet D, Pelet S, Grondin C, Dumont J, Belzile EL, Michou L (2012) *Épidémiologie et caractéristiques des fractures sous-trochantériennes et diaphysaires fémorales atypiques*. 25e Congrès Français de Rhumatologie. Paris, France. December 9-12, 2012. **Oral Presentation**.
312. Poole K, Treece G, Gee A, **Brown JP**, McClung MR, Wang A, Libanati C (2013) *Denosumab Treatment Is Associated With Progressive Improvements in Cortical Mass and Thickness at the Hip in Regions Relevant to Fracture Protection*. (2013). ISCD'S 19<sup>th</sup> Annual Scientific Meeting, Tampa, Florida, USA. March 20-23, 2013. Journal of Clinical Densitometry Vol. 16, Issue 3, Pages 266-267.
313. Benhamou CL, Seefried L, Agodoa I, van den Bergh J, Prince R, Josse R, Viswanathan H, Ghelani P, **Brown JP**, Roux C, Ferreira I, O'Malley C, Ho PR, Resch H (2013) *Treatment Satisfaction in Postmenopausal Women Suboptimally Adherent to Alendronate Who Transitioned to Denosumab vs Risedronate*. European Congress on Osteoporosis and Osteoarthritis. Rome, Italy, April 17-20, 2013. Osteoporos Int (2013) 24 (Suppl 1): S159. Abstract P263.
314. Bruyere O, Richette P, Bellamy N, **Brown J**, Chapurlat R, Chevalier X, Czerwinski E, Devogelaer JP, March L, Pavelka K, Punzi L, Cooper C, Reginster JY (2013) *Strontium Ranelate improves osteoarthritis symptoms compared to placebo in patients with knee OA - the SEKOIA study*. European Congress on Osteoporosis and Osteoarthritis. Rome, Italy, April 17-20, 2013. Osteoporos Int (2013) 24 (Suppl 1):
315. McClung MR, Grauer A, Boonen S, **Brown JP**, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG (2013) *Inhibition of Sclerostin With Romosozumab in Postmenopausal Women With Low Bone Mineral Density: Phase 2 Trial Results*. European Congress on Osteoporosis and Osteoarthritis. Rome, Italy, April 17-20, 2013. Osteoporos Int (2013) 24 (Suppl 1):
316. Poole K, Treece G, Gee A, **Brown JP**, McClung MR, Wang A, Libanati C (2013) *Progressive improvements in cortical mass and thickness throughout the hip with denosumab (DMAb)*. European Congress on Osteoporosis and Osteoarthritis. Rome, Italy, April 17-20, 2013. Osteoporos Int (2013) 24 (Suppl 1): S214. Abstract P376.
317. Hofbauer LZ, Fahrleitnerpammer A, Ho P-R, Hawkins F, Roux C, Micaelo M, Minisola S, Papaioannou NA, Stone M, Wark J, Zillikens MC, Ferreira I, Siddhanti S, Wagman RB, **Brown JP** (2013) *Efficacy And Safety Of Denosumab Vs. Risedronate In Postmenopausal Women Suboptimally Adherent To Alendronate: Results From A Randomized Open-Label Study*. European Congress on Osteoporosis and Osteoarthritis. Rome, Italy, April 17-20, 2013. Osteoporos Int (2013) 24 (Suppl 1): S218. Abstract P383.
318. Bruyere O, Richette P, Bellamy N, **Brown J**, Chapurlat R, Chevalier X, Czerwinski E, Devogelaer JP, March L, Pavelka K, Punzi L, Cooper C, Reginster JY (2013) *Strontium Ranelate increases the number of patients with improvement in osteoarthritis symptoms compared to placebo in the SEKOIA study*. 2013 World Congress on Osteoarthritis. Philadelphia, PA, USA. April 18-21, 2013. Osteoarthritis and Cartilage Vol. 21Supplement, Page S143.
319. Hawkins F, Roux C, Fahrleitner-Pammer A, Ho PR, Hofbauer LC, Micaelo M, Minisola S, Papaioannou N, Stone M, Wark J, Zillikens MC, Ferreira I, Siddhanti S, Wagman RB, **Brown JP** (2013) *Denosumab versus risedronato en mujeres posmenopáusicas con adherencia subóptima al tratamiento con alendronato*:

*resultados de eficacia y seguridad de un ensayo aleatorizado abierto*. 39 Congreso Nacional de la Sociedad Española de Reumatología. May 21-23, 2013.

320. Poole K, Treece G, Gee A, **Brown JP**, McClung MR, Wang A, Libanati C. *Denosumab is associated with progressive improvements in hip cortical mass and thickness*. Accepted for an oral poster at the ECTS Annual Meeting. Lisbon, Portugal. May 18-21, 2013. Bone Abstracts Vol 1. Abstract PP433.
321. Recknor C, Roux C, Ran Ho P-R, Hall J, Bone H, Bonnick S, van der Bergh J, Ferreira I, Wagman R, **Brown J** (2013) *Bone mineral density BMD changes in patients with prior fracture suboptimally treated with a bisphosphonate (BP): results from denosumab (DMAb)/ibandronate (IBN) and DMAb/risedronate (RIS) trials*. ECTS Annual Meeting. Lisbon, Portugal. May 18-21, 2013. Bone Abstracts Vol 1. Abstract PP436.
322. **Brown JP**, Wagman R, Dempster DW, Kendler D, Miller P, Bolognese M, Valter I, Beck Jensen J-E, Zerbini C, Zanchetta JR, Daizadeh N, Reid I (2013) *Bone histology and histomorphometry: effects of 5 years of denosumab (DMAb) in the FREEDOM extension*. ECTS Annual Meeting. Lisbon, Portugal. May 18-21, 2013. Bone Abstracts Vol 1. Abstract PP434.
323. Morin SN, Godbout B, Wall M, Belzile EL, Michou L, Ste-Marie LG, Karaplis AC, de Guise JA, **Brown JP** (2013) *Femur Geometrical Parameters of Patients with Atypical Femur Fractures measured with the EOS™ imaging system*. Accepted for an oral presentation at the ECTS Annual Meeting. Lisbon, Portugal. May 18-21, 2013. Bone Abstracts Vol 1. Abstract OC1.6.
324. Guay-Belanger SG, Gagnon E, Morissette J, **Brown JP**, Michou L (2013) *SQSTM1/P392L post-zygotic mutations in unrelated patients with Paget's disease of bone*. ECTS Annual Meeting. Lisbon, Portugal. May 18-21, 2013. Bone Abstracts Vol 1. Abstract PP270.
325. Lacerte P, Paquet-Bouchard C, Brunet A, **Brown J**, Gosselin J (2013) *L'infection herpétique dans la progression de l'arthrite rhumatoïde*. Journée de la recherche de la Faculté de médecine de l'Université Laval. Quebec, Quebec, Canada. May 31, 2013.
326. Roux C, Fahrleitner-Pammer A, Ho P, Hawkins F, Hofbauer L, Micaelo M, Minisola S, Papaioannou N, Stone M, Wark J, Zillikens M, Ferreira I. F. I, Siddhanti S, Wagman R, **Brown J** (2013) *Denosumab Versus Risedronate: Efficacy And Safety In Postmenopausal Women Suboptimally Adherent To Alendronate Therapy In A Randomized Open-Label Study*. EULAR Annual European Congress of Rheumatology. Madrid, Spain. June 12-15, 2013.
327. McClung MR, Grauer A, Boonen S, **Brown JP**, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG (2013) *Inhibition of Sclerostin With Romosozumab in Postmenopausal Women With Low Bone Mineral Density: Phase 2 Trial Results*. Accepted as an oral presentation at the EULAR Annual European Congress of Rheumatology. Madrid, Spain. June 12-15, 2013.
328. Bruyere O, Richette P, Bellamy N, **Brown J**, Chapurlat R, Chevalier X, Czerwinski E, Devogelaer JP, March L, Pavelka K, Punzi L, Cooper C, Reginster JY (2013) *Strontium Ranelate improves osteoarthritis symptoms compared to placebo in patients with knee OA - the SEKOIA study*. Accepted as a poster presentation at the EULAR Annual European Congress of Rheumatology. Madrid, Spain. June 12-15, 2013.
329. Silverman SL, Siris E, Kendler DL, Belazi D, **Brown JP**, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Pinzone J, Siddhanti S, Stolshek B, Recknor C (2013) *Design and Baseline Characteristics of a Prospective Observational Study in the United States and Canada to Evaluate Persistence With*

*Denosumab in Postmenopausal Women With Osteoporosis*. Accepted as a poster presentation by the Endocrine Society's 95<sup>th</sup> Annual Meeting & Expo. San Francisco, CA, USA. June 15-18, 2013.

330. Mahjoub Z, Jean S, Leclerc J-T, **Brown JP**, Boulet D, Pelet S, Grondin C, Dumont J, Belzile EL, Michou L (2013) *Incidence and characteristics of atypical femoral fractures*. Accepted as a poster presentation by the Canadian Orthopaedic Association and Canadian Orthopaedic Research Society Annual Meeting. Winnipeg, MB, Canada. June 20-22, 2013.
331. Beaudoin C, Jean S, Bessette L, Ste-Marie L.G., **Brown JP** (2013) *Characteristics Influencing Quality of Life in Women 6 Months After Suffering a Fragility Fracture*. Accepted as a poster presentation by the 2<sup>nd</sup> Fragility Fracture Network Global Congress. Berlin, Germany. August 29-31, 2013.
332. Beaudoin C, Bessette L, Jean S, Davison KS, Ste-Marie L.G., **Brown JP**. (2013) *Does a Clinical Definition of Fragility Fracture Based on its Cause and Circumstances Adequately Classify Women with Characteristics Predisposing to Osteoporosis?* Accepted as an oral and poster presentations by to the 2<sup>nd</sup> Fragility Fracture Network Global Congress. Berlin, Germany. August 29-31, 2013.
333. **Brown JP**, Beaudoin C, Davison KS, Jean S, Bessette L, Ste-Marie L.G. (2013) *A Clinical Definition of Fragility Fracture*. Accepted as a poster presentation by the 2<sup>nd</sup> Fragility Fracture Network Global Congress. Berlin, Germany. August 29-31, 2013.
334. Beaudoin C, Jean S, Bessette L, Ste-Marie L.G., **Brown JP** (2013) *Impact of a Fragility Fracture on Quality of Life 6 and 18 Months Post Fracture*. Accepted as a poster presentation by the 2<sup>nd</sup> Fragility Fracture Network Global Congress. Berlin, Germany. August 29-31, 2013.
335. Bessette L, Beaudoin C, Jean S, Davison KS, Ste-Marie L.G., **Brown JP** (2013) *An Overview of the Principal Results from the Recognizing Osteoporosis and its Consequences in Quebec (ROCQ) Programme*. Accepted as a poster presentation by the 2<sup>nd</sup> Fragility Fracture Network Global Congress. Berlin, Germany. August 29-31, 2013.
336. Hofbauer LC, Fahrleitner-Pammer A, Ho P-R, Hawkins F, Roux C, Micaelo M, Minisola S, Papaioannou NA, Stone M, Wark J, Zillikens MC, Ferreira I, Siddhanti S, Wagman RB, **Brown JP** (2013) *Denosumab versus risedronate in women with postmenopausal osteoporosis suboptimally adherent to alendronate: efficacy and safety results from a randomised, open-label study*. Accepted by the Australian and New Zealand Bone and Mineral Society (ANZBMS) annual scientific meeting. Melbourne, Australia. September 8-11, 2013.
337. **Brown JP**, Davison KS, Olszynski WP, Beattie KA, Adachi JD. *A critical review of brand and generic alendronate for the treatment of osteoporosis*. Springerplus. 2013 Oct 21; 2:550.
338. Beaudoin C, Jean S, Bessette L, Ste-Marie L-G, Brown JP (2013) *Characteristics Influencing Quality of Life in Women 6 Months After Suffering a Fragility Fracture*. *J Bone Miner Res* 28 (Suppl 1). Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=90fb1ebd-1e91-4a4b-a36d-bd721dac0463>. Accessed on December 17, 2013.
339. Beaudoin C, Jean S, Bessette L, Ste-Marie L-G, Brown JP (2013) *Impact of a Fragility Fracture on Quality of Life 6 and 18 Months Post Fracture*. *J Bone Miner Res* 28 (Suppl 1). Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=f183bf07-253d-4c99-b747-0282c6884c96>. Accessed on December 17, 2013.
340. Gajic-Veljanoski O, Tomlinson G, Srighanthan J, Adachi JD, Josse R, **Brown JP**, Cheung AM (2013) *Effect of Odanacatib on BMD and Fractures: a Bayesian bivariate meta-analysis*. *J Bone Miner Res* 28

(Suppl 1). Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=68c6e3e7-5485-45b0-98d4-35f2325fd1e5>. Accessed on December 17, 2013

341. Genant HK, Boonen S, Bolognese MA, Mautalen C, **Brown JP**, Recknor C, Goemaere S, Engelke K, Yang Y-C, Austin M, Grauer A, Libanati C (2013) *Effect of Romosozumab on Lumbar Spine and Hip Bone Mineral Density as Assessed by Quantitative Computed Tomography (QCT)*. J Bone Miner Res 28 (Suppl 1). Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=67672d13-3ff4-4d27-81cc-eb47f22ecf45>. Accessed on December 17, 2013
342. Dempster DW, Zhou H, Recker RR, **Brown JP**, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson, III GC, Lindsay R, Binkley N, Alam J, Ruff VA, Janos B, Taylor KA (2013) *A longitudinal study of Skeletal Histomorphometry in subjects On Teriparatide (TPTD) or Zoledronic acid (ZOL), the SHOTZ study*. J Bone Miner Res 28 (Suppl 1) Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=f79c180a-ee29-4a62-91d7-729948ccc2f7>. Accessed on December 17, 2013.
343. Audet M-C, Beaudoin C, Dumont J, **Brown JP**, Michou L (2013) *Environmental factors are associated with Paget's disease of bone or with the SQSTM1/P392L mutation carriage*. J Bone Miner Res 28 (Suppl 1). Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=bc3d6ce8-d784-44ec-9c45-48e0dbf54697>. Accessed on December 17, 2013.
344. Morin SN, Godbout B, Wall M, Belzile EL, Michou L, Moser T, Ste-Marie L-G, Karaplis AC, de Guise JA, **Brown JP** (2013) *Lower Limb Geometrical Parameters in the Pathogenesis of Atypical Femur Fractures*. J Bone Miner Res 28 (Suppl 1). Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=390955e4-f288-4998-9a17-6ecf945c595c>. Accessed on December 17, 2013. **Oral presentation**.
345. Guay-Belanger S, Gagnon E, Morissette J, **Brown JP**, Michou L (2013) *Case-control Study of the SQSTM1/P392L Post-zygotic Mutation in Paget's disease of Bone*. J Bone Miner Res 28 (Suppl 1) Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=3f4d3cdb-666b-4995-aded-4a1c74d982b1>. Accessed on December 17, 2013.
346. Mahjoub Z, Jean S, Leclerc J-T, **Brown JP**, Boulet D, Pelet S, Grondin C, Dumont J, Belzile EL, Michou L (2013) *Incidence and characteristics of atypical femoral fractures*. J Bone Miner Res 28 (Suppl 1). Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=9a39823b-5c15-4e3e-9359-7106831159c4>. Accessed on December 17, 2013.
347. Jean S, Gamache P, Bessette L, Belzile E, Morin S, Gagné M, **Brown JP** (2013) *The Burden of osteoporotic fracture: Epidemiology and health-care utilisation in older adults, 1997-2010*. J Bone Miner Res 28 (Suppl 1). Available at <http://www.asbmr.org/asbmr-2013-abstract-detail?aid=9b58dfdf-b0dc-4cf8-bac2-db296a69546d>. Accessed on December 17, 2013.
348. Silverman SL, Siris E, Kendler DL, Belazi D, **Brown JP**, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Pinzone J, Siddhanti S, Stolshek B, Recknor C (2013) *Persistence with Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis: 12-Month Data From a Prospective Observational Study*. Arthritis & Rheumatism 2013; 65(10): S523.
349. Sunkureddi P, Toth E, **Brown JP**, Moericke R, Nebesky M, Krammer G, Tao A, John M, Kivitz A (2013) *Efficacy and safety of canakinumab pre-filled syringe versus triamcinolone acetone in acute gouty arthritis patients*. Arthritis & Rheumatism 2013; 65(10): S498.

350. **Brown JP**, Bolognese MA, Ho PR, Hall J, Roux C, Bone HG, Bonnick S, van den Bergh J, Ferreira I, Ghelani P, Dakin P, Wagman RB, Recknor C (2013) *Denosumab Leads to Significantly Greater Increases in Bone Mineral Density than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously Treated with an Oral Bisphosphonate*. *Arthritis & Rheumatism* 2013; 65(10): S522.
351. Genant HK, Boonen S, Bolognese MA, Mautalen C, **Brown JP**, Recknor C, Goemaere S, Engelke K, Yang Y-C, Austin M, Grauer A, Libanati C (2013) *Romsozumab Administration is Associated With Significant Improvements in Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide*. *Arthritis & Rheumatism* 2013; 65(10): S368.
352. Mahjoub Z, Jean S, Leclerc J-T, **Brown JP**, Boulet D, Pelet S, Grondin C, Dumont J, Belzile E, Michou L (2013) *Épidémiologie et caractéristiques des fractures sous-trochantériennes et diaphysaires fémorales atypiques*. Accepted by the 88<sup>th</sup> annual meeting of the Société Française de Chirurgie Orthopédique et Traumatologique. Paris, France. November 11-15, 2013.
353. Belanger A, Turcotte A, Morin F, Hamilton CJ, **Brown JP** (2013) *Development and Implementation of an Osteoporosis Screening Tool for Family Practitioners in Québec*. 2013 Family Medicine Forum. November 2013.
354. Hawkins F, Roux C, Fahrleitner-Pammer A, Ho PR, Hofbauer LC, Micaelo M, Minisola S, Papaioannou N, Stone M, Wark J, Zillikens MC, Ferreira I, Siddhanti S, Wagman RB, **Brown JP** (2013) *Eficacia Y Seguridad De Denosumab Versus Risedronato En Mujeres Posmenopáusicas Con Adherencia Subóptima Al Tratamiento Con Alendronato: Ensayo Aleatorizado Abierto*. XVIII Congreso de la Sociedad Española de Investigación Ósea y Metabolismo Mineral, Tarragona, Spain. Noviembre 13-15, 2013.
355. **Brown JP**, Mcclung MR, Grauer A, Boonen S, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Katz L, Maddox J, Yang Y-C3, Libanati C, Bone HG (2013) *Inhibition de la sclérostine par le romosozumab chez des femmes ménopausées ayant une DMO basse : résultats de l'étude de phase 2*. 26th congress of the Société Française de Rhumatologie. Paris, France. December 1-3, 2013.
356. Hanley D, **Brown J**, Adachi J, Davison K, Olszynski W. *The impact of vitamin D and calcium intake on estimated bone stiffness as assessed by multisite quantitative ultrasound: the Canadian Multicentre Osteoporosis study*. *Bone Abstracts*. 2014; 3:235.
357. **Brown J**, Adachi J, Hanley D, Davison K, Olszynski W. *The impact of physical activity on estimated bone stiffness as assessed by multisite quantitative ultrasound: the Canadian Multicentre Osteoporosis study*. *Bone Abstracts*. 2014;3:231.
358. Olszynski W, Hanley D, **Brown J**, Davison K, Adachi J. *Discordance between bone mineral density and speed of sound measures of bone: the Canadian Multicentre Osteoporosis study*. *Bone Abstracts*. 2014; 3:224.
359. **Brown JP**, Bolognese MA, Ho P-R, Roux C, Bone HG, Bonnick SL, van den Bergh J, Ferreira I, Ghelani P, Dakin P, Wagman RB, Recknor C. *In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and Risedronate*. *Bone Abstracts*. 2014; 3:357.
360. Bilezikian JP, Benhamou CL, Lin CJF, **Brown JP**, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C. 2014 *Denosumab Restores Cortical Bone Loss at the Distal Radius Associated With Aging and Reduces Wrist Fracture Risk: Analyses*

From the FREEDOM Extension Cross-over Group. *J Bone Miner Res* 29(Suppl1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=3302d1bd-f620-4961-8f72-f3aea8b0bd81>. Accessed on October 30, 2014.

361. Whitmarsh T, Treece G, Gee A, Bolognese M, **Brown JP**, Goemaere S, Grauer A, Hanley D, Mautalen C, Recknor C, Yang YC, Libanati C, Poole K. 2014 *Romosozumab and Teriparatide Effects on Vertebral Cortical Mass, Thickness and Density in Postmenopausal Women With Low Bone Mineral Density (BMD)*. *J Bone Miner Res* 29 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=8a7a2802-9f86-4a72-8c31-53a23957439e>. Accessed on October 30, 2014.
362. McClung MR, Chines A, **Brown JP**, Diez-Perez A, Resch H, Caminis J, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Rosen O, Bray S, Grauer A. 2014 *Effects of 2 Years of Treatment With Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density*. *J Bone Miner Res* 29 (Suppl1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=9114bfe4-a51e-4e38-8a67-5d0deef408c6>. Accessed on October 30, 2014.
363. Guay-Bélanger S, Simonyan D, Gagnon E, Morissette J, **Brown JP**, Michou L. 2014 *Gene-gene Interactions in Paget's Disease of Bone*. *J Bone Miner Res* 29 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=63f092bb-0593-49ee-a37b-a9d615e4d0ce>. Accessed on October 30, 2014.
364. Beaudoin C, Jean S, Bessette L, Ste-Marie LG, **Brown JP**. *High Body Mass Index Is a Risk Factor for Low Trauma Fractures in Women Who Have Sustained an Upper Arm or Lower Leg Fracture*. ASBMR Annual Meeting. Poster Session, Presentation Number MO0320. George R. Brown Convention Center, Discovery Hall-Hall E. September 15, 2014.
365. Jean S, **Brown JP**, Gamache P, Morin S, O'Donnell S, Leslie W, Bessette L. 2014 *Identification of Osteoporosis Cases in Administrative Healthcare Databases: A Validation Study in the Province of Quebec, Canada*. *J Bone Miner Res* 29 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=9f1ce8c2-707a-4722-916e-cf1adc39252c>. Accessed on October 30, 2014.
366. Teramachi J, Kitagawa Y, Windle J, Michou L, **Brown JP**, Kurihara N, Roodman GD. 2014 *MVNP Expression in Osteoblast Induces IGF1 to Increase EphrinB2/EphB4 and Osteoblast Differentiation*. *J Bone Miner Res* 29 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=d1f2df31-31c3-44b1-8b1f-36bbabf361ff>. Accessed on October 30, 2014.
367. Ferrari S, Libanati C, Lin CJF, Adami S, **Brown JP**, Cosman F, Czerwiński C, de Gregório LH, Malouf J, Reginster JY, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM, Cummings S. 2014 *Percentage of Women Achieving Non-osteoporotic BMD T-scores at the Spine and Hip Over 8 Years of Denosumab Treatment*. *J Bone Miner Res* 29 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=f764059c-0f9e-4a3b-b495-5798d8aace74>. Accessed on October 30, 2014.
368. Silverman SL, Siris E, Kendler DL, Belazi D, **Brown JP**, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Quinn G, Balasubramanian A, Mirza FM, Ho P, Siddhanti S, Stolshek B, Recknor C. 2014 *Persistence With Prolia® (Denosumab) for 1 Year in Relation to Patient-reported Data: Interim Results From a Prospective Observational Study of Postmenopausal Women With Osteoporosis*. *J Bone Miner Res* 29 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=5458ba89-27d3-40cb-9da1-309b3944f6e5>. Accessed on October 30, 2014.
369. Morin S, Harvey E, Belzile E, **Brown JP**, Jean S. *Temporal Trend in High- and low-trauma Hip, Femur and Pelvic Fracture Rates and Selected Quality of Care Indicators in Québec, Canada*. *J Bone Miner Res*

29 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=585aaa1b-2b57-4804-b0cb-af12e762ed2d>. Accessed on October 30, 2014.

370. Jean S, Harvey E, Belzile E, **Brown JP**, Morin S. 2014 *Temporal Trends in Pelvic Fracture Rates and Selected Quality of Care Indicators in Québec, Canada*. J Bone Miner Res 29 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=44d7e383-b518-4189-afe0-3f067a9d4a97>. Accessed on October 30, 2014.
371. Genant H, Bolognese M, Mautalen C, **Brown J**, Recknor C, Goemaere S, Engelke K, Yang YC, Austin M, Grauer A, Libanati C. *Romozosumab Administration Is Associated With Significant Improvements in Lubar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide*. EULAR. Ann Rheum Dis 2014; 73(Suppl2).
372. Sunkureddi P, Toth E, **Brown J**, Kivitz A, Stancati A, Richard D, Lheritier K, Möricke R. *Canakinumab Pre-filled Syringe vs Triamcinolone Acetonide in the Treatment of Acute Gouty Arthritis Attacks: Results From A Post-Hoc Analysis in Difficult-to-Treat Patients*. EULAR. Ann Rheum Dis 2014; 73(Suppl2).
373. Sunkureddi P, Toth E, **Brown J**, Kivitz A, Stancati A, Richard D, Lheritier K, Möricke R. *Efficacy and Safety of Canakinumab Pre-filled Syringe in Acute Gouty Arthritis Patients With Chronic Kidney Disease Stage  $\geq 3$* . EULAR. Ann Rheum Dis 2014; 73(Suppl2).
374. Audet MC, Beaudoin C, Guay-Bélanger S, Dumont J, **Brown JP**, Michou L. *Environmental Factors Associated With Paget's Disease of Bone or With the SQSTM1/P392L Mutation Carriage*. EULAR. Ann Rheum Dis 2014; 73(Suppl2).
375. Murray N, Brousseau G, **Brown JP**. *Le diagnostic radiologique des fractures vertébrales ostéoporotiques à la tomodensitométrie : Apport des reconstructions sagittales systématiques*. Université Laval, November 10, 2014.
376. Chines A, **Brown JP**, Diez-Perez A, Resch H, Caminis J, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Rosen O, Bray S, Grauer A. *Effects of 2 Years of Treatment with Romozosumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density*. American College of Rheumatology, Boston, USA, November 14-19, 2014.
377. Bilezikian JP, Benhamou CL, Lin CJF, **Brown JP**, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C. *Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-over Group in the Extension of the Denosumab Pivotal Fracture Trial*. American College of Rheumatology, Boston, USA, November 14-19, 2014.
378. Bessette L, Beaudoin C, Jean S, Davison KS, Ste-Marie L-G, **Brown JP** (2014) *Est-ce qu'une définition clinique de la fracture de fragilisation basée sur ses causes et circonstances classe adéquatement les femmes ayant des facteurs de risque prédisposant à l'ostéoporose?* Accepté pour une présentation orale au 27e congrès annuel de la Société française de rhumatologie. Paris, France. 7-9 décembre 2014.
379. Bessette L, Beaudoin C, Davison KS, Jean S, Ste-Marie L-G, **Brown JP** (2014) *Une définition clinique de la fracture de fragilisation*. Accepté pour une présentation orale au 27e congrès annuel de la Société française de rhumatologie. Paris, France. 7-9 décembre 2014.

380. Bessette L, Beaudoin C, Jean S, Davison KS, Ste-Marie L-G, **Brown JP** (2014) Un aperçu des résultats principaux du programme Reconnaître l'Ostéoporose et ses Conséquences au Québec (ROCQ). Accepté pour une présentation orale au 27<sup>e</sup> congrès annuel de la Société française de rhumatologie. Paris, France. 7-9 décembre 2014.
381. Beaudoin C, Jean S, Bessette L, Ste-Marie L-G, **Brown JP**. (2015) *The relationship between body mass index and level of trauma in a cohort of women who have sustained a fracture*. J Rheum; 42(7): 1314.
382. Beaudoin C, Bessette L, Jean S, Davison KS, Ste-Marie L-G, **Brown JP**. *Does a Clinical Definition of Fragility Fracture Based on its Cause and Circumstances Adequately Classify Women with Characteristics Predisposing to Osteoporosis?* J Rheum; 42(7): 1313-14.
383. Olszynski WP, Hanley DA, Davison KS, **Brown JP**, Adachi JD. (2015) *Changes in Multisite Quantitative Ultrasound Speed of Sound over Five Years of Follow-Up: the Canadian Multicentre Osteoporosis Study*. IBMS BoneKEY 13, Article number: 673. Poster Presentation 286.
384. Ferrari S, Libanati C, Lin CJF, Adami S, **Brown JP**, Cosman F, Czerwinski E, de Gregório LH, Malouf J, Reginster J-Y, Daizadeh NS, Wang A, Wagman RB, Lewieck EM. (2015) *Percentage of Women Achieving Non-Osteoporotic BMD T-Scores at the Spine and Hip during up to 8 Years of Denosumab (Dmab) Treatment*. IBMS BoneKEY 13, Article number: 673. Poster Presentation 350.
385. Bilezikian J, Benhamou CL, Lin C, **Brown J**, Daizadeh N, Ebeling P, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller P, Simon , Valter I, Zerbini, Libanati C (2015) *Denosumab (DMab) Restores Cortical Bone Loss at the 1/3 Radius Associated with Ageing and Reduces Wrist Fracture Risk: Analyses from the FREEDOM Extension Cross-over Group*. IBMS BoneKEY 13, Article number: 673. Poster Presentation 356.
386. Mörnicke R, Sunkureddi P, Toth E, **Brown JP**, Machein U, Lheritier K, Junge G, Kivitz A (2015) *Long-term safety and maintenance of efficacy of canakinumab liquid formulation in acute gouty arthritis patients: results from a 36 week extension study*. Ann Rheum Dis 2015;74(Suppl2): 1209.
387. McClung MR, Chines A, **Brown JP**, Diez-Perez A, H Resch, Caminis J, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Rosen O, Bray S, Grauer A (2015) *Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density*. Ann Rheum Dis 2015;74(Suppl2): 166. **Oral Presentation**.
388. Bilezikian JP, Benhamou CL, Lin CJF, **Brown JP**, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C (2015) *Denosumab Restores Cortical Bone Loss at the 1/3 Radius Associated With Aging and Reduces Wrist Fracture Risk: Analyses From the FREEDOM Extension Cross-over Group*. Accepted as a poster presentation at the 6<sup>th</sup> Central European congress on osteoporosis and osteoarthritis. Cracow, Poland, September 25-26, 2015
389. Dempster DW, **Brown JP**, Yue S, Farlay D, Rizzo S, Song J, Wang A, Wagman RB, Boivin G (2015) *Effects of Denosumab on Bone Matrix Mineralization: Results From the Phase 3 FREEDOM Trial*. J Bone Miner Res 30 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=a7e54533-9c31-40f0-aac0-645753ef2075>. Accessed December 10, 2015. **Oral presentation**.



390. Ferrari S, Libanati C, Lin CJF, Adami S, **Brown JP**, Cosman F, Czerwiński E, de Gregório LH, Malouf J, Reginster J-Y, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM (2015) *Relationship Between Total Hip BMD T-score and Incidence of Nonvertebral Fracture With up to 8 Years of Denosumab Treatment*. J Bone Miner Res 30 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=11d861c9-68e4-4994-88e0-c6b94948e898>. Accessed December 10, 2015.
391. Bone HG, et al. (2015) *Ten Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the FREEDOM Extension Trial*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=8434ca0f-ef68-406e-8eae-0e2839ac10d3>. Accessed December 10, 2015.
392. Watts NB, **Brown JP**, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, Wagman RB, Wang A, Daizadeh NS, Smith S, Bone HG (2015) *Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During FREEDOM and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension*. J Bone Miner Res 30 (Suppl 1). Available at : <http://www.asbmr.org/education/AbstractDetail?aid=33cdb228-980f-4585-beb0-f55d6de83929>. Accessed December 10, 2015.
393. Silverman SL, Siris E, Kendler DL, Belazi D, **Brown JP**, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Quinn G, Yue S, Cheng LI, Stolshek B, Recknor C (2015) *Factors Affecting Persistence With Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis: Results From a Prospective Observational Study*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=abfd56cb-3f96-42fb-82bf-f6c8c75369da>. Accessed December 10, 2015.
394. **Brown JP**, Dakin P, Hadji P, McClung MR, Miller P, Reginster JY, Wagman RB, Wang A, McCloskey E (2015) *Can We Use Bone Turnover Markers as Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? An Analysis From the DECIDE and STAND Clinical Trials*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=afe80486-5405-40d1-af49-01de7d725a1e>. Accessed December 10, 2015.
395. Kendler DL, Silverman SL, Siris E, **Brown JP**, Gold DT, Lewiecki EM, Simonelli C, Quinn G, Yue S, Stolshek B, Recknor C (2015) *Effect of Denosumab on BMD Outcomes in Persistent Patients in a Prospective Observational Study*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=d7357f64-1f00-48f9-bd34-f0e43809be7b>. Accessed December 10, 2015.
396. Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, **Brown JP**, Langdahl BL, Yan C, Grauer A, Libanati C (2015) *Romosozumab Improves Strength at the Lumbar Spine and Hip in Postmenopausal Women With Low Bone Mass Compared With Teriparatide*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=8384bb09-47ff-4cb6-b1f4-f214c00c55d9>. Accessed December 10, 2015. **Oral presentation.**
397. Tarride JE, Hopkins RB, Bessette L, Burke N, **Brown JP**, Leslie WD, Morin SM, Papaioannou A, Periculous L, Adachi JD (2015) *Loss in health related quality of life following low-trauma fractures in frail elderly*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=6dc90c36-0688-4015-af1d-bee026d31347>. Accessed December 10, 2015.
398. Hopkins RB, Adachi JD, Bessette L, Burke N, **Brown JP**, Leslie WD, Morin SN, Papaioannou A, Periculous L, Tarride JE (2015) *Potential years of life lost following low-trauma fractures in Canada*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=db5b7178-5916-4082-ac9b-14a9bb6df0c4>. Accessed December 10, 2015.

399. Langsetmo L, Berger C, Goltzman D, Morin S, Hanley D, Kaiser S, Prior J, Lentle B, Patel M, Kreiger N, Jamal S, Josse R, **Brown J**, Adachi J, Papaioannou A, Davison K, Olszynski W, Kovacs C, Leslie W, Anastassiades T, Towheed T (2015) *Skeletal-site Specific Heterogeneity in the Association Between Bisphosphonate Use and Incident Non-vertebral Fracture*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=2da659f5-dedc-40c7-991e-1f44ecb1fc0b>. Accessed December 10, 2015.
400. Morin SN, Moser TP, Godbout B, Belzile EL, Wall M, Michou L, Ste-Marie L-G, de Guise JA, **Brown JP** (2015) *Increased Femoral Cortical Thickness in Patients with Atypical Femur Fractures; the Quebec Registry for Atypical Femur Fractures*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=eb95108d-98bb-43a5-b3ad-73cde721f5ac>. Accessed on December 10, 2015.
401. Wong AKO, Davison KS, Adachi JD, **Brown J**, Josse R, Khan A, Grader-Beck T, Cheung AMW (2015) *Higher femoral shaft density and thickness as measured using Hip Structural Analysis (HSA) are risk factors for atypical femur fractures (AFFs)*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=2d780956-0876-4e3a-86b0-5800c410f7bd>. Accessed on December 10, 2015.
402. Schneider PS, Harvey EJ, Wall M, Belzile EL, **Brown JP**, Morin SN (2015) *Surgical Treatment and Functional Outcomes Following Atypical Femur Fractures: the Quebec Atypical Femur Fracture Registry*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=0d977167-6a91-4660-8cf5-c384e92094b9>. Accessed on December 10, 2015.
403. Beaudoin C, Jean S, Bessette L, Ste-Marie L-G, **Brown JP** (2015) *Denosumab Compared to Other Treatments to Prevent or Treat Osteoporosis: a Systematic Review and Meta-analysis*. J Bone Miner Res 30 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=c3a77ec1-02a3-4751-86ff-30683c624840>. Accessed on December 10, 2015.
404. Beaudoin C, Jean S, Bessette L, Ste-Marie L-G, **Brown JP** (2015) *A Clinical Definition of Fragility Fracture*. J Bone Miner Res 30 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=4ba90fdc-fc2a-4bb0-8b2a-aeda48834268>. Accessed December 10, 2015.
405. Dempster D, Zhou H, Recker R, **Brown JP**, Recknor C, Lewiecki EM, Miller P, Rao S, Kendler D, Krege J, Alam J, Taylor K, Janos B, Ruff V (2015) *Anabolism versus Antiresorption (AVA Study): A Comparison of the Mechanism of Action (MOA) of Teriparatide (TPTD) and Denosumab (DMAb) in Postmenopausal Women with Osteoporosis Using Quadruple Fluorochrome Labeled Bone Histomorphometry*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=9a623f12-93f6-413d-a491-ef4b362103d9>. Accessed December 10, 2015.
406. Miller P, Pannacciulli N, **Brown JP**, Czerwinski E, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB (2015) *Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates: Efficacy and Safety Results From a Randomized Double-blind Study*. J Bone Miner Res 30 (Suppl 1). Available at : <http://www.asbmr.org/education/AbstractDetail?aid=088f180b-c4c5-4717-9a28-fe5e19794026>. Accessed December 10, 2015.
407. Numan MS, Jean S, Dumont J, **Brown JP**, Michou L (2015) *Exploration of associations between air pollutants and Paget's disease of bone*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=4a084a7a-0f98-4690-9718-c22226c0d754>. Accessed December 10, 2015.

408. Nagata Y, Mohammad K, Guise T, Michou L, **Brown JP**, Windle JJ, Kurihara N, Roodman GD (2015) *Measles Virus Nucleocapsid Protein Expression in Osteoclasts Increases SPHK1/S1P/S1PR3 to Enhance Osteoblast Differentiation in Paget's Disease*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=c3c51615-1d48-40ca-b265-238448198fbb>. Accessed December 10, 2015.
409. Teramachi J, Inagaki Y, Mohammad K, Guise T, Michou L, **Brown JP**, Windle JJ, Kurihara N, Roodman GD (2015) *Measles Virus Nucleocapsid Protein Increases IL-6 and IGF1 in Osteoclasts to Enhance Osteoblast Differentiation in Paget's Disease*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=917df2fb-defc-4372-bf1e-7470880418d3>. Accessed December 10, 2015.
410. Sun Q, Zhang P, Adamik J, Windle JJ, Michou L, **Brown JP**, Kurihara N, Roodman GD, Galson D (2015) *MVNP Alters The Balance Of TBK1 And Optineurin In Osteoclast Lineage Cells To Generate Pagetic Osteoclasts*. J Bone Miner Res 30 (Suppl 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=8aabb2d8-29ab-4b79-a039-d3f17880b4ca>. Accessed December 10, 2015.
411. Malouf J, Ferrari S, Libanati C, Lin CJF, Adami S, **Brown JP**, Cosman F, Czerwiński E, De Gregório LH, Reginster J-Y, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM (2015) *Porcentaje de mujeres que alcanzan una puntuación T de DMO no osteoporótica en la columna lumbar y en la cadera total durante el tratamiento de hasta 8 años con denosumab*. Spanish Society of Osteoporosis Annual Congress. Bilbao, Spain, 21-23 October, 2015
412. Keaveny T, Crittenden D, Bolognese M, Genant H, Engelke K, Oliveri B, **Brown J**, Langdahl B, Yang Y, Grauer A, Libanati C. *Strength at the Lumbar Spine and Hip Improves with Romosozumab Compared with Teriparatide in Postmenopausal Women with Low Bone Mass* [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/strength-at-the-lumbar-spine-and-hip-improves-with-romosozumab-compared-with-teriparatide-in-postmenopausal-women-with-low-bone-mass/>. Accessed December 10, 2015.
413. Ferrari S, Libanati C, Lin C, Adami S, **Brown J**, Cosman F, Czerwinski E, de Gregório L, Malouf J, Reginster JY, Daizadeh N, Wang A, Wagman R, Lewiecki E. *Relationship Between Total Hip BMD T-Score and Incidence of Nonvertebral Fracture with up to 8 Years of Denosumab Treatment* [abstract]. **Arthritis Rheumatol**. 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/relationship-between-total-hip-bmd-t-score-and-incidence-of-nonvertebral-fracture-with-up-to-8-years-of-denosumab-treatment/>. Accessed December 10, 2015.
414. Miller P, Pannacciulli N, **Brown J**, Czerwinski E, Nedergaard B, Bolognese M, Malouf J, Bone H, Reginster J, Singer A, Wang C, Wagman R, Cummings S. *A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate* [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/a-randomized-double-blind-study-of-denosumab-compared-with-zoledronic-acid-in-postmenopausal-women-with-osteoporosis-previously-treated-with-oral-bisphosphonate/>. Accessed December 10, 2015.
415. **Brown J**, Dakin P, Hadji P, McClung M, Miller P, Reginster JY, Wagman R, Wang A, McCloskey E. *Can We Use Bone Turnover Markers As Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? an Analysis from Two Phase 3 Clinical Trials* [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/can-we-use-bone-turnover-markers-as-targets-for-antiresorptive-treatment-in-postmenopausal-osteoporosis-an-analysis-from-two-phase-3-clinical-trials/>. Accessed December 10, 2015.

416. Watts N, **Brown J**, Papapoulos S, Lewiecki E, Kendler D, Dakin P, Wagman R, Wang A, Daizadeh N, Smith S, Bone H. *Safety Observations with 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab during the Pivotal 3-Year Trial and Subjects Who Crossed over to Denosumab during the Extension* [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/safety-observations-with-3-years-of-denosumab-exposure-comparison-between-subjects-who-received-denosumab-during-the-pivotal-3-year-trial-and-subjects-who-crossed-over-to-denosumab-during-the-extensi/>. Accessed December 10, 2015.
417. Choquette D, Bessette L, Haraoui B, Massicotte F, Pelletier JP, Raynauld JP, Rémillard MA, Sauvageau D, Villeneuve, Coupal L, **Brown J**, Turcotte A. *Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry* [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/use-of-rituximab-compared-to-anti-tnf-agents-as-second-and-third-line-therapy-in-patients-with-rheumatoid-arthritis-6-year-follow-up-report-from-the-rhumadata-clinical-database-and-registry/>. Accessed December 10, 2015.
418. Choquette D, Bessette L, **Brown J**, Haraoui B, Massicotte F, Pelletier JP, Raynauld JP, Rémillard MA, Sauvageau D, Turcotte A, Villeneuve, Coupal L. *Etanercept Has a Better Retention Rate at 10 Years Than Adalimumab in Patients with Rheumatoid Arthritis. Results from Rhumadata®: A Real-Life Clinical Database and Registry* [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/etanercept-has-a-better-retention-rate-at-10-years-than-adalimumab-in-patients-with-rheumatoid-arthritis-results-from-rhumadata-a-real-life-clinical-database-and-registry/>. Accessed December 10, 2015.
419. Choquette D, Bessette L, **Brown J**, Haraoui B, Massicotte F, Pelletier JP, Raynauld JP, Rémillard MA, Sauvageau D, Turcotte A, Villeneuve, Coupal L. *Comparative 10-Year Retention Rates of Adalimumab Used in Mono and Combination Therapy in Rheumatoid Arthritis (RA) Patients from the Rhumadata Clinical Database and Registry* [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/comparative-10-year-retention-rates-of-adalimumab-used-in-mono-and-combination-therapy-in-rheumatoid-arthritis-ra-patients-from-the-rhumadata-clinical-database-and-registry/>. Accessed December 10, 2015.
420. Sunkureddi P, Moericke R, Tóth E, **Brown JP**, Machein U, Lheritier K, Junge G, Kivitz AJ. *Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study* [abstract]. *Arthritis Rheumatol.* 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/canakinumab-liquid-formulation-in-acute-gouty-arthritis-patients-long-term-safety-and-efficacy-results-from-a-36-week-extension-study/>. Accessed December 10, 2015.
421. Bone HG, Brandi ML, **Brown JP**, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lipinur K, Reginster J-Y, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Dakin P, Wagman RB, Papapoulos S (2016) *Ten Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the FREEDOM Extension Trial.* 2015 Professional Conference and 18<sup>th</sup> Annual Meeting of the Canadian Society of Endocrinology and Metabolism. November 30-December 3, 2015. Vancouver, BC, Canada.  
**Oral presentation.**
422. Benhamou CL, Bilezikian JP, Lin CJF, **Brown JP**, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C (2015) *Le denosumab inverse le processus de perte osseuse corticale au radius distal associée à l'âge, et réduit le risque de fracture du poignet : analyses des données du groupe de novo de l'extension de FREEDOM.* 28<sup>e</sup> congrès de la Société Française de Rhumatologie. December 13-15, 2015. Paris, France

423. Ferrari S, Libanati C, Lin CJF, Adami S, **Brown JP**, Cosman F, Czerwiński E, De Gregório LH, Malouf J, Reginster J.-Y, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM, Cummings S (2015) *Pourcentage de femmes atteignant des T-scores de DMO non ostéoporotiques au rachis lombaire (RL) et à la hanche totale (HT) après 8 ans de traitement par denosumab (DMAb)*. 28<sup>e</sup> congrès de la Société Française de Rhumatologie. December 13-15, 2015. Paris, France.
424. Bessette L, Coupal L, **Brown JP**, Haraoui H, Massicotte F, Pelletier J-P, Raynauld J-P, Rémillard M-A, Sauvageau D, Turcotte A, Villeneuve E, Choquette D (2015) *Taux de rétention de l'abatacept et des inhibiteurs du TNF après six ans de traitement de l'arthrite rhumatoïde : expérience en vie réelle du registre Rhumadata*. 28<sup>e</sup> congrès de la Société Française de Rhumatologie. December 13-15, 2015. Paris, France.
425. Bessette L, Coupal L, **Brown JP**, Haraoui H, Massicotte F, Pelletier J-P, Raynauld J-P, Rémillard M-A, Sauvageau D, Turcotte A, Villeneuve E, Choquette D (2015) *Facteurs cliniques et thérapeutiques pouvant influencer la rétention à long terme des traitements biologiques : données du registre Rhumadata*. 28<sup>e</sup> congrès de la Société Française de Rhumatologie. December 13-15, 2015. Paris, France.
426. Bone H, Brandi M-L, **Brown J**, Chapurlat R, Cummings S, Czerwinski E, Fahrleitner-Pamer A, Kendler D, Lippinur K, Reginster J-Y, Vittinghoff E, Daizadeh N, Wang A, Dakin P, Wagman R, Papapoulos S (2016) *Ten Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the FREEDOM Extension Trial*. J Rheum.; 43(6): 1209.
427. **Brown JP**, Dakin P, Hadji P, McClung MR, Miller P, Reginster JY, Wagman RB, Wang A, McCloskey E (2016) *Can We Use Bone Turnover Markers as Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? An Analysis From the DECIDE and STAND Clinical Trials*. J Rheum. 43(6):1208-1209.
428. Choquette D, Bessette L, **Brown J**, Haraoui B, Massicotte F, Pelletier J.-P., Raynauld J.-P., Rémillard M.-A., Sauvageau D, Turcotte A, Villeneuve E, Coupal L (2016) *Six-Year Retention Rates With Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry*. J Rheum.; 43(6):1211-1212.
429. Choquette D, Bessette L, **Brown J**, Haraoui B, Massicotte F, Pelletier J.-P., Raynauld J.-P., Rémillard M.-A., Sauvageau D, Turcotte A, Villeneuve E, Coupal L (2016) *Disease and Treatment Characteristics That Might Influence Long-Term Retention With Biologics in the Real-World Clinical Setting: Experience From the Rhumadata Clinical Database and Registry*. J Rheum.; 43(6): 1212.
430. Choquette D, Bessette L, **Brown J**, Haraoui B, Massicotte F, Pelletier J.-P., Raynauld J.-P., Rémillard M.-A., Sauvageau D, Turcotte A, Villeneuve E, Coupal L (2016) *Use of Rituximab Compared to Anti-TNF Agents as Second And Third Line Therapy in Patients With Rheumatoid Arthritis. A 6-Year Follow-Up Report from the Rhumadata® Clinical Database and Registry*. J Rheum.; 43(6):1212-1213.
431. Choquette D, Bessette L, **Brown J**, Haraoui B, Massicotte F, Pelletier J.-P., Raynauld J.-P., Rémillard M.-A., Sauvageau D, Turcotte A, Villeneuve E, Coupal L (2016) *Six Years Tocilizumab Use in Patients With Rheumatoid Arthritis With One Previous Anti-TNF Agent Exposure: Comparison With Adalimumab and Etanercept from the Provincial Electronic Database and Registry Rhumadata®* J Rheum.; 43(6):1213.
432. Numan MS, Jean S, Dumont J, **Brown JP**, Michou L (2016) *Exploration of associations between air pollutants and familial or non familial forms of Paget's disease of bone*. J Rheum.; 43(6):1185.

433. Miller PD, Pannacciulli N, **Brown JP**, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) *Denosumab Treatment is Associated With Greater Transient Increases in Serum Intact Parathyroid Hormone Concentrations Compared With Zoledronic Acid: Results from a Study in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates*. *Endocrine Reviews*; 37(2):OR1. **Oral presentation.**
434. Langdahl B, Libanati C, Crittenden DB, Bolognese MA, **Brown JP**, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Restrepo JFM, Ulla MR, Grauer A (2016) *Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study*. *Endocrine Reviews*; 37(2):OR1. **Oral presentation.**
435. Schneider PS, Wall M, Belzile EL, **Brown JP**, Cheung AM, Harvey E, Morin SN (2016) *Management of Atypical Femur Fractures: A Survey of Current Practices in Orthopaedic Surgery*. 13<sup>th</sup> Annual Meeting of the Combined Orthopaedic Associations. April 11-16, 2016. Cape Town, Africa.
436. Malouf J, Langdahl B, Libanati C, Crittenden DB, Bolognese MA, **Brown JP**, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Massari FE, Molina JF, Ulla MR, Grauer A (2016) *Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared With Teriparatide in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-Label Structure Study*. *Osteoporosis International*; 27 (Suppl. 1): OC3.
437. Miller P, Pannacciulli N, **Brown JP**, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster J-Y, Singer A, Wang C, Wagman RB, Cummings SR (2016) *A Randomized Double-Blind Study of Denosumab (DMAB) Compared With Zoledronic Acid (ZOL) in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates*. *Osteoporosis International*; 27 (Suppl. 1): OC4.
438. Morin SN, Jean S, **Brown JP**, Ste-Marie LG, Dubois P, Boire G, Gaboury I, Cabana F, Fernandes J, Delisle J, Wall M, Theriault D, Beaulieu MC (2016) *Towards a Strategy for Secondary Fracture Prevention in Quebec*. *Osteoporosis International*; 27 (Suppl. 1): P402.
439. Won AKO, Davison KS, Adachi JD, **Brown JP**, Josse R, Khan A, Cheung AMW (2016) *Thicker and denser cortices at the radius but less intact trabeculae at the tibia are associated with atypical femur fractures: a cross-sectional case-cohort analysis*. *Osteoporosis International*; 27 (Suppl. 1): P341.
440. Ferrari S, Adami S, **Brown JP**, Cosman F, Czerwiński E, de Gregório LH, Malouf J, Reginster J-Y, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM (2016) *Relationship Between Total Hip BMD T-score and Incidence of Nonvertebral Fracture With up to 10 Years of Denosumab (DMAB) Treatment*. *Osteoporosis International*; 27 (Suppl. 1): OC17.
441. Bone HG, Brandi ML, **Brown JP**, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Vittinghoff E, Daizadeh NS, Wang A, Dakin P, Wagman RB, Papapoulos SE (2016) *Ten Years of Denosumab (DMAB) Treatment in Postmenopausal Women With Osteoporosis : Results From the Freedom Extension Trial*. *Osteoporosis International*; 27 (Suppl. 1): P217.
442. Dempster D, **Brown JP**, Yue S, Farlay D, Rizzo S, Song J, Wang A, Wagman RB, Boivin G (2016) *Effects of Denosumab (DMAB) on Bone Matrix Mineralization: Results From the Phase 3 Freedom Trial* (2016) *Osteoporosis International*; 27 (Suppl. 1): P243.

443. Beaudoin C, Jean S, Moore L, Bessette L, Ste-Marie L-G, **Brown JP** (2016) *Prediction of osteoporotic fractures in individuals aged of 50 and older from the province of Quebec using administrative databases: A Research Proposal*. Accepted as a poster presentation at the Journée de la recherche des étudiants de l'axe Santé des populations et pratiques optimales en santé. Québec, Québec, Canada. 2 mai 2016.
444. Beaudoin C, Moore L, Gagné M, Bessette L, Ste-Marie L-G, **Brown JP**, Jean S (2016) *Performance of Predictive Tools to Identify Individuals at Risk of Non-traumatic Fractures: a Systematic Review and Meta-analysis*. Accepted as an **oral presentation** at the Journée de la recherche des étudiants de l'axe Santé des populations et pratiques optimales en santé. Québec, Québec, Canada. 2 mai 2016.
445. Beaudoin C, Moore L, Gagné M, Bessette L, Ste-Marie L-G, **Brown JP**, Jean S (2016) *Performance des outils de prédiction du risque de fracture ostéoporotique : résultats d'une revue systématique avec méta-analyse*. Journée de la recherche en santé. May 25-26, 2016. Quebec, QC. Canada.
446. Ferrari S, Adami S, **Brown JP**, Cosman F, Czerwiński E, de Gregório LH, Malouf J, Reginster J-Y, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM (2016) *Relationship Between Total Hip (TH) BMD T-score and Incidence of Nonvertebral Fracture (NVFX) With up to 10 Years of Denosumab (DMab) Treatment*. Bone; 6: OC1.4.
447. Dempster DW, **Brown JP**, Yue S, Farlay D, Rizzo S, Song J, Wang A, Wagman RB, Boivin G (2016) *Effects of Denosumab (Dmab) on bone matrix mineralization: results from the phase 3 FREEDOM trial*. Bone; 6: OC3.2.
448. Langdahl B, Libanati C, Crittenden D, Bolognese M, **Brown J**, Daizadeh N, Dokoupilova E, Engelke K, Finkelstein J, Genant H, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny T, Kendler D, Lakatos P, Maddox J, Malouf J, Massari F, Molina J, Ulla M, Grauer A (2016) *Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy: Results of the phase 3 open-label structure study*. Bone; 5: HT5. **Oral presentation.**
449. Haraoui B, Bessette L, **Brown J**, Coupal L, Massicotte F, Pelletier J-P, Raynauld J-P, Rémillard M-A, Sauvageau D, Villeneuve E, Choquette D (2016) *The Incidence of Herpes Zoster (Hz) in a Population of Patients With Inflammatory Arthritis: A 12-Year Analysis From the Rhumadata Clinical Database And Registry*. Ann Rheum Dis 2016; 75(Suppl2): 471
450. Langdahl B, Libanati C, Crittenden D, Bolognese M, Brown J, Daizadeh N, Dokoupilova E, Engelke K, Finkelstein J, Genant H, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny T, Kendler D, Lakatos P, Maddox J, Malouf J, Massari F, Molina J, Ulla M, Grauer A (2016) *Superior Gains in Bone Mineral Density and Estimated Strength at the Hip tor Romosozumab Compared With Teriparatide in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-Label Structure Study*. Ann Rheum Dis 2016; 75(Suppl2): 92
451. Bone H, Brandi M, **Brown J**, Chapurlat R, Cummings S, Czerwinski E, Fahrleitner-Pammer A, KendlerD, Lippuner K, Reginster J-Y, Vittinghoff E, Daizadeh N, Wang A, Dakin P, Wagman R, Papapoulos S (2016) *Ten years of denosumab treatment in postmenopausal women with osteoporosis: Results from the freedom extension trial*. Ann Rheum Dis 2016; 75(Suppl2): 173.

452. Raynauld J-P, Bessette L, **Brown J**, Coupal L, Haraoui B, Massicotte F, Pelletier J-P, Rémillard M-A, Sauvageau D, Villeneuve E, Choquette D (2016) *Use of Rituximab Compared to Anti-Tnf Agents as Second and Third-Line Therapy in Patients With Rheumatoid Arthritis. A 6-Year Follow-Up Report From the Rhumadata® Clinical Database and Registry*. Ann Rheum Dis 2016; 75(Suppl2): 190.
453. Bessette L, **Brown J**, Coupal L, Haraoui B, Massicotte F, Pelletier J-P, Raynauld J-P, Rémillard M-A, Sauvageau D, Turcotte A, Villeneuve E, Choquette D (2016) *Six Years Tocilizumab Use in Patients With Rheumatoid Arthritis With One Previous Anti-Tnf Agent Exposure: Comparison With Adalimumab and Etanercept From the Provincial Electronic Database and Registry Rhumadata®* Ann Rheum Dis 2016; 75(Suppl2): 190.
454. GHDV authors. *Anabolism versus Antiresorption (AVA Study): A Comparison of the Mechanism of Action (MOA) of Teriparatide (TPTD) and Denosumab (DMAb) in Postmenopausal Women with Osteoporosis Using Quadruple Fluorochrome Labeled Bone Histomorphometry*. Poster presentation at the Australian & New Zealand Bone & Mineral Society - 26th Annual Scientific Meeting. August 21-24, 2016. Broadbeach, Queensland, Australia.
455. Ferrari S, Libanati C, Lin CJF, Adami S, **Brown JP**, Cosman F, Czerwiński E, de Gregório LH, Malouf J, Reginster J-Y, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM. *Relationship Between Total Hip BMD T-score and Incidence of Nonvertebral Fracture With up to 8 Years of Denosumab Treatment*. Poster presentation at the Australian & New Zealand Bone & Mineral Society - 26th Annual Scientific Meeting. Broadbeach, Queensland, Australia. August 21-24, 2016.
456. Dempster DW, **Brown JP**, Yue S, Farlay D, Rizzo S, Song J, Wang A, Wagman RB, Boivin G. *Effects of Denosumab on Bone Matrix Mineralisation: Results From the Phase 3 FREEDOM Trial*. Poster presentation at the Australian & New Zealand Bone & Mineral Society - 26th Annual Scientific Meeting. Broadbeach, Queensland, Australia. August 21-24, 2016.
457. Beaulieu MC, Morin S, Jean S, **Brown J**, Ste-Marie LG, Boire G, Gaboury I, Cabana F, Fernandes J, Delisle J, Wall M, Theriault D. *Towards a strategy for secondary fracture prevention in Quebec*. 5<sup>th</sup> Fragility Fracture Network Global Congress, Rome, Italy, September 1-3, 2016.
458. Schneider PS, Wall M, **Brown J**, Cheung A M-W, Harvey EJ, Morin SM (2016) *Atypical Femur Fractures: A Survey of Current Practices in Orthopaedic Surgery*. Canadian Musculoskeletal Conference. Toronto, Canada, October 14-15, 2016.
459. Dempster DW, Daizadeh N, Fahrleitner-Pammer A, Beck Jensen J-E, Kendler D, Valter I, Yue S, **Brown JP** (2016) *Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the FREEDOM Extension Study*. J Bone Miner Res 31 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=ac4e0394-b2b8-48ef-90d4-f66f5ce48d8e>. Accessed on November 1, 2016.
460. Laurier E, Amiable N, Gagnon E, **Brown JP**, Michou L (2016) *Effect of a rare genetic variant of TM7SF4 gene on osteoclast phenotype in Paget's disease of bone*. J Bone Miner Res 31 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=3fffa9fe-0155-4094-8595-e00a82d99bbc>. Accessed on November 1, 2016.
461. Beaudoin C, Moore L, Gagné M, Bessette LB, Ste-Marie L-G, **Brown JP**, Jean S (2016) *Performance of Predictive Tools to Identify Individuals at Risk of Osteoporotic Fractures: a Systematic Review and Meta-analysis*. J Bone Miner Res 31 (Suppl 1). Available at



<http://www.asbmr.org/education/AbstractDetail?aid=4ac7419b-483f-47e4-ab4e-eaee6a44a79b>. Accessed on November 1, 2016.

462. Jean S, Gamache P, **Brown JP**, Bessette L, Morin S (2016) *Temporal Trends Analysis of the Post-fracture Management: A Population-based Study, 2000-2012*. J Bone Miner Res 31 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=3f91cada-b643-4875-9dcf-744120a5d035>. Accessed on November 1, 2016.
463. Lentle L, Berger C, Langsetmo L, Thomas D, Fine B, Lian K, Shergill A, Trollip J, Probyn L, **Brown JP**, Leslie WD, Prior JC and Goltzman D for the CaMos Investigator (2016) *The Canadian Multicentre Osteoporosis Study (CaMos) and Vertebral Fractures*. J Bone Miner Res 31 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=0bf81aef-4776-41ca-b0ce-47a9ee4127e3>. Accessed on November 1, 2016.
464. Schneider PS, Wall M, **Brown JP**, Cheung AM, Harvey E, Morin SN (2016) *Atypical Femur Fractures: A Survey of Current Practices in Orthopaedic Surgery*. J Bone Miner Res 31 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=6a3a45fd-7894-41a1-93be-dab60f134c02>. Accessed on November 1, 2016.
465. Dempster DW, Zhou H, Recker RR, **Brown JP**, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam JA, Taylor KA, Ruff VA (2016) *Longitudinal Changes in Modeling- and Remodeling-Based Bone Formation with an Anabolic vs. an Antiresorptive Agent in the AVA Osteoporosis Study*. J Bone Miner Res 31 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=e4c9ec70-f8de-4199-8f9c-9717791dd96d>. Accessed on November 1, 2016. **Oral presentation.**
466. Wong AKO, Davison KS, Leslie WD, Adachi JD, **Brown JP**, Josse RG, Khan A, Cheung AM. *Lower TBS Score is a Risk Factor for Atypical Femur Fractures but not Independent of Duration of Antiresorptive Therapy*. J Bone Miner Res 31 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=f144506b-5889-469b-9050-446248784b6d>. Accessed on November 1, 2016.
467. Dempster DW, Brown JP, Yue S, Rizzo S, Farlay D, Wagman RB, Wang A, Yin X, Boivin G (2016) *Effects of Up to 10 Years of Denosumab Treatment on Bone Matrix Mineralization: Results From the FREEDOM Extension*. J Bone Miner Res 31 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=aa6b8e24-2399-40fa-8a20-125295300c00>. Accessed on November 1, 2016. **Oral presentation.**
468. Schneider PS, Wall M, **Brown JP**, Cheung AM, Harvey E, Morin SN (2016) *Atypical Femur Fractures: A Survey of Current Practices in Orthopaedic Surgery*. 2016 Orthopaedic Trauma Association Annual Meeting. National Harbor, Maryland, USA. October 5-8, 2016.
469. Michou L, Numan MS, **Brown JP**, Jean S (2016) *Association between the p.Pro392Leu mutation within SQSTM1 gene and air pollutants in Paget's disease of bone*. ASHG 2016. Vancouver, BC. October 18-22, 2016.
470. Beaulieu M-C, Boire G, Cabana F, Gaboury I, **Brown J**, Jean S, Delisle J, Morin S (2016) *Towards a Strategy For Secondary Fracture Prevention In Quebec* (2016) Submitted to the 4th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD). Barcelona, Spain. October 20-22, 2016.

471. Dempster DW, Daizadeh N, Fahrleitner-Pammer A, Beck Jensen J-E, Kendler D, Valter I,<sup>6</sup> Wagman RB, Yue S, **Brown JP** (2016) *Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Open-label Extension of a Phase 3 Placebo-controlled Study of Denosumab*. *Arthritis & Rheumatology*; 68 (Supplement S10), Abstract 323. Version of Record online: 8 NOV 2016.
472. Ferdinand I, Bessette L, Bourré-Tessier J, Haraoui B, **Brown J**, Massicotte F, Pelletier J-P, Raynauld J-P, Rémillard M-A, Sauvageau D, Turcotte A, Villeneuve E, Coupal L (2016) *Does Combination of Conventional Synthetic Disease Modifying Antirheumatic Drug with Anti-TNF Influence the Long Term Retention Compared to Anti-TNF Monotherapy in Psoriatic Arthritis? An Analysis from Rhumadata® over 12 Years*. *Arthritis & Rheumatology*; 68 (Supplement S10), Abstract 2514. Version of Record online: 8 NOV 2016.
473. Lentle BC, Probyn L, Berger C, **Brown JP**, Langsetmo L, Thomas D, Fine B, Lian K, Shergill A, Trollip JJ, Leslie WD, Kaiser SM, Adachi JD, Towheed T, Hanley DA, Davison KS, Prior JC, and Goltzman D for the CaMos Investigators (2016) *The Canadian Multicentre Osteoporosis Study (CaMOS) and Vertebral Fractures*. RSNA (Radiological Society of North American) 2016. November 27, 2016. Chicago, IL, USA. **Oral Presentation.**
474. Boivin G, **Brown JP**, Yue S, Farlay D, Rizzo S, Song J, Wang A, Wagman RB, Dempster D (2016) *Effet du denosumab (DMAb) sur la minéralisation de la matrice osseuse : résultats de l'étude de phase 3 FREE-DOM*. 29<sup>e</sup> congrès de Rhumatologie. Paris, France. December 11-13, 2016.
475. Numan M, Jean S, Dumont J, **Brown J**, Michou L (2017) *Exploration of Associations between Air Pollutants and Familial or Non Familial Forms of Paget's Disease of Bone*. Downloaded from www.jrheum.org on July 25, 2017 - Published by The Journal of Rheumatology.
476. **Brown J**, Dakin P, Hadji P, McClung M, Miller P, Reginster J-Y, Wagman R, Wang A, McCloskey E (2017) *Can we use Bone Turnover Markers as Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? An Analysis from the DECIDE and STAND Clinical Trials*. Downloaded from www.jrheum.org on July 25, 2017 - Published by The Journal of Rheumatology.
477. Bone H, Brandi M-L, **Brown J**, Chapurlat R, Cummings S, Czerwinski E, Fahrleitner-Pamer A, Kendler D, Lippinur K, Reginster J-Y, Vittinghoff E, Daizadeh N, Wang A, Dakin P, Wagman R. (2017) *Ten Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results from the FREEDOM Extension Trial*. Downloaded from www.jrheum.org on July 25, 2017 - Published by The Journal of Rheumatology.
478. Choquette D, Bessette L, Haraoui B, Raynauld J-P, Sauvageau D, Turcotte A, Villeneuve E, Massicotte F, **Brown J**, Coupal L (2017) *Six-Year Retention Rates with Abatacept vs TNF inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-world Rhumadata Clinical Database and Registry*. Downloaded from www.jrheum.org on July 25, 2017 - Published by The Journal of Rheumatology.
479. Choquette D, Bessette L, Haraoui B, Raynauld J-P, Sauvageau D, Turcotte A, Villeneuve E, Massicotte F, **Brown J**, Coupal L (2017) *Disease and Treatment Characteristics that Might Influence Long-term Retention with Biologics in the Real-world Clinical Setting: Experience from the Rhumadata Clinical Database and Registry*. Downloaded from www.jrheum.org on July 25, 2017 - Published by The Journal of Rheumatology.

480. Choquette D, Bessette L, **Brown J**, Haraoui B, Massicotte F, J-P Pelletier, Raynauld J-P, Remillard M-A, Sauvageau D, Villeneuve E, Coupal L (2017) *Use of Rituximab Compared to Anti-TNF Agents as Second and Third Line Therapy in Patients with Rheumatoid Arthritis. A 6 Year FollowUp Report from the Rhumadata Clinical Database and Registry*. Downloaded from www.jrheum.org on July 25, 2017 - Published by The Journal of Rheumatology.
481. Choquette D, Bessette L, Haraoui B, Massicotte F, Pelletier J-P, Raynauld J-P, Remillard M-A, **Brown J**, Sauvageau D, Villeneuve E, Coupal L (2017) *Six Years Tocilizumab Use in Patients with Rheumatoid Arthritis with One Previous Anti-TNF Agent Exposure: Comparison with Adalimumab and Etanercept from the Provincial Electronic Database and Registry Rhumadata*. Downloaded from www.jrheum.org on July 25, 2017 - Published by The Journal of Rheumatology.
482. Schneider PS, Wall M, **Brown JP**, Cheung AM, Harvey E, Morin SN (2017) *Atypical Femur Fractures: A Survey of Current Practices in Orthopaedic Surgery*. Presented at the 2017 American Academy of Orthopaedic Surgeons meeting. March 14-18, 2017. San Diego, CA.
483. **Brown JP**, Ferrari S, Gilchrist N, Beck Jensen J-E, Pannacciulli N, Recknor C, Roux C, Smith S, Törring O, Valter I, Wagman RB, Wang A, Cummings SR (2017) *Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from Freedom and its Extension*. Osteoporosis International; 28 (Supplement 1): OC6. **Oral Presentation**.
484. Dempster DW, **Brown JP**, Yue S, Rizzo S, Farlay D, Wagman RB, Wang A, Yin X, Boivin G (2017) *Effects of up to 10 Years of Denosumab Treatment on Bone Matrix Mineralization: Results from the FREEDOM Extension (EXT)*. Osteoporosis International; 28 (Supplement 1): P209.
485. Dempster DW, Zhou H, Recker RR, **Brown JP**, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay RL, Krege JH, Alam J, Taylor KA, Ruff VA (2017) *Modeling- and Remodeling-Based Bone Formation in the Anabolic Versus Antiresorptive (AVA) Study in Postmenopausal Women With Osteoporosis*. Osteoporosis International; 28 (Supplement 1): P240.
486. Dempster DW, Daizadeh N, Fahrleitner-Pammer A, Beck Jensen JE, Kendler D, Valter I, Wagman RB, Yue S, **Brown JP** (2017) *Effect of 10 Years of Denosumab (DMAb) Treatment on Bone Histology and Histomorphometry in the FREEDOM Extension Study*. Osteoporosis International; 28 (Supplement 1): OC20. **Oral Presentation**.
487. McClung MR, Bolognese MA, **Brown JP**, Reginster J-Y, Langdahl BL, Maddox J, Yan C, Yue S, Meisner P, Grauer A (2017) *Transition to Zoledronic Acid After Romosozumab Treatment Maintains Bone Mineral Density Gains*. Endocrine Reviews. Volume 38, Issue 3 (Supplement, June 2017): OR08-2.
488. Ferrari S, **Brown JP**, Pannacciulli N, Gilchrist N, Roux C, Törring O, Valter I, Wagman RB, Wang AT, Cumming SR (2017) *Vertebral Fracture Incidence After Discontinuation of Denosumab Treatment: Analysis From FREEDOM and its Extension*. Endocrine Reviews. Volume 38, Issue 3 (Supplement, June 2017): OR08-3. **Oral Presentation**.
489. Dempster DW, Brown JP, Yue S, Rizzo S, Farlay D, Wagman RB, Wang A, Yin X, Boivin G (2017) *Effects of Up to 10 Years of Denosumab (DMAb) on Bone Matrix Mineralization: Results from the FREEDOM Extension*. Calcified Tissue International. 100, (Supplement 1, May 2017).
490. Morin SN, Belzile EL, Brown JP, Jean S (2017) *In-Hospital Mortality following Hip, Femur and Pelvic fractures in Québec, Canada*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=5cf33c85-e6ca-4ff7-97a0-6efb35381fc7>. Accessed on December 19, 2017.

491. Morin SN, Wall M, Belzile EL, Michou L, Ste-Marie LG, Harvey E, Schneider PS, Jean S, Brown JP (2017) *Characterization of > 100 Patients with Atypical Femur Fractures: The Quebec Atypical Femur Fracture Registry*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=3930dd01-afcd-4fc9-9e3b-ff88dde572ae>. Accessed on December 19, 2017.
492. Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie LG, Brown JP (2017) *History of fractures for prediction of a subsequent fracture in individuals from the general population in Quebec, Canada*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=03955704-e4fa-4347-99bf-a8c665161f1b>. Accessed on December 19, 2017. **Oral presentation.**
493. Chavassieux P, Chapurlat R, Portero-Muzy N, Garcia P, Brown JP, Horlait S, Libanati C, Boyce R, Wang A, Grauer A (2017) *Effects of Romosozumab in Postmenopausal Women With Osteoporosis After 2 and 12 Months: Bone Histomorphometry Substudy*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=4fa99062-226a-43a1-8722-cba14d4c9632>. Accessed on December 19, 2017.
494. Roux J-P, Chavassieux P, Chapurlat R, Portero-Muzy N, Garcia P, Brown JP, Libanati C, Boyce R, Wang A, Grauer A (2017) *Effects of Romosozumab in Postmenopausal Women With Osteoporosis After 2 and 12 Months Assessed by MicroCT on Iliac Crest Bone Biopsies*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=83a1dc35-3525-484f-974b-af20cafe3147>. Accessed on December 19, 2017
495. Lentle B, Berger C, Probyn L, Brown JP, Langsetmo L, Fine B, Lian K, Shergill A, Trollip J, Jackson S, Leslie WD, Prior JC, Kaiser SM, Hanley DA, Cheung A, Adachi JD, Towheed T, Davison KS, Goltzman D (2017) *Are grade 1 vertebral fractures, true fractures?* J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=21099692-9db2-4afa-af12-528b77ff84d0>. Accessed on December 19, 2017.
496. Miller P, Pannacciulli N, Malouf J, Singer A, Czerwinski E, Bone HG, Wang C, Wagman RB, Brown JP (2017) *A Meta-Analysis of 4 Clinical Trials of Denosumab Compared With Bisphosphonates in Postmenopausal Women Previously Treated With Oral Bisphosphonates*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=ed7648f3-3dae-433e-bc36-55c08465d6c7>. Accessed on December 19, 2017.
497. Dessay M, Jobin Gervais F, Samson A, **Brown JP**, Michou L (2017) *Phenotype assessment of adult offspring carriers of the SQSTM1/P392L mutation in familial forms of Paget's disease of bone*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=a66804bb-c475-4645-bb25-8f321eb5a236>. Accessed on December 19, 2017.
498. Jean S, Harvey EJ, Belzile EL, **Brown JP**, Morin SN (2017) *Temporal Trends in Length of Stay after Hip, Femur and Pelvic Fracture in Québec, Canada*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=94bc0972-421a-49f2-b673-bd9e248476f6>. Accessed on December 19, 2017.
499. Sun Q, Zhang P, Adamik J, Subler MA, Windle JJ, Michou LM, **Brown JP**, Kurihara N, Roodman GD, Dempster DW, Verdelis K, Zhou H, Galson DL (2017) *Transgenic expression of TBK1 In Osteoclast Lineage Cells Increased Both Osteoclasts and Bone Formation*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=2e0e0cbd-1ae7-4b67-9d03-4be6176852de>. Accessed on December 19, 2017.

500. **Brown JP**, Dempster DW, Yue S, Rizzo S, Farlay D, Wagman RB, Yin X, Boivin G (2017) *Bone Matrix Mineralization After Denosumab Treatment Discontinuation*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=1d52ffb3-efca-49b6-9d6c-4375044137ae>. Accessed on December 19, 2017.
501. Ferrari S, Adami S, **Brown JP**, Cosman F, Czerwinski E, de Gregório LH, Malouf J, Reginster J-Y, Daizadeh N S, Wang A, Wagman RB, Lewiecki EM (2017) *Relation entre DMO à la hanche et fractures non vertébrales incidentes jusqu'à 10 ans de traitement par denosumab (DMAb)*. Presented as a poster at the 30e Congrès français de rhumatologie.
502. Boisvert M-E, **Brown J**, Laframboise R, Vallée M, Morin S, Gagnon E, Droit A, Michou L (2018) *Identification of a Rare Genetic Variant of OFDI Gene in a Familial Form of Adult-onset Multiple Diaphyseal Insufficiency Fractures Associated with Facial and Teeth Hypoplasias*. The Journal of Rheumatology; 45:7. Abstract 16.
503. Chavassieux P, Chapurlat R, Portero-Muzy N, Roux J-P, Garcia P, **Brown JP**, Horlait S, Libanati C, Boyce R, Wang A, Grauer A (2018) *Effects of romosozumab in postmenopausal women with osteoporosis after 2 and 12 months by micro computed tomography (MicroCT) and histomorphometry on iliac crest bone biopsies*. Calcif Tissue Int (2018) 102(Suppl 1): 1. <https://doi.org/10.1007/s00223-018-0418-0>. Accessed on August 1, 2019. **Plenary Oral Presentation**.
504. **Brown J**, Dempster DW, Yue S, Rizzo S, Farlay D, Wagman RB, Yin X, Boivin G. *Bone matrix mineralization after denosumab (DMAb) treatment discontinuation*. (2018) Calcif Tissue Int (2018) 102(Suppl 1): 1. <https://doi.org/10.1007/s00223-018-0418-0>. Accessed on August 1, 2019. **Plenary Oral Presentation**.
505. Khan TS, Ioannidis G, Papaioannou A, Kennedy C, Berger C, Lentle B, **Brown J**, Probyn L, Kovacs CS, Hanley DA, Prior J, Goltzman D, Kaiser SM, Morin SN, Leslie WD, Davison KS, Towheed T, Hopman W, Olszynski W, Adachi JD (2018) *Grade 1 vertebral height loss is not associated with frailty in the Canadian Multicentre Osteoporosis Study (CaMos)*. Calcif Tissue Int (2018) 102(Suppl 1): 1. <https://doi.org/10.1007/s00223-018-0418-0>. Accessed on August 1, 2019.
506. Lentle BC, **Brown JP**, Probyn L, Hammond I, Hu J, Fine B, Lian K, Shergill A, Trollip J, Berger C, Leslie WD, Prior JC, Hanley DA, Adachi JD, Josse RG, Cheung AM, Davison KS, Kaiser SM, Towheed T, Kovacs CS, Wong AKO, Goltzman D (2018) *Low-grade morphometric vertebral deformities result from historical events and are unlikely to be primarily osteoporotic in provenance*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=0d4eba34-1cde-461b-aa27-2f1044b9d952>. Accessed on August 1, 2019.
507. Boisvert M-E, **Brown JP**, Laframboise R, Vallée M, Fournier F, Morin SN, Gagnon E, Droit A, Michou L (2018) *Novel genetic variants of OFDI gene are associated with a familial form of stress fractures of long bones and a sporadic case of atypical femur fracture associated with bisphosphonate use*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=99fe2a65-9ab1-4ab6-8923-1802f5182281>. Accessed on August 1, 2019.
508. Morin SN, O'Donnell S, Jean S, Jaglal S, Siminoski K, Papaioannou A, **Brown J**, Ix LM, Leslie WD (2018) *Post-Fracture Care gap in Canada from 2000-2001 to 2011-2012: A Nationwide Population-based Analysis*. J Bone Miner Res 32 (Suppl. 1). Available at: <http://www.asbmr.org/education/AbstractDetail?aid=e8e047e2-b756-42ae-abbf-44e7229f549b>. Accessed on August 1, 2019. **Oral Presentation**.

509. Dessay M, Vallée M, Fournier F, Droit A, Gagnon E, **Brown JP**, Michou L (2018) *Search for modifier genes by whole exome sequencing in familial form of Paget's disease of bone linked to the SQSTM1/P392L mutation*. Available at: <http://www.asbmr.org/education/AbstractDetail?aid=02ab5cd9-6474-4ef9-abf2-d465deb96946>. Accessed on August 1, 2019.
510. Sun Q, Zhang P, Adamik J, Subler MA, Kurihara N, Michou L, **Brown JP**, Roodman GD, Auron PE, Dempster DW, Windle JJ, Verdelis K, Zhou H, Galson DL (2018) *TBK1 expression and activity in OCL lineage cells generates a pagetic-like bone disease in mice*. Available at: <http://www.asbmr.org/education/AbstractDetail?aid=bd23c669-e222-4a2e-99a4-d3111846aaa8>. Accessed on August 1, 2019.
511. Beaudoin C, Gamache P, Morin SN, **Brown JP**, Bessette L, Jean S (2018) *Temporal Trends in Prevalence and Incidence of Diagnosed Osteoporosis in Quebec, Canada*. Available at: <http://www.asbmr.org/education/AbstractDetail?aid=bd23c669-e222-4a2e-99a4-d3111846aaa8>. Accessed on August 1, 2019.
512. Adachi J, **Brown J**, Schemitsch E, McErlain D, Burke N, Hume M (2019) *Incidence of Imminent Fracture and the Subsequent Fracture Cascade after Index Fragility Fracture in Ontario, Canada*. The Journal of Rheumatology; 46:7. Abstract 164.
513. Eriksen EF, Chapurlat R, Boyce R, **Brown JP**, Horlait S, Libanati C, Shi Y, Wagman RB, Chavassieux P (2019). Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial. J Bone Miner Res 34 (Suppl 1). **Oral presentation 1049**. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=d112527c-6efe-46cd-96af-04ce66040dcd> Assessed on June 29, 2021.
514. **Brown JP**, Chines A, Chapurlat R, Foldes J, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini C, Yang W, Recknor C, Libanati C (2019). Romosozumab improves lumbar spine bone mineral density and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial. J Bone Miner Res 34 (Suppl 1). **Oral presentation 1050**. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=5edcfa7c-866d-452a-955f-f30aca81a7ea> Assessed on June 29, 2021.
515. Farlay D, Rizzo S, Ste-Marie LG, Michou L, Morin S, Qiu S, Rao SD, **Brown JP**, Boivin G (2019). Altered Bone Quality in Long-term bisphosphonate Users with Atypical Femur Fracture (AFF). J Bone Miner Res 34 (Suppl 1). **Oral presentation 1087**. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=b16959a7-dee7-44a0-bf9e-37a50335907f> Assessed on June 29, 2021.
516. Adachi JD, **Brown JP**, Schemitsch EH, Tarride JE, Motsepe-Ditshego P, Burke N, Colgan SM, Slatkovska L (2019). Real-world outcomes and imminent fractures after index fragility fracture: A population study. J Bone Miner Res 34 (Suppl 1). Poster FRI-644. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=bf892598-05c4-47d2-b38f-22508ca596d2> Assessed on June 29, 2021.
517. Tarride JE, Adachi JD, **Brown JP**, Schemitsch EH, Motsepe-Ditshego P, Colgan SM, Burke N (2019). Real-world outcomes and cost of management of osteoporotic fractures in Ontario, Canada. J Bone Miner Res 34 (Suppl 1). Poster SAT-687. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=09827823-2469-4fff-acd4-91e104ab36fe> Assessed on June 29, 2021.
518. Dessay M, Couture E, Gagnon E, Michou L, **Brown JP** (2019). Impact on the clinical and osteoclastic phenotypes of a rare variant in the *DOCK6* gene in familial forms of Paget's disease linked to the p.Pro392Ley mutation in the *SQSTM1* gene. J Bone Miner Res 34 (Suppl 1). Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=919dc87e-53e4-4fbd-a3e1-7b12238b2801> Assessed on June 29, 2021.

519. Eriksen EF, Boyce RW, Shi Y, **Brown JP**, Horlait S, Libanati C, Chapurlat R, Chavassieux P (2020). Kinetic Reconstruction of the Cancellous and Endocortical Remodeling Unit Reveals a Net Positive Bone Balance After 12 Months of Treatment with Romosozumab. *J Bone Miner Res* 35 (Suppl 1). **Oral presentation 1041**. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=507ed589-5087-4329-bd99-e5b396f49294> Assessed on June 29, 2021.
520. Farlay D, Rizzo S, Dempster D, Huang S, Chen L, Chines A, **Brown JP**, Boivin G (2020). Bone Matrix quality in transiliac biopsies from post-menopausal women treated with denosumab for up to 10 years (FREEDOM and FREEDOM Extension Trials). *J Bone Miner Res* 35 (Suppl 1). **Oral presentation 1064**. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=da7a5ee4-b699-4464-a329-500711259925> Assessed on June 29, 2021.
521. Michou L, Boisvert ME, Couture E, Laframboise R, Fournier F, Morin SN, Gagnon E, Gagnon C, MacWay F, Rouabhia M, Ste-Marie LG, Droit A, **Brown JP** (2020). Impact on osteoblasts/osteocytes *in vitro* of a novel genetic variant of the *OFDI* gene linked to X-linked osteoporosis, dental/facial hypoplasia and spontaneous adult-onset multiple long bone insufficiency fractures similar to atypical femur fractures. *J Bone Miner Res* 35 (Suppl 1). Poster P-840. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=a6a43f05-8658-45d8-9842-2e0afc334ce3> Assessed on June 29, 2021.
522. McClung MR, Bolognese MA, **Brown JP**, Reginster JY, Langdahl BL, Ruiz-Santiago N, Shi Y, Rojeski M, Timoshanko J, Libanati C, Kassahun H, Oates M (2020). Romosozumab after denosumab improves lumbar spine and maintains total hip bone mineral density in postmenopausal women with low bone mass. *J Bone Miner Res* 35 (Suppl 1). Poster P-642. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=76b7887a-0389-475d-b29a-1c5e37298591> Assessed on June 29, 2021.
523. Schemitsch E, Adachi JD, **Brown JP**, Tarride JE, Burke N, Oliviera T, Slatkovska L (2020). The fragility hip fracture: Not only a marked burden of disease, but also a significant predictor of subsequent hip fracture risk. *J Bone Miner Res* 35 (Suppl 1). Poster P-571. Available at: <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=d5aca43c-8804-455b-9d71-af037606d0bb> Assessed on June 29, 2021.
524. Michou L, Gamache P, Guertin JR, Tarride JE, Brown JP, Jean S (2021). Burden of Paget's disease of bone: Temporal Trend over 20 years in Quebec, Canada. *J Bone Miner Res* 36 (Suppl 1). Virtual Poster 420. Available at : <https://www.asbmr.org/meetings/annualmeeting/AbstractDetail?aid=fd19dd96-a83e-4cb7-b636-bc70ca293ada>
525. Vincent G, Adachi JD, Schemitsch E, Tarride JE, Luen M, Wani RJ, **Brown JP** (2022). One- and five-year survival after fragility fracture: Real-world retrospective matched-cohort study in Ontario, Canada. *J Bone Miner Res* 37 (Suppl 1). Poster FRI-523. Available at: <https://www.asbmr.org/ItineraryBuilder/PresentationDetail.aspx?pid=9e521b87-08a7-4ff4-8840-c2f39ae77c0f&ptag=WebItinerarySearch> Assessed on October 18, 2022.
526. Gendron E, Bouchard F, Singbo N, **Brown JP**, Michou L (2022). Decline in clinical severity of Paget's disease of bone: comparison between a contemporary cohort and a historical cohort. *J Bone Miner Res* 37 (Suppl 1). Poster FRI-007. Available at: <https://www.asbmr.org/ItineraryBuilder/PresentationDetail.aspx?pid=5bfc2316-4e1a-43b9-8c16-c4e383282c35&ptag=WebItinerarySearch> Assessed on Oct 18, 2022.

527. Kendler DL, Brown JP, Juby AG, Schneider P, Wani R, Oliveira T, Avcil S, Li S, Farris MS, Graves E, McMullen S, Packalen M (2022). Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada. *J Bone Miner Res* 37 (Suppl 1). Poster SAT-536. Available at: <https://www.as-bmr.org/ItineraryBuilder/PresentationDetail.aspx?pid=0d2fc7ec-67c7-424a-89bb-b2eb2c596cf1&ptag=WebItinerarySearch> Assessed on Oct 18, 2022.
528. Eriksen EF, Boyce RW, Shi Y, Brown JP, Betah D, Libanati C, Oates M, Chapurlat R, Chavassieux P. Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment. Danish Bone Meeting, May 2023.

#### Articles in professional or cultural journals without review committee

1. Gagné M, **Brown J**, Lussier A, Pleszczynski MR, Camerlain M (1983). *Maladie de Whipple sans manifestation digestive : Arthropathie de diagnostic tardif*. *L'Union Médicale du Canada* ; 112(7) : 628-32.
2. **Brown JP**, Delmas PD, Malaval L, Meunier PJ (1984). *Serum bone GLA-protein a specific marker of bone formation in postmenopausal osteoporosis*. *Osteoporosis Proceedings of the Copenhagen International Symposium on Osteoporosis*; 1: 127-131.
3. **Brown JP**. (2002). *L'ostéoporose : en quête d'une solution thérapeutique*. *Les sélections de médecine / sciences*; 21:4-7.
4. **Brown JP** (2003). *L'ostéoporose*. *Le Spécialiste*.
5. Morin S, Fortin MB, Chauvin P, Dagenais M, Fournier C, Kauzman A, McKee MD, Ste-Marie L-G, **Brown J** (2010) *Recommandations pour une santé buccodentaire optimale chez les patients qui reçoivent des bisphosphonates pour traiter l'ostéoporose*. *Journal de l'Ordre des dentistes du Québec*; 47(5):15-17.
6. Jean S, Godi M-J, **Brown JP**, Morin S, Belzile É, Bessette L. (2015) *Portrait des fractures ostéoporotiques chez les adultes québécois de 50 ans et plus pour la période 1997-1998 à 2011-2012*. Institut national de santé publique du Québec, 19p. [en ligne] <http://www.inspq.qc.ca>.
7. Beaudoin C, Jean S, Gamache P, Morin SN, **Brown JP**, Bessette L (2019). Surveillance de l'ostéoporose au Québec : prévalence et incidence. Institut national de santé publique du Québec. Québec. 16 p.